Clinical outcomes and synergistic effect between radiotherapy and immunotherapy in patients with extensive-stage small cell lung cancer: A real-world study

Clinical outcomes and synergistic effect between radiotherapy and immunotherapy in patients with extensive-stage small cell lung cancer: A real-world study | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article Clinical outcomes and synergistic effect between radiotherapy and immunotherapy in patients with extensive-stage small cell lung cancer: A real-world study Meiling Sun, Huaijun Ji, Fang Deng, Ning Xu, Yu Li This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-4594148/v1 This work is licensed under a CC BY 4.0 License Status: Published Journal Publication published 30 Sep, 2024 Read the published version in BMC Cancer → Version 1 posted 4 You are reading this latest preprint version Abstract Background Patients with extensive-stage small cell lung cancer (ES-SCLC) experience significant therapeutic challenges and limited survival rates. This study aimed to investigate the efficacy of combining immunotherapy (IT) with chemotherapy (CT) for treating ES-SCLC and to explore the synergistic effect between radiotherapy (RT) and IT. Methods This retrospective analysis examined patients with ES-SCLC who received treatment at three centers. Furthermore, propensity score-matched (PSM) analysis was conducted. The Kaplan‒Meier method and Cox proportional hazards regression were used to compare the survival outcomes. Results A total of 257 eligible patients with ES-SCLC were included in the analysis. Among all patients, the median overall survival (mOS) was 18.0m in the chemoimmunotherapy (CT + IT) group and 15.7m in the CT group ( p = 0.208 ). The median real-world progression-free survival (mrwPFS) was 7.7m and 6.8m (p = 0.043 ) in the CT + IT and CT group, respectively. Moreover, the mOS was 22.0m in the chemoradiotherapy (CT + RT) group and 13.6m in the CT group ( p < 0.001 ). The mrwPFS was 7.4m and 6.0m ( p = 0.175 ) in the CT + RT group and CT group, respectively. The multivariate analyses revealed that sex, liver metastasis and RT were independent prognostic factors for OS (p < 0.05), while liver metastasis and IT were found to be independent predictive factors of rwPFS (p < 0.05). After PSM, the mOS was 23.2m in the CT + IT group and 13.0m in the CT group ( p = 0.008 ). The mrwPFS was 7.3m and 6.2m (p = 0.096) in the CT + IT group and the CT group, respectively. Moreover, the mOS was 21.4m in the CT + RT group and 12.5m in the CT group ( p < 0.001 ). The mrwPFS was 7.3m and 5.2m ( p = 0.220 ) in the CT + RT group and the CT group, respectively. Additionally, our study revealed that in the PD-1 group, RT significantly improved patient survival (36.0m vs. 15.8m, p = 0.041 ). Conclusion An increasing number of treatment options are being explored for ES-SCLC, and CT is the cornerstone of treatment for this disease. Combining CT with IT and RT has demonstrated remarkable efficacy and excellent safety profiles, and such treatments are worthy of further exploration. Extensive-stage small cell lung cancer chemotherapy immunotherapy radiotherapy propensity score matching Figures Figure 1 Figure 2 Figure 3 Figure 4 Figure 5 Background Lung cancer is the malignant tumor with the highest morbidity and mortality rates in China and the world; specifically, small-cell lung cancer (SCLC) accounts for approximately 15% of lung cancer cases [ 1 ]. Clinically, SCLC is classified into extensive-stage SCLC (ES-SCLC) and limited-stage SCLC (LS-SCLC), and it is characterized by rapid proliferation and early development of widespread metastases. Patients with SCLC usually present with ES-SCLC at the time of diagnosis [ 2 ]. In the chemoradiotherapy era, the traditional treatment for SCLC is comprehensive chemotherapy (CT). The median survival time of patients receiving this treatment is reportedly 18–24 months for LS-SCLC patients and only 10–12 months for ES-SCLC patients, with a 5-year survival rate of only 7% [ 3 ]. Recent phase 3 trials of the programmed cell death ligand 1 (PD-L1) inhibitor atezolizumab or durvalumab combined with CT revealed significantly prolonged overall survival (OS) in patients with ES-SCLC [ 4 – 6 ]. In addition, the programmed cell death 1 (PD-1) inhibitor serplulimab plus CT significantly improved OS, and pembrolizumab plus CT prolonged progression-free survival (PFS) [ 7 , 8 ]. In addition, the CREST trial showed that thoracic radiotherapy (TRT) after first-line CT could increase local control rates and improve OS [ 9 ]. Studies have shown that patients who underwent TRT after chemo-immunotherapy (CT + IT) had significantly longer OS and PFS in patients with ES-SCLC [ 10 ]. This study aimed to explore the clinical efficacy and safety of IT and radiotherapy (RT) in ES-SCLC patients in the real world. Methods Data collection We retrospectively extracted data from the electronic health records of patients with ES-SCLC who received first-line CT with or without immunotherapy (IT) from April 2016 to August 2023 across three public tertiary hospitals (Weihai Municipal Hospital, Qilu Hospital of Shandong University Dezhou Hospital and Qilu Hospital Affiliated to Shandong University). The patients’ basic information was collected. All data were obtained from clinical medical records and followed up from the date of diagnosis until the date of all-cause death or up to the latest available follow-up. Patient selection (1) The inclusion criteriawere as follows: aged 18 years or older; had an ECOG PS ranging from 0 to 3; had a pathological diagnosis of SCLC; and had undergone at least two cycles of chemotherapy. (2) The exclusion criteria were as follows: no clear pathological diagnosis information; patients with other tumors at the same time; ECOG PS >3; less than 2 cycles of chemotherapy; no efficacy evaluation after treatment or loss to follow-up; and autoimmune diseases. Efficacy assessment The response to therapies was evaluated based on imaging examinations according to the Response Evaluation Criteria in Solid Tumors version 1.1. The primary endpoint was OS, which was defined as the time from the date of chemotherapy initiation to all-cause mortality or censored on the date of the last follow-up. The secondary endpoint was rwPFS, which was defined as the time from chemotherapy initiation to tumor progression, death from no progression or the last follow-up. Adverse effects were assessed based on the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0. The patients were followed up by consulting outpatient records, hospitalization medical records, and telephone inquiries. The latest follow-up date was January 31, 2024. Statistical analysis Standard descriptive statistics or contingency tables were used for demographic and baseline characteristics. Proportions were compared between groups using the chi-squared test. Propensity score matching was conducted using a 1:1 matching design with a tolerance of 0.02. A logistic regression model was constructed to estimate the propensity score, which included the following covariates: age, sex, smoking history, hypertension status, diabetes status, ECOG PS score, brain metastasis status, liver metastasis status, bone metastasis status, lung metastasis status, adrenal gland metastasis status, chemotherapy status and radiotherapy status. Kaplan-Meier analysis was performed to estimate the survival rate, and the log-rank test was performed to test the differences in survival distribution. To investigate predictors of OS and rwPFS, univariate and multivariate Cox regression models were used. All the statistical analyses were performed using SPSS version 27.0. P<0.05 was considered to indicate statistical significance. Ethical statement This program was performed in accordance with the principles of good clinical practice and was approved by the institutional review board of each hospital. Because this study was retrospective, informed consent from the included patients was not required, and patient information was anonymized. Results Data collection A total of 495 patients were initially screened, 183 patients with LS-SCLC were excluded, 19 patients were excluded because of less than 2 cycles of CT or less than 2 cycles of IT, 13 patients were excluded because they did not receive first-line IT, and 23 patients were excluded because both OS and rwPSF were uncertain. A total of 257 eligible patients were included in the analysis. A total of 105 patients had both OS and rwPSF data , 81 patients had only OS data, and 71 patients had only rwPFS data. Overall, OS data from 186 patients were analyzed, including 106 patients who received CT alone and 80 patients who received CT+IT. Additionally, rwPFS data from 176 patients were analyzed, including 97 patients who received CT alone and 79 patients who received CT+IT. (Figure 1) Figure 1. Diagram of patient's selection process Baseline characteristics OS The median age was 65 years (32-85). The majority of patients were males (75.8%). The ECOG PS0-1 group constituted 95.2% of the cohort. Brain metastasis was present in 20.4% of the cohort, liver metastasis was present in 21.0%, bone metastasis was present in 28.0%, lung metastasis was present in 19.9% and adrenal gland metastasis was present in 9.1%. Among them, CT combined with RT accounted for 46.8% of the treatment regimens, while CT combined with IT accounted for 43.0%. The CT regimen used for 174 patients was carboplatin (n = 67) or cisplatin (n =107) combined with etoposide; 8 patients received nedaplatin combined with etoposide, and 4 patients received irinotecan combined with cisplatin. (Table 1) Regarding IT, 35 patients received PD-1 (including 17 who received tislelizumab, 5 who received serplulimab, 5 who received camrelizumab, 3 who received sintilimab, 3 who received pembrolizumab, 1 who received toripalimab and 1 who received penpulimab), and 45 patients received PD-L1 (including 34 who received durvalumab, 7 who received atezolizumab and 4 who received adebrelimab). The radiation dose was decided by a doctor based on the guidelines of the Chinese Society of Clinical Oncology guidelines or National Comprehensive Cancer Network. The total radiation dose ranged from 30 Gy to 60 Gy, with a median dose of 45 Gy. rwPFS The median age of this group was 65 years (41-85). Most of the patients were males (75.6%). The ECOG PS0-1 group accounted for 96.0% of the cohort. Brain metastasis was present in 28.7% of the cohort, liver metastasis was present in 22.7%, bone metastasis was present in 30.1%, lung metastasis was present in 28.7% and adrenal gland metastasis was present in 8.5%. Among them, the combination of CT with RT accounted for 52.8% of the treatment regiemnts, and CT plus IT accounted for 44.9%. The CT regimens used for 166 patients were carboplatin (n = 56) or cisplatin (n =110) combined with etoposide; 4 patients received nedaplatin combined with etoposide; 2 patients received irinotecan combined with cisplatin; 2 patients received irinotecan combined with carboplatin; and 2 patients received the single agent etoposide. (Table 1) Regarding IT, 37 patients received PD-1 (including 3 who received sintilimab, 3 who received pembrolizumab, 18 who received tislelizumab, 6 who received camrelizumab, 3 who received serplulimab, 2 who received toripalimab and 2 who received penpulimab) and 42 received PD-L1 (including 28 who received durvalumab, 9 who received atezolizumab and 5 who received adebrelimab). Table 1. Baseline characteristics of patients before and after PSM according to first-line therapy. OS Before matching, n (%) After matching, n (%) After matching, n (%) Characteristics All patients N=186(%) CT+IT N=80(43.0) CT N=106(57.0) P -Value All patients N=120(%) CT+IT N=60(%) CT N=60(%) P-value All patients N=122 (%) CT+RT N=61(%) CT N=61(%) P -Value Median age 65(32-85) 65(32-85) 65(44-81) 65(32-85) 65(32-85) 64.5(44-81) Age, year 0.550 0.713 0.856 ≤65 yrs 100(53.8) 41(51.3) 59(55.7) 68(56.7) 33(55.0) 35(58.3) 63(51.6) 32(52.5) 31(50.8) ＞65 yrs 86(46.2) 39(48.7) 47(44.3) 52(43.3) 27(45.0) 25(41.7) 59(48.4) 29(47.5) 30(49.2) Gender 0.022 1.0 0.523 Female 45(24.2) 26(32.5) 19(17.9) 30(25.0) 15(25.0) 15(25.0) 29(23.8) 16((26.2) 13(21.3) Male 141(75.8) 54(67.5) 87(72.1) 90(75.0) 45(75.0) 45(75.0) 93(76.2) 45(73.8) 48(78.7) Smoking history 0.519 0.709 0.856 Never smoked 81(43.5) 37(46.3) 44(41.5) 48(40.0) 25(41.7) 23(38.3) 57(46.7) 29(47.5) 28(45.9) Former/current 105(56.5) 43(53.7) 62(58.5) 72(60.0) 35(58.3) 37(61.7) 65(53.3) 32(52.5) 33(54.1) Family tumor history 0.100 0.068 0.839 No 140(75.3) 65(81.2) 75(70.8) 86(71.7) 48(80.0) 38(63.3) 89(73.0) 44(72.1) 45(73.8) Yes 46(24.7) 15(18.8) 31(29.2) 34(28.3) 12(20.0) 22(36.7) 33(27.0) 17(27.9) 16(26.2) Hypertension 0.626 1.0 1.0 No 129(69.4) 57(71.3) 72(67.9) 86(71.7) 43(71.7) 43(71.7) 84(68.9) 42(68.9) 42(68.9) Yes 57(30.6) 23(28.7) 34(32.1) 34(28.3) 17(28.3) 17(28.3) 38(31.1) 19(31.1) 19(31.1) Diabetes 0.871 1.0 0.610 No 159(85.5) 68(85.0) 91(85.8) 104(86.7) 52(86.7) 52(86.7) 104(85.2) 53(86.9) 51(83.6) Yes 27(14.5) 12(15.0) 15(14.2) 16(13.3) 8(13.3) 8(13.3) 18(14.8) 8(13.1) 10(16.4) ECOG PS 0.584 0.648 1.0 0-1 177(95.2) 77(96.3) 100(94.3) 115(95.8) 58(96.7) 57(95.0) 120(98.4) 60(98.4) 60(98.4) 2 9(4.8) 3(3.7) 6(5.7) 5(4.2) 2(3.3) 3(5.0) 2(1.6) 1(1.6) 1(1.6) Brain Metastasis 0.329 1.0 0.783 No 148(79.6) 61(76.3) 87(82.1) 94(78.3) 47(78.3) 47(78.3) 107(87.8) 53(86.9) 54(88.5) Yes 38(20.4) 19(23.7） 19(17.9) 26(21.7) 13(21.7) 13(21.7) 15(12.2) 8(13.1) 7(11.5) Liver Metastasis 0.057 0.827 0.817 No 147(79.0) 58(72.5) 89(84.0) 93(77.5) 47(78.3) 46(76.7) 99(81.1) 50(82.0)） 49(80.3) Yes 39(21.0) 22(27.5) 17(16.0) 27(22.5) 13(21.7) 14(23.3) 23(18.9) 11(18.0) 12(19.7) Bone Metastasis 0.385 0.559 0.832 No 134(72.0) 55(68.8) 79(74.5) 81(67.5) 42(70.0) 39(65.0) 93(76.2) 47(77.0) 46(75.4) Yes 52(28.0) 25(31.2) 27(25.5) 39(32.5) 18(30.0) 21(35.0) 29(23.8) 14(23.0) 15(24.6) Lung Metastasis 0.010 1.0 0.667 No 149(80.1) 71(88.8) 78(73.6) 102(85.0) 51(85.0) 51(85.0) 94(77.0) 48(78.7) 46(75.4) Yes 37(19.9) 9(11.2) 28(26.4) 18(15.0) 9(15.0) 9(15.0) 28(23.0) 13(21.3) 15(24.6) Adrenal gland Metastasis 0.058 0.697 0.464 No 169(90.9) 69(86.3) 100(94.3) 113(94.2) 56(93.3) 57(95.0) 114(93.4) 58(95.1) 56(91.8) Yes 17(9.1) 11(13.7) 6(5.7) 7(5.8) 4(6.7) 3(5.0) 8(6.6) 3(4.9) 5(8.2) Radiotherapy 0.310 1.0 Yes 87(46.8) 34(42.5) 53(50.0) 56(46.7) 28(46.7) 28(46.7) No 99(53.2) 46(57.5) 53(50.0) 64(53.3) 32(53.3) 32(53.3) Immunotherapy 0.127 Yes 80(43.0%) 60(50.0%) 42(34.4) 25(41.0) 17(27.9) No 106(57.0%) 60(50.0%) 80(65.6) 36(59.0) 44(72.1) Chemotherapy 0.836 0.618 0.069 EC 67(36) 27(33.8) 40(37.7) 41(34.2) 18(30.0) 23(38.3) 42(34.4) 18(29.5) 24(39.3) EP 107(57.5) 48(60.0) 59(55.7) 71(59.1) 38(63.3) 33(55.0) 71(58.2) 41(67.2) 30(49.2) Other 12(6.5) 5(6.2) 7(6.6) 8(6.7) 4(6.7) 4(6.7) 9(7.4) 2(3.3) 7(11.5) rwPFS Before matching, n (%) After matching, n (%) After matching, n (%) Characteristics All patients N=176(%) CT+IT N=79(%) CT N=97(%) P -Value All patients N=116(%) CT+IT N=58(%) CT N=58(%) P-value All patients N=114 (%) CT+RT N=57(%) CT N=57(%) P -Value Median age 65(41-85) 64(45-85) 65(41-81) 65(41-85) 65(32-85) 64.5(44-81) Age, year 0.888 0.264 0.183 ≤65 yrs 97(55.1) 44(55.7) 53(54.6) 62(53.5) 34(58.6) 28(48.3) 67(58.8) 37(64.9) 30(52.6) ＞65 yrs 79(44.9) 35(44.3) 44(45.4) 54(46.5) 24(41.4) 30(51.7) 47(41.2) 20(35.1) 27(47.4) Gender 0.044 1.0 0.372 Female 43(24.4) 25(31.6) 18(18.6) 30(25.9) 15(25.9) 15(25.9) 26(22.8) 15(26.3) 11(19.3) Male 133(75.6) 54(68.4) 79(71.4) 86(74.1) 43(74.1) 43(74.1) 88(77.2) 42(73.7) 46(80.7) Smoking history 0.733 0.849 0.704 Never smoked 76(43.2) 33(41.8) 43(44.3) 45(38.8) 22(37.9) 23(39.7) 48(42.1) 25(43.9) 23(40.4) Former/current 100(56.8) 46(58.2) 54(55.7) 71(61.2) 36(62.1) 35(60.3) 66(57.9) 32(56.1) 34(59.6) Family tumor history 0.361 0.150 0.663 No 130(73.9) 61(77.2) 69(71.1) 83(71.6) 45(77.6) 38(65.5) 86(75.4) 42(73.7) 44(77.2) Yes 46(26.1) 18(22.8) 28(28.9) 33(28.4) 13(22.4) 20(34.5) 28(24.6) 15(26.3) 13(22.8) Hypertension 0.626 1.0 0.317 No 117(66.5) 51(64.6) 66(68.0) 72(62.1) 36(62.1) 36(62.1) 77(67.5) 36(63.2) 41(71.9) Yes 59(33.5) 28(35.4) 31(32.0) 44(37.9) 22(37.9) 22(37.9) 37(32.5) 21(36.8) 16(28.1) Diabetes 0.711 0.623 0.802 No 149(84.7) 66(83.5) 83(85.6) 96(82.8) 49(84.5) 47(81.0) 95(83.3) 47(82.5) 48(84.2) Yes 27(15.3) 13(16.5) 14(14.4) 20(17.2) 9(15.5) 11(19.0) 19(16.7) 10(17.5) 9(15.8) ECOG PS 0.506 0.309 0.079 0-1 169(96.0) 75(94.9) 94(96.9) 112(96.6) 57(98.3) 55(94.8) 111(97.4) 57(100) 54(94.7) 2 7(4.0) 4(5.1) 3(3.1) 4(3.4) 1(1.7) 3(5.2) 3(2.6) 0(0) 3(5.3) Brain Metastasis 0.044 0.623 0.646 No 143(81.3) 59(74.7) 84(86.6) 96(82.8) 49(84.5) 47(81.0) 90(78.9) 44(77.2) 46(80.7) Yes 33(28.7) 20(25.3) 13(13.4) 20(17.2) 9(15.5) 11(19.0) 24(21.1) 13(22.8) 11(19.3) Liver Metastasis 0.143 0.816 0.395 No 136(77.3) 57(72.2) 79(81.4) 93(80.2) 46(79.3) 47(81.0) 84(73.7) 40(70.2) 44(77.2) Yes 40(22.7) 22(27.8) 18(18.6) 23(19.8) 12(20.7) 11(19.0) 30(26.3) 17(29.8) 13(22.8) Bone Metastasis 0.689 0.844 0.558 No 123(69.9) 54(68.4) 69(71.1) 77(66.4) 39(67.2) 38(65.5) 73(64.0) 35(61.4) 38(66.7) Yes 53(30.1) 25(31.6) 28(28.9) 39(33.6) 19(32.8) 20(34.5) 41(36.0) 22(38.6) 19(33.3) Lung Metastasis 0.275 1.0 0.590 No 143(81.3) 67(84.4) 76(78.4) 94(81.0) 47(81.0) 47(81.0) 98(86.0) 48(84.2) 50(87.7) Yes 33(28.7) 12(15.6) 21(21.6) 22(19.0) 11(19.0) 11(19.0) 16(14.0) 9(15.8) 7(12.3) Adrenal gland Metastasis 0.076 1.0 0.728 No 161(91.5) 69(87.3) 92(94.8) 108(93.1) 54(93.1) 54(93.1) 105(92.1) 52(91.2) 53(93.0) Yes 15(8.5) 10(12.7) 5(5.2) 8(6.9) 4(6.9) 4(6.9) 9(7.9) 5(8.8) 4(7.0) Radiotherapy 0.256 1.0 Yes 93(52.8) 38(48.1) 55(56.7) 54(46.6) 27(46.6) 27(46.6) 57(50.0) No 83(47.2) 41(51.9) 42(43.3) 62(53.4) 31(53.4) 31(53.4) 57(50.0) Immunotherapy 0.450 Yes 79(44.9) 58(50.0) 50(43.9) 27(47.4) 23(40.4) No 97(55.1) 58(50.0) 64(56.1) 30(52.6) 34(59.6) chemotherapy 0.812 0.893 0.925 EC 56(31.8) 27(34.2) 29(29.9) 35(30.2) 18(31.0) 17(29.3) 30(26.3) 15(26.3) 15(26.3) EP 110(62.5) 48(60.8) 62(63.9) 74(63.8) 36(62.1) 38(65.5) 77(67.5) 39(68.4) 38(66.7) Other 10(5.7) 4(5.0） 6(6.2) 7(6.0) 4(6.9) 3(5.2) 7(6.2) 3(5.3) 4(7.0) Survival analysis OS A total of 186 patients were included in the OS analysis. The median OS (mOS) was 16.5 months (95% CI 16.0-23.7) for all patients. The 1-year and 5-year OS rates were 66.2% and 7.0%, respectively. (Table 2) Table 2. The survival rate of OS and rwPFS. OS (n=186) rwPFS (n=176) Time 1-year 2-year 3-year 4-year 5-year 6-month 12-month 18-month All patients 66.2% 33.7% 17.2% 11.1% 7.0% 59.0% 13.9% 6.8% CT+IT 72.5% 42.7% 22.9% 11.4% 0 63.2% 19.8% 12.1% CT 61.8% 28.6% 14.4% 10.2% 7.3% 55.7% 9.3% 3.1% CT+RT 75.4% 43.8% 28.5% 19.8% 12.3% 68.8% 14.3% 6.2% CT 58.0% 23.7% 4.7% 0 0 48.1% 13.6% 7.7% Among these patients, 80 (43.0%) received CT+IT, and 106 (57.0%) were treated with CT alone. During the follow-up period, 138 (74.2%) patients reached the primary endpoint, including 48 (60.0%) in the CT+IT group and 90 (84.9%) in the CT-alone group. There were no significant differences in OS between patients who received CT+IT and those who received CT alone (18.0 m vs. 15.7 m, respectively; p = 0.208). The 1-year OS rates in the CT+IT and CT alone group were 72.5% and 61.8%, respectively; the 2-year OS rates were 42.7% and 28.6%, respectively, and the 3-year OS rates were 22.9% and 14.4%, respectively. In addition, 87 (46.8%) patients received chemoradiotherapy (CT+RT), and 99 (53.2%) patients were treated with CT alone. During the follow-up period, 62 (71.7%) patients in the CT+RT group and 76 (76.8%) in the CT-alone group reached the primary endpoint. Patients who received RT had a better prognosis (22.0 m; 95% CI [16.1-27.9] vs. 13.6 m; 95% CI [10.8-16.4]; p <0.001). The 1-year OS rates in the CT+RT and CT alone group were 75.4% and 58.0%, respectively; the 2-year OS rates were 43.8% and 23.7%, respectively; and the 3-year OS rates were 28.5% and 4.7%, respectively. (Figure 2, Table 2) Figure 2. (A)Kaplan-Mier curves showing OS based on immunotherapy. (B) Kaplan-Mier curves showing PFS based on immunotherapy. (C) Kaplan-Mier curves showing OS based on radiotherapy. (D) Kaplan-Mier curves showing PFS based on radiotherapy. Univariate survival analysis was used to determine the associations between OS and clinical features. Sex (p=0.002), liver metastasis (p=0.015), and radiotherapy (p<0.001) were found to be significant prognostic factors for OS. Multivariate analysis revealed that sex (HR, 0.571; 95% CI [0.370-0.882]; p=0.011), liver metastasis (HR, 0.661; 95% CI [0.444-0.984]; p=0.041), and radiotherapy (HR, 0.524; 95% CI [0.367-0.748]; p<0.001) were independent prognostic factors for OS. (Table 3) Table 3. Analysis of potential risk factors for OS and rwPFS using univariate and multivariate Cox proportional hazard models Characteristics OS rwPFS Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis HR (95% CI) P -Value HR (95% CI) P -Value HR (95% CI) P -Valu HR (95% CI) P -Value Age, year(≤65 yrs vs. >65 yrs) 0.846(0.622-1.152) 0.289 Gender(Female vs. Male) 0.509(0.331-0.782) 0.002 0.571(0.370-0.882) 0.011 0.722(0.501-1.040) 0.080 Smoking history(Never vs. Former/current) 0.719(0.514-1.007) 0.055 0.863(0.633-1.176) 0.351 Family tumor history(No vs. Yes) 1.189(0.795-1.778) 0.398 1.093(0.769-1.552) 0.620 Hypertension(No vs. Yes) 0.994(0.658-1.354) 0.755 1.146(0.827-1.589) 0.413 Diabetes(No vs. Yes) 0.737(0.463-1.175) 0.200 0.714(0.469-1.088) 0.117 ECOG PS(0-1 vs. ≥2) 0.704(0.344-1.441) 0.337 0.881(0.412-1.883) 0.744 Brain Metastatic(No vs. Yes) 1.056(0.688-1.620) 0.802 0.897(0.609-1.320) 0.580 Liver Metastatic(No vs. Yes) 0.612(0.412-0.908) 0.015 0.661(0.444-0.984) 0.041 0.621(0.434-0.889) 0.009 0.609(0.425-0.872) 0.007 Bone Metastatic(No vs. Yes) 0.855(0.590-1.239) 0.408 1.145(0.819-1.600) 0.429 Lung Metastatic(No vs. Yes) 0.972(0.645-1.465) 0.892 0.939(0.631-1.397) 0.756 Adrenal gland Metastasis(No vs. Yes) 1.184(0.622-2.256) 0.607 0.969(0.549-1.170) 0.914 Radiotherapy(Yes vs. No) 0.497(0.349-0.708) <0.001 0.524(0.367-0.748) <0.001 0.812(0.597-1.104) 0.184 Immunotherapy(Yes vs. No) 0.799(0.561-1.138) 0.214 0.730(0.535-0.998) 0.048 0.716(0.524-0.979) 0.037 Chemotherapy(EC vs. EP) 1.360(0.950-1.947) 0.093 1.132(0.811-1.579) 0.468 rwPFS A total of 176 patients were included in the rwPFS analysis. The median rwPFS (mrwPFS) was 7.0 months (95% CI 6.5-7.5) for all patients. The 6-month, 12-month and 18-month PFS rates were 59.0%, 13.9% and 6.8%, respectively. (Table 2) Among these patients, 79 (44.9%) received CT+IT, and 97 (55.1%) were treated with CT alone. During the follow-up period, 166 (94.3%) patients reached the endpoint: 69 (87.3%) in the CT+IT group and 97 (100%) in the CT-alone group. The mrwPFS was 7.7 months (95% CI [6.8-8.6]) in the CT+IT cohort and 6.8 months (95% CI [6.1-7.5]) in the CT-alone cohort ( p=0.043 ). The 6-month rwPFS rates in the CT+IT and CT alone group were 63.2% and 55.7%, respectively; the 12-month rwPFS rates were 19.8% and 9.3%, respectively; and the 18-month rwPFS rates were 12.1% and 3.1%, respectively. In addition, 93 (52.8%) patients received CT+RT, and 83 (47.2%) were treated with CT alone. During the follow-up period, 90 (96.8%) patients in the CT+RT group and 76 (91.6%) in the CT-alone group reached the endpoint. There were no significant differences in rwPFS between the two groups (7.4 m vs. 6.0 m, p = 0.175). The 6-month rwPFS rates in the CT+RT and CT alone group were 68.8% and 48.1%, respectively; the 12-month rwPFS rates were 14.3% and 13.6%, respectively; and the 18-month rwPFS rates were 6.2% and 7.7%, respectively. (Figure 2, Table 2) Univariate analysis revealed that liver metastasis (p=0.009) and immunotherapy (p=0.048) were significant prognostic factors for rwPFS. Multivariate analysis revealed that liver metastasis (HR, 0.609; 95% CI [0.425-0.872]; p=0.007) and immunotherapy (HR, 0.716; 95% CI [0.524-0.979]; p=0.037) were independent prognostic factors for rwPFS. (Table 3) Survival outcomes after PSM OS To reduce the interference of confounding factors and potential biases, PSM was carried out. PSM was used to match the CT+IT group and the CT group. A total of 60 pairs completed PSM, with comparable baseline characteristics. The mOS was 23.2 m (95% CI [15.1-31.3]) in the CT+IT cohort and 13.0 m (95% CI [10.3-15.7]) in the CT cohort ( p=0.008 ). Similarly, PSM was also used to match the CT+RT group and the control group. Among the 61 pairs completed, the mOS was 21.4 m (95% CI [13.4-29.4]) in the CT+RT group and 12.5 m (95% CI [11.2-13.8]) in the control cohort ( p <0.001 ). (Figure 3, Table 1) Figure 3.(A)Kaplan-Mier curves showing OS based on immunotherapy after PSM. (B) Kaplan-Mier curves showing PFS based on immunotherapy after PSM. (C) Kaplan-Mier curves showing OS based on radiotherapy after PSM. (D) Kaplan-Mier curves showing PFS based on radiotherapy after PSM. rwPFS PSM was used to match the CT+IT group and the control group. Among the 58 pairs that were subjected to PSM, there was no significant difference in the mrwPFS (7.3 m; 95% CI [6.5-8.1] vs. 6.2 m; 95% CI [5.5-6.9]; p =0.096) , but we found that IT tended to improve PFS . Similarly, PSM was also used to match the CT+RT group and the control group. Among the 57 pairs that were subjected to PSM, the mrwPFS was not significantly different (7.3 m vs. 5.2 m, p = 0.220) . (Figure 3, Table 1) Survival Outcomes in Selected Patient Subgroups Division into four groups according to RT and IT We divided all patients into four groups: 34 patients in the RT+IT group, 53 in the RT group, 46 in the IT group, and 53 in the CT-alone group. The mOS for these groups was 25.0 m, 21.4 m, 16.6 m, and 12.0 m, respectively. The three groups showed significant improvements in OS compared with the CT-alone group ( p<0.001, p<0.001, p=0.021 ), but there was no significant difference among the 3 groups. In terms of rwPFS, there were 38 patients in the RT+IT group, 55 in the RT group, 41 in the IT group, and 42 in the CT group. The mrwPFS for these groups was 7.8 m, 7.1 m, 6.8 m, and 5.3 m, respectively. Similarly, the 3 groups showed significant improvements in PFS compared with the CT-alone group ( p=0.005, p=0.005, p=0.015 ), and there was no significant difference among the 3 groups. (Figure 4, Table 4) Figure 4. (A) Kaplan-Mier curves showing OS about four groups. (B) Kaplan-Mier curves showing PFS about four groups. (C) Kaplan-Mier curves showing OS in the PD-1 group. (D) Kaplan-Mier curves showing OS based on radiotherapy combined with PD-1/PD-L1 inhibitors. Table 4. Survival outcomes of four groups OS rwPFS N mOS RT IT CT N mPFS RT IT CT RT+IT 34 25.0 0.951 0.149 <0.001 38 7.8 0.589 0.895 0.005 RT 53 21.4 0.148 <0.001 55 7.1 0.571 0.005 IT 46 16.6 0.021 41 6.8 0.015 CT 53 12.0 42 5.3 Comparison of PD-1 inhibitors, PD-L1 inhibitors and radiotherapy For OS, 80 patients received IT, including 35 patients in the PD-1 group and 45 patients in the PD-L1 group, and the mOS was 23.2 m versus 18.0 m (p=0.380). In the PD-1 group, RT significantly improved patient survival (36.0 m vs. 15.8 m, p=0.041 ). The same results were not observed in the PD-L1 group (15.0 m vs. 21.0, p=0.926). In addition, 34 patients received RT, 46 did not receive RT, and the mOS was 25.0 m versus 16.6 m (p=0.149). In the RT group, PD-1 inhibitors tended to improve OS compared with PD-L1 inhibitors (36.0 m vs. 15.0 m, p=0.086 ). (Figure 4-5, Table 5) Figure 5. (A) The bar chart showing OS comparison of PD-1/PD-Ll inhibitors and radiotherapy. (B) Treatment-related adverse events in all ES-SCLC patients. Table 5. Comparison of PD-1 inhibitors, PD-L1 inhibitors and radiotherapy OS rwPFS N mOS P -Value mOS P -Value N mrwPFS P -Value mrwPFS P -Value PD-1 IT 19 15.8 0.041 23.2 0.380 16 5.9 0.505 8.3 0.785 RT+IT 16 36.0 21 9.2 PD-L1 IT 27 21.0 0.926 18.0 25 6.8 0.817 7.0 RT+IT 18 15.0 17 7.3 RT+IT PD-1 16 36.0 0.085 25.0 0.149 21 9.2 0.571 7.8 0.895 PD-L1 18 15.0 17 7.3 IT PD-1 19 15.8 0.533 16.6 16 5.9 0.540 6.8 PD-L1 27 21.0 25 6.8 For rwPFS, 79 patients received IT, including 37 patients in the PD-1 group and 42 patients in the PD-L1 group, and thirty-eight patients received RT. We found that treatment with PD-1 inhibitors combined with RT (9.2 m vs. 5.9 m) prolonged the mrwPFS more than treatment with PD-L1 inhibitors (7.3 m vs. 6.8 m), but there were no significant differences (p>0.05). Additionally, patients who underwent RT had longer mPFS when treated with PD-L1 inhibitors were combined with RT, whereas those who did not receive RT had longer mPFS in the PD-L1 group. This finding is similar to the results obtained in the OS analysis (p>0.05).( Table 5) Synchronous and sequential radiotherapy For OS, a total of 87 patients received RT. After excluding 1 patient who received prophylactic cranial irradiation, the mOS for synchronous (n=15) and sequential (n=71) RT was 31.0 m versus 18.0 m (p=0.854). After excluding 21 patients who received brain radiation and 2 who received bone radiation, a total of 63 patients received thoracic radiotherapy (TRT), and the mOS for synchronous (n=11) and sequential (n=52) TRT was 32.0 m and 25.0 m, respectively (p=0.955). To eliminate the impact of IT on RT, we further analyzed the survival of patients who did not receive IT. The results also showed no statistically significant difference (32.0 m vs. 24.0 m, p=0.925). Similarly, in the analysis of the PFS population, no favorable outcomes were observed.( Table 6) Table 6. Synchronous and sequential radiotherapy N mOS P -Value mOS N mrwPFS P -Value mrwPFS RT synchronous 15 31.0 0.854 22.0 13 7.3 0.806 7.4m sequential 71 18.5 79 7.4 TRT synchronous 11 32.0 0.955 28.5 11 7.3 0.466 8.0m sequential 52 25.0 56 8.0 RT(no IT) synchronous 10 23.2 0.913 18.5 7 7.0 0.722 7.0m sequential 42 18.0 47 7.1 TRT(no IT) synchronous 8 32.0 0.925 24.0 6 7.0 0.495 8.0m sequential 30 24.0 33 8.0 Treatment-related adverse events (trAEs) Among all eligible patients, 207 (80.5%) experienced at least one trAE, including 124 (48.2%) with grades 1-2 and 83 (32.3%) with grades 3-4. The rates of trAEs in the 4 groups were not significantly different (p = 0.385). No patient exhibited grade 5 trAEs. Pneumonitis and esophagitis were the most common immune-related or radiation-related toxicities. Eleven patients developed grade 3 pneumonitis, and 4 patients developed grade 3 esophagitis.( Table 7, Figure 5) Table 7. Treatment-related adverse event Total(257) RT+IT(53) RT(72) IT(63) CT(69) P -Value No 50(19.5%) 10(18.9%) 9(12.5%) 16(25.4%) 15(21.7%) 0.385 Grade 1-2 124(48.2%) 23(43.4%) 35(48.6%) 31(49.2%) 35(50.7%) Grade 3-4 83(32.3%) 20(37.7%) 28(38.9%) 16(25.4%) 19(27.6%) Pneumonia 11(4.3%) 5(9.4%) 3(4.2%) 3(4.8%) 0 Esophagitis 4(1.6%) 2(3.8%) 1(1.4%) 1(1.6%) 0 Discussion ES-SCLC represents a particularly challenging subset of lung cancer characterized by a poor prognosis and limited therapeutic options. Platinum-based chemotherapy (CT) has been the mainstay treatment for ES-SCLC patients. Despite the achievement of objective response rates ranging from 50-70%, the median survival time is limited to 9-12 months, with a dismal 5-year survival rate of less than 7% owing to rapid progression posttreatment resistance [11]. Recently, the most promising development in the treatment of ES-SCLC was the addition of immunotherapy (IT) to standard platinum-based first-line CT. Various clinical trials, including Checkmate032, Keynote028, IMpower133, ASTRUM005 and CASPIAN, have explored the safety and efficacy of anti-PD-1/PD-L1 therapy in SCLC patients, demonstrating encouraging outcomes marked by significant enhancements in survival metrics compared to historical data with CT alone [4, 5, 8, 12, 13]. Based on the results of these clinical studies, the relevant diagnosis and treatment guidelines approved PD-1/PD-L1 inhibitors combined with CT for the first-line treatment of ES-SCLC. However, the clinical benefits of IT in real-world patients with ES-SCLC are still worth exploring. Therefore, we conducted a real-world study to investigate the application of IT in patients with ES-SCLC. Our study demonstrated that in terms of OS, there was no significant improvement in the CT+IT group compared to the CT-alone group in the entire cohort (18.0 m vs. 15.7 m, p = 0.208). Due to the baseline imbalance between the two groups, we conducted PSM and ultimately matched 60 pairs of data. Further analysis revealed a significant increase of 9.8 months in survival time for the CT+IT group compared to the CT-alone group (23.2 months vs. 13.0 months, p=0.008 ). Regarding rwPFS, there was a significant improvement in the CT+IT group compared to the CT-alone group in the overall cohort (7.7 m vs. 6.8 m, p=0.043 ), and IT tended to improve rwPFS in the matched cohort (7.3 m vs. 6.2 m, p =0.096). It is worth noting that our OS outcomes in patients treated with CT+IT were numerically better than those in some prospective studies, such as the IMpower133, CASPIAN, CAPSTONE-1 and ASTRUM-005 studies [4, 5, 8, 14], and retrospective studies (17.3 m vs. 13.4 m; p = 0.001) [15]. Similarly, our study data surpass those of several prospective studies on the mrwPFS, such as the mPFS of the IT group and CT group, which were 4.5-5.8 months and 4.3-5.6 months, respectively. This could be attributed to approximately half of the patients receiving RT in our study. Previously, the CREST trial showed that thoracic radiotherapy (TRT) after first-line CT could increase local control rates and improve OS [9]. In the era of CT, several prospective studies and meta-analyses have demonstrated that consolidative TRT offers survival benefits in comparison with CT alone [16,17]. Moreover, studies have shown that RT can prolong the survival of patients with SCLC [18, 19]. Our research revealed that in terms of OS, both in the overall population and in the 61 matched pairs, RT significantly extended the OS of patients with ES-SCLC (22.0 m vs. 13.6 m, p<0.001 ; 21.4 m vs. 12.5 m, p<0.001 ). These findings are consistent with previous research. Regarding rwPFS, no significant benefit was observed in either the overall cohort (7.4 m vs. 6.0 m, p = 0.175 ) or the matched cohort (7.3 m vs. 5.2 m, p = 0.220) , which may be due to the heterogeneity in the timing of RT in our retrospective study. Furthermore, subgroup analysis suggested that synchronous RT may confer greater benefits with or without IT for ES-SCLC patients, although this difference did not reach statistical significance (31.0 m vs. 18.5 m; p=0.854). Previous studies have demonstrated that both PD-1 and PD-L1 inhibitors combined with CT can prolong the survival of patients with ES-SCLC. One meta-analysis suggested that anti-PD-1 agents and anti-PD-L1 agents are likely to have comparable effectiveness [20]. Another meta-analysis revealed that compared with anti-PD-L1 agents, anti-PD-1 agents were linked to favorable survival results [21]. For anti-PD-1 agents, the RATIONAL-312 study suggested that the OS of patients treated with tislelizumab combined with CT reached 15.5 months [22]; in the ASTRUM-005 study, the OS of patients treated with serplulimab reached 15.4 months [8]; in the EXTENTORCH study, the OS of patients treated with toripalimab reached 14.6 months [23]. Regarding anti-PD-L1 agents, the IMpower133 study showed that the OS of patients treated with atezolizumab reached 12.3 months [5]; in the CASPIAN study, the OS of patients treated with durvalumab reached 12.9 months [4]; and in the CAPSTONE-1 study, the OS of patients treated with adebrelimab reached 15.3 months [15]. The first large prospective real-world study The ORIENTAL study was the first large, prospective, real-world study on this topic and reported that theOS of ES-SCLC patients treated with durvalumab reached 14.8 months. These studies suggest that there is a trend toward stronger improvement with anti-PD-1 agents than with anti-PD-L1 agents [24]. According to our findings, no significant difference was observed between patients who received anti-PD-1 agents and those who received anti-PD-L1 agents, although the survival was longer in the PD-1 group (23.2 m vs. 18.0 m, p=0.380). However, after controlling for the effect of RT, we found that there appeared to be a greater survival benefit with anti-PD-L1 agents than with anti-PD-1 agents (21.0 m vs. 15.8 m, p=0.533). A similar trend was observed for rwPFS. This suggests that there is an interaction effect between RT and IT in the treatment of ES-SCLC. Daher et al. showed that patients who underwent TRT after IT had a significantly longer OS (27.7 m vs. 13.2 m, p < 0.007) and PFS (8.5 m vs. 5.6 m, p < 0.003), with an acceptable safety profile in patients with ES-SCLC [25]. In addition, studies have demonstrated that RT has the potential to increase the expression of tumor antigens on the surface of tumor cells and enhance the binding of antibodies to tumor cells, and IT could enhance the abscopal effect of RT [26, 27]. Several preclinical and clinical investigations have indicated that the combination of RT and IT can bolster local control and improve systemic antitumor immune responses through synergistic mechanisms [27,28]. The LEAD study, presented at this year's ELCC, highlighted the feasibility and potential application of combining systemic therapy with local treatments in clinical practice [29]. According to our subgroup analysis, the mOS was 25.0 m for the RT+IT+CT group, 21.4 m for the RT+CT group, 16.6 m for the IT+CT group and 12.0 m for the CT group. Moreover, our research revealed that the combination of anti-PD-1 agents with RT significantly improved survival (36.0 vs. 15.8 m, p= 0.041). Conversely, the combination of anti-PD-L1 agents with RT not only failed to confer benefits but also had detrimental effects on patients (15.0 m vs. 21.0 m, p=0.926). A similar trend was observed for rwPFS. These findings suggest a potentially greater synergistic effect between RT and anti-PD-1 agents. However, whether anti-PD-1 and PD-L1 agents combined with RT cause different clinical outcomes remains unclear, and additional research is needed. Recent retrospective studies have assessed the safety and efficacy of the combination of IT with TRT in patients with ES-SCLC and revealed that the addition of TRT to IT did not exhibit an apparent association with increased toxicity in patients with SCLC [30]. Furthermore, the occurrence of TRT-related adverse events was in line with previous findings from other studies and was considered manageable [18, 19]. Our retrospective study, which was conducted across three medical centers, revealed similar rates of adverse events across the four cohorts, confirming the safety of combining IT with RT in ES-SCLC patients. The main strength of this article is that it not only confirms the efficacy and safety but also further validates the synergistic effects of RT and IT in patients with ES-SCLC. Additionally, the combination of anti-PD-1 agents with RT resulted in significant survival benefits, and anti-PD-L1 agents without RT seemed to be more effective. This will be the focus of our subsequent research. However, our study has some limitations worth considering. First, as the study design was retrospective, PSM could not completely exclude confounding variables and selection bias. Second, although half of the total patients underwent RT, it included TRT, brain RT, and bone RT, which also affected the results of our analysis. Third, there was no examination of the optimal dose and timing of RT. Last, the small number of patients receiving IT, along with the use of multiple anti-PD-1/PD-L1 agents, was likely to have impacted the analysis outcomes. Therefore, further large-scale studies are warranted to validate our results. Conclusions An increasing number of treatment options are being explored for ES-SCLC, and chemotherapy is the cornerstone. Our study demonstrated that both IT and RT can prolong survival in patients with ES-SCLC and have excellent safety profiles. In addition, these data reflect a synergistic effect between RT and anti-PD-1 agents. Despite some limitations, this combination therapy is worthy of further investigation for optimizing treatment strategies in patients with ES-SCLC. Declarations Ethics approval and consent to participate This study was approved by the Medical Ethics Committee of each hospital. Because this study was retrospective, informed consent from the included patients was not required, and patient information was anonymized. This study was conducted in accordance with the World Medical Association Declaration of Helsinki, Good Clinical Practices, and local ethical/legal requirements. Consent for publication Not applicable. Availability of data and materials The datasets generated and/or analysed during the current study are not publicly available due these data will be prepared for further studies, we will release relevant data when all the studies are completed, but are available from the corresponding author on reasonable request. To request data please contact Huaijun Ji (email: [email protected] ). Competing interests The authors declare that they have no competing interests. Funding Not applicable. Authors’ contributions MS and HJ drafted the manuscript. YL and HJ were involved in conception and design. MS and HJ were involved in analysis and interpretation of data. MS, HJ, FD and NX were involved in data collection. All authors contributed in review, revise and approve the manuscript; and agree to be accountable to all aspects of the work. Acknowledgments We express our gratitude to all the patients participated in this retrospective study. We are grateful to all the doctors at the participating institutions. References Rudin CM, Brambilla E, Faivre-Finn C, et al. Small-cell lung cancer. Nat Rev Dis Primers. 2021;7(1):3. Kim D, Kim HJ, Wu HG, et al. Intrathoracic Progression Is Still the Most Dominant Failure Pattern after First-Line Chemo-immunotherapy in Extensive-Stage Small-Cell Lung Cancer: Implications for Thoracic Radiotherapy. Cancer Res Treat. 2024;56:430–41. Socinski MA, Smit EF, Lorigan P, et al. Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer. J Clin Oncol. 2009;28:4787–92. Goldman JW, Dvorkin M, Chen Y, et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2021;22:51–65. Liu SV, Reck M, Mansfield AS, et al. Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133). J Clin Oncol. 2021;39:619–30. Horn L, Mansfield AS, Szczęsna A, et al. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. N Engl J Med. 2018;23:2220–9. Rudin CM, Awad MM, Navarro A, et al. Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study. J Clin Oncol. 2020;21:2369–79. Cheng Y, Han L, Wu L, et al. Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer: The ASTRUM-005 Randomized Clinical Trial. JAMA. 2022;12:1223–32. Slotman BJ, van Tinteren H, Praag JO, et al. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Lancet. 2015;385:36–42. Li H, Zhao Y, Ma T, et al. Radiotherapy for extensive-stage small-cell lung cancer in the immunotherapy era. Front Immunol. 2023;14:1132482. Tian Y, Ma J, Jing X, et al. Radiation therapy for extensive-stage small-cell lung cancer in the era of immunotherapy. Cancer Lett. 2022;541:215719. Antonia SJ, López-Martin JA, Bendell J, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol. 2016;17:883–95. Ott PA, Elez E, Hiret S, et al. Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study. J Clin Oncol. 2017;34:3823–9. Wang J, Zhou C, Yao W, et al. Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022;23:739–47. Xie J, Chen M, Han H, et al. Clinical impact of first-line PD-1 or PD-L1 inhibitors combined with chemotherapy in extensive-stage small cell lung cancer patients: A real-world multicenter propensity score-matched study. Thorac Cancer. 2023;15:1327–38. Duan J, Cui L, Zhao X, et al. Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysis. JAMA Oncol. 2020;6:375–84. Cheng Y, Fan Y, Zhao Y et al. Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage SCLC (RATIONALE-312): A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical Trial. J Thorac Oncol. 2024; 7:S1556-0864(24)00115-1. Cheng Y, Liu Y, Zhang W, et al. EXTENTORCH: A randomized, phase III trial of toripalimab versus placebo, in combination with chemotherapy as a first-line therapy for patients with extensive stage small cell lung cancer (ES-SCLC). ESMO; 2023. p. LBA93. Cheng Y, Wang J, Yao W et al. Final results and subgroup analysis of ORIENTAL: A phase IIIB study of durvalumab plus platinum-etoposide in first-line treatment of Chinese patients with extensive-stage small-cell lung cancer (ES-SCLC). 2023; ESMO Asia. 519P. Rathod S, Jeremic B, Dubey A, et al. Role of thoracic consolidation radiation in extensive stage small cell lung cancer: A systematic review and meta-analysis of randomised controlled trials. Eur J Cancer. 2019;110:110–9. Li AM, Zhou H, Xu YY, et al. Role of thoracic radiotherapy in extensive stage small cell lung cancer: a systemic review and meta-analysis. Ann Transl Med. 2021;9:299. Peng J, Zhang L, Wang L, et al. Real-world outcomes of PD-L1 inhibitors combined with thoracic radiotherapy in the first-line treatment of extensive stage small cell lung cancer. Radiat Oncol. 2023;18:111. Xie Z, Liu J, Wu M, et al. Real-World Efficacy and Safety of Thoracic Radiotherapy after First-Line Chemo-Immunotherapy in Extensive-Stage Small-Cell Lung Cancer. J Clin Med. 2023;12:3828. Pillai RN, Behera M, Owonikoko TK, et al. Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: A systematic analysis of the literature. Cancer. 2018;124:271–7. Daher SNAA, Rottenberg Y, et al. Real-world data of consolidative radiotherapy for extensive stage (ES)-SCLC treated by chemo-immunotherapy (chemo-IO). Ann Oncol. 2022;33:S97–104. Zhang Z, Liu X, Chen D, et al. Radiotherapy combined with immunotherapy: the dawn of cancer treatment. Signal Transduct Target Ther. 2022;7:258. Formenti SC, Rudqvist NP, Golden E, et al. Radiotherapy induces responses of lung cancer to CTLA-4 blockade. Nat Med. 2018;24:1845–51. Longo V, Della Corte CM, Russo A, et al. Consolidative thoracic radiation therapy for extensive-stage small cell lung cancer in the era of first-line chemoimmunotherapy: preclinical data and a retrospective study in Southern Italy. Front Immunol. 2024;14:1289434. Zhang Y. Phase II study of low-dose radiation (LDRT) plus durvalumab (D) and etoposide/platinum (EP) as first-line treatment in ES-SCLC (LEAD): Efficacy and safety results. 2024; ELCC 2024. Diamond BH, Verma N, Shukla UC, et al. Consolidative Thoracic Radiation Therapy After First-Line Chemotherapy and Immunotherapy in Extensive-Stage Small Cell Lung Cancer: A Multi-Institutional Case Series. Adv Radiat Oncol. 2021;7:100883. Additional Declarations No competing interests reported. Cite Share Download PDF Status: Published Journal Publication published 30 Sep, 2024 Read the published version in BMC Cancer → Version 1 posted Editorial decision: Revision requested 18 Jun, 2024 Editor assigned by journal 17 Jun, 2024 Submission checks completed at journal 17 Jun, 2024 First submitted to journal 17 Jun, 2024 You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-4594148","acceptedTermsAndConditions":true,"allowDirectSubmit":false,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":316052820,"identity":"76d3b29c-57cb-4352-81b3-2b355ed10e01","order_by":0,"name":"Meiling Sun","email":"","orcid":"","institution":"Qilu Hospital, Shandong University","correspondingAuthor":false,"prefix":"","firstName":"Meiling","middleName":"","lastName":"Sun","suffix":""},{"id":316052821,"identity":"f93c0130-5f3a-46ba-9579-49a3fe20dbdf","order_by":1,"name":"Huaijun Ji","email":"","orcid":"","institution":"Weihai Municipal Hospital, Shandong University","correspondingAuthor":false,"prefix":"","firstName":"Huaijun","middleName":"","lastName":"Ji","suffix":""},{"id":316052824,"identity":"0a4e3785-acff-4db0-a6eb-db6ce63a8972","order_by":2,"name":"Fang Deng","email":"","orcid":"","institution":"Qilu Hospital of Shandong University Dezhou Hospital","correspondingAuthor":false,"prefix":"","firstName":"Fang","middleName":"","lastName":"Deng","suffix":""},{"id":316052826,"identity":"5825fcb3-1be5-4123-863d-65b930087040","order_by":3,"name":"Ning Xu","email":"","orcid":"","institution":"Weihai Municipal Hospital, Shandong University","correspondingAuthor":false,"prefix":"","firstName":"Ning","middleName":"","lastName":"Xu","suffix":""},{"id":316052830,"identity":"15719195-4203-495c-b4cc-76530d6cd8a6","order_by":4,"name":"Yu Li","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAAvklEQVRIiWNgGAWjYDACduaGAxBGY+PDD0RpYWaEauE53GwsQawWCEMivU2AhxgdfIcZGw/ztt2Tk5/5sI1BgsFOTreBgBbJw4wNQC3Fxga3E9seFDAkG5sdIKDFAKIlIXGDdGK7gQTDgcRtxGqpnz/zYJsEDylaEhhuMBKpBeSXg3POJRhuOJMIDGQDIvzCd7z58Ic3ZQny8u3HHz78UGEnR1ALA1ABEyI6DAgph2ph/EGMwlEwCkbBKBi5AAALA0Znc1VY+QAAAABJRU5ErkJggg==","orcid":"","institution":"Qilu Hospital, Shandong University","correspondingAuthor":true,"prefix":"","firstName":"Yu","middleName":"","lastName":"Li","suffix":""}],"badges":[],"createdAt":"2024-06-17 12:33:27","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-4594148/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-4594148/v1","draftVersion":[],"editorialEvents":[{"content":"https://doi.org/10.1186/s12885-024-12942-y","type":"published","date":"2024-09-30T15:58:02+00:00"}],"editorialNote":"","failedWorkflow":false,"files":[{"id":60353963,"identity":"89c6a04c-9c10-4fd4-aee7-b23c3a3bbe41","added_by":"auto","created_at":"2024-07-15 23:50:40","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":73616,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eDiagram of patient's selection process\u003c/strong\u003e\u003c/p\u003e","description":"","filename":"Onlinefloatimage1.png","url":"https://assets-eu.researchsquare.com/files/rs-4594148/v1/32b5fb831d931a0c8a6270cb.png"},{"id":60353964,"identity":"c89619c6-96ae-42bf-aa95-33ca47f45fd5","added_by":"auto","created_at":"2024-07-15 23:50:40","extension":"png","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":44490,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003e(A)Kaplan-Mier curves showing OS based on immunotherapy. (B) Kaplan-Mier curves showing PFS based on immunotherapy. (C) Kaplan-Mier curves showing OS based on radiotherapy. (D) Kaplan-Mier curves showing PFS based on radiotherapy.\u003c/strong\u003e\u003c/p\u003e","description":"","filename":"Onlinefloatimage2.png","url":"https://assets-eu.researchsquare.com/files/rs-4594148/v1/39cb85f977727569db92c1bd.png"},{"id":60355034,"identity":"69f2fe8c-03ff-44e5-9482-741d6c418ff0","added_by":"auto","created_at":"2024-07-15 23:58:40","extension":"png","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":43293,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003e(A)Kaplan-Mier curves showing OS based on immunotherapy after PSM. (B) Kaplan-Mier curves showing PFS based on immunotherapy after PSM. (C) Kaplan-Mier curves showing OS based on radiotherapy after PSM. (D) Kaplan-Mier curves showing PFS based on radiotherapy after PSM\u003c/strong\u003e\u003c/p\u003e","description":"","filename":"Onlinefloatimage3.png","url":"https://assets-eu.researchsquare.com/files/rs-4594148/v1/602afd9e8218bc3a170ea5c9.png"},{"id":60353737,"identity":"52ba7626-2539-419d-9e7b-1dece8118289","added_by":"auto","created_at":"2024-07-15 23:42:40","extension":"png","order_by":4,"title":"Figure 4","display":"","copyAsset":false,"role":"figure","size":40316,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003e(A) Kaplan-Mier curves showing OS about four groups. (B) Kaplan-Mier curves showing PFS about four groups. (C) Kaplan-Mier curves showing OS in the PD-1 group. (D) Kaplan-Mier curves showing OS based on radiotherapy combined with PD-1/PD-L1 inhibitors.\u003c/strong\u003e\u003c/p\u003e","description":"","filename":"Onlinefloatimage4.png","url":"https://assets-eu.researchsquare.com/files/rs-4594148/v1/52529b5854dbd40b990afec0.png"},{"id":60353740,"identity":"3f2482b8-30e3-4ac7-9d8b-0c5ba22483cf","added_by":"auto","created_at":"2024-07-15 23:42:40","extension":"png","order_by":5,"title":"Figure 5","display":"","copyAsset":false,"role":"figure","size":16230,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003e(A)The bar chart showing OS comparison of PD-1/PD-Ll inhibitors and radiotherapy. (B) Treatment-related adverse events in all ES-SCLC patients.\u003c/strong\u003e\u003c/p\u003e","description":"","filename":"Onlinefloatimage5.png","url":"https://assets-eu.researchsquare.com/files/rs-4594148/v1/71edf3e26cbfc1578eb5427d.png"},{"id":66097415,"identity":"53e89137-0775-4ec1-887c-f1f8e19daf4a","added_by":"auto","created_at":"2024-10-07 16:14:05","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":2338198,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-4594148/v1/ce8834ac-49b2-428e-bc20-14ba2e1fb12e.pdf"}],"financialInterests":"No competing interests reported.","formattedTitle":"Clinical outcomes and synergistic effect between radiotherapy and immunotherapy in patients with extensive-stage small cell lung cancer: A real-world study","fulltext":[{"header":"Background","content":"\u003cp\u003eLung cancer is the malignant tumor with the highest morbidity and mortality rates in China and the world; specifically, small-cell lung cancer (SCLC) accounts for approximately 15% of lung cancer cases [\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e]. Clinically, SCLC is classified into extensive-stage SCLC (ES-SCLC) and limited-stage SCLC (LS-SCLC), and it is characterized by rapid proliferation and early development of widespread metastases. Patients with SCLC usually present with ES-SCLC at the time of diagnosis [\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e]. In the chemoradiotherapy era, the traditional treatment for SCLC is comprehensive chemotherapy (CT). The median survival time of patients receiving this treatment is reportedly 18\u0026ndash;24 months for LS-SCLC patients and only 10\u0026ndash;12 months for ES-SCLC patients, with a 5-year survival rate of only 7% [\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eRecent phase 3 trials of the programmed cell death ligand 1 (PD-L1) inhibitor atezolizumab or durvalumab combined with CT revealed significantly prolonged overall survival (OS) in patients with ES-SCLC [\u003cspan additionalcitationids=\"CR5\" citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e]. In addition, the programmed cell death 1 (PD-1) inhibitor serplulimab plus CT significantly improved OS, and pembrolizumab plus CT prolonged progression-free survival (PFS) [\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e, \u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e]. In addition, the CREST trial showed that thoracic radiotherapy (TRT) after first-line CT could increase local control rates and improve OS [\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e]. Studies have shown that patients who underwent TRT after chemo-immunotherapy (CT\u0026thinsp;+\u0026thinsp;IT) had significantly longer OS and PFS in patients with ES-SCLC [\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e]. This study aimed to explore the clinical efficacy and safety of IT and radiotherapy (RT) in ES-SCLC patients in the real world.\u003c/p\u003e"},{"header":"Methods","content":"\u003cp\u003e\u003cstrong\u003eData collection\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eWe retrospectively extracted\u0026nbsp;data\u0026nbsp;from the electronic health records of patients with ES-SCLC who received first-line\u0026nbsp;CT with or without immunotherapy\u0026nbsp;(IT) from April 2016 to August 2023\u0026nbsp;across\u0026nbsp;three public tertiary hospitals\u0026nbsp;(Weihai Municipal Hospital, Qilu Hospital of Shandong University Dezhou Hospital and Qilu Hospital Affiliated to Shandong University).\u0026nbsp;The patients\u0026rsquo; basic information was collected. All data were obtained from clinical medical records and followed up from the date of diagnosis\u0026nbsp;until\u0026nbsp;the date of all-cause death or up to the latest available follow-up.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003ePatient selection\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e(1)\u0026nbsp;The inclusion\u0026nbsp;criteriawere as follows: aged\u0026nbsp;18 years or older;\u0026nbsp;had\u0026nbsp;an ECOG PS\u0026nbsp;ranging from\u0026nbsp;0 to 3;\u0026nbsp;had a\u0026nbsp;pathological diagnosis of SCLC; and\u0026nbsp;had undergone\u0026nbsp;at least two cycles of chemotherapy. (2) The exclusion criteria were as follows: no clear pathological diagnosis information; patients with other tumors at the same time; ECOG PS \u0026gt;3; less than 2 cycles of chemotherapy; no efficacy evaluation after treatment or\u0026nbsp;loss\u0026nbsp;to follow-up;\u0026nbsp;and\u0026nbsp;autoimmune diseases.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eEfficacy assessment\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe response to therapies was evaluated based on imaging examinations according to the Response Evaluation Criteria in Solid Tumors version 1.1. The primary endpoint was OS, which was defined as the time from the date of chemotherapy initiation to all-cause mortality or censored on the date of the last follow-up. The secondary endpoint was rwPFS, which was defined as the time from chemotherapy initiation to tumor progression, death from no progression or the last follow-up. Adverse effects were assessed based on\u0026nbsp;the\u0026nbsp;National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0. The patients were followed up by consulting outpatient records, hospitalization medical records, and telephone inquiries.\u0026nbsp;The\u0026nbsp;latest follow-up date was January 31, 2024.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eStatistical analysis\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eStandard descriptive statistics or contingency tables were used for demographic and baseline characteristics. Proportions were compared between groups using the chi-squared test. Propensity score\u0026nbsp;matching was conducted using a 1:1 matching design with a tolerance of 0.02. A logistic regression model was\u0026nbsp;constructed\u0026nbsp;to estimate the propensity score, which included the following covariates: age, sex, smoking history, hypertension\u0026nbsp;status, diabetes\u0026nbsp;status, ECOG PS\u0026nbsp;score, brain\u0026nbsp;metastasis status, liver\u0026nbsp;metastasis status, bone\u0026nbsp;metastasis status, lung\u0026nbsp;metastasis status, adrenal gland metastasis\u0026nbsp;status, chemotherapy\u0026nbsp;status\u0026nbsp;and radiotherapy\u0026nbsp;status. Kaplan-Meier analysis was performed to estimate the survival rate,\u0026nbsp;and the log-rank test was performed to test the differences in survival distribution.\u0026nbsp;To\u0026nbsp;investigate predictors\u0026nbsp;of\u0026nbsp;OS and rwPFS, univariate and multivariate Cox regression models were used. All\u0026nbsp;the\u0026nbsp;statistical analyses were performed using SPSS version 27.0. P\u0026lt;0.05 was considered\u0026nbsp;to indicate statistical significance.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eEthical statement\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThis program was performed in accordance with the principles of good clinical practice and was approved by the institutional review board of each hospital. Because this study was retrospective, informed consent from the included patients was not required, and patient information was anonymized.\u0026nbsp;\u003c/p\u003e"},{"header":"Results","content":"\u003cp\u003e\u003cstrong\u003eData collection\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eA total of\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e495 patients were initially screened, 183 patients with LS-SCLC were excluded, 19 patients were excluded because of less than 2 cycles of CT or less than 2 cycles of IT, 13\u0026nbsp;patients\u0026nbsp;were excluded because they did not receive first-line IT,\u0026nbsp;and\u0026nbsp;23\u0026nbsp;patients\u0026nbsp;were excluded because both OS and rwPSF were uncertain. A total of 257 eligible patients were included in the analysis. A total of 105 patients had both OS and rwPSF data\u0026nbsp;,\u0026nbsp;81 patients had only OS data, and 71 patients had only rwPFS data. Overall, OS data from 186 patients were analyzed, including 106 patients\u0026nbsp;who\u0026nbsp;received CT alone and 80 patients\u0026nbsp;who\u0026nbsp;received CT+IT. Additionally, rwPFS data from 176 patients were analyzed, including 97 patients\u0026nbsp;who\u0026nbsp;received CT alone and 79 patients\u0026nbsp;who\u0026nbsp;received CT+IT.\u003cstrong\u003e(Figure 1)\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFigure 1. Diagram of patient\u0026apos;s selection process\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eBaseline characteristics\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eOS\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe median age was 65 years (32-85). The majority of patients were males (75.8%). The ECOG PS0-1 group constituted 95.2% of the cohort. Brain metastasis was present in 20.4% of the cohort, liver metastasis was present in 21.0%, bone metastasis was present in 28.0%, lung metastasis was present in 19.9% and adrenal gland metastasis was present in 9.1%. Among them, CT combined with RT accounted for 46.8% of the treatment regimens, while CT combined with IT accounted for 43.0%. The CT regimen used for 174 patients was carboplatin (n = 67) or cisplatin (n =107) combined with etoposide; 8 patients received nedaplatin combined with etoposide, and 4 patients received irinotecan combined with cisplatin. \u003cstrong\u003e(Table 1)\u003c/strong\u003e Regarding IT, 35 patients received PD-1 (including 17 who received tislelizumab, 5 who received serplulimab, 5 who received camrelizumab, 3 who received sintilimab, 3 who received pembrolizumab, 1 who received toripalimab and 1 who received penpulimab), and 45 patients received PD-L1 (including 34 who received durvalumab, 7 who received atezolizumab and 4 who received adebrelimab).\u003c/p\u003e\n\u003cp\u003eThe radiation\u0026nbsp;dose\u0026nbsp;was decided by\u0026nbsp;a doctor\u0026nbsp;based on the guidelines of the Chinese Society of Clinical Oncology guidelines or National Comprehensive Cancer Network. The total radiation dose\u0026nbsp;ranged\u0026nbsp;from 30 Gy to 60 Gy, with a median dose of 45 Gy.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003erwPFS\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe median age of this group was\u0026nbsp;65 years\u0026nbsp;(41-85). Most of the patients were males (75.6%). The ECOG PS0-1\u0026nbsp;group\u0026nbsp;accounted for 96.0% of the cohort. Brain metastasis\u0026nbsp;was\u0026nbsp;present in 28.7% of the cohort, liver metastasis\u0026nbsp;was\u0026nbsp;present in 22.7%, bone metastasis\u0026nbsp;was\u0026nbsp;present in 30.1%, lung metastasis\u0026nbsp;was\u0026nbsp;present in 28.7% and adrenal gland metastasis\u0026nbsp;was\u0026nbsp;present in 8.5%. Among them,\u0026nbsp;the combination of CT with RT accounted for 52.8% of the treatment regiemnts,\u0026nbsp;and CT plus IT\u0026nbsp;accounted\u0026nbsp;for 44.9%. The CT\u0026nbsp;regimens used for\u0026nbsp;166 patients\u0026nbsp;were\u0026nbsp;carboplatin (n = 56) or cisplatin (n =110) combined with etoposide; 4 patients received nedaplatin combined with etoposide; 2\u0026nbsp;patients\u0026nbsp;received irinotecan combined with cisplatin; 2\u0026nbsp;patients\u0026nbsp;received irinotecan combined with carboplatin; and 2\u0026nbsp;patients\u0026nbsp;received\u0026nbsp;the\u0026nbsp;single agent etoposide.\u003cstrong\u003e(Table 1)\u0026nbsp;\u003c/strong\u003eRegarding IT, 37 patients received PD-1 (including 3 who received sintilimab, 3 who received pembrolizumab, 18 who received tislelizumab, 6 who received camrelizumab, 3 who received serplulimab, 2 who received toripalimab and 2 who received penpulimab) and 42 received PD-L1 (including 28 who received durvalumab, 9 who received atezolizumab and 5 who received adebrelimab).\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eTable 1. Baseline characteristics of patients before and after PSM according to first-line therapy.\u003c/strong\u003e\u003c/p\u003e\n\u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"0\" width=\"754\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd width=\"11.02257636122178%\" valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eOS\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"31.07569721115538%\" colspan=\"4\" valign=\"top\"\u003e\n \u003cp\u003eBefore matching, n (%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"29.614873837981406%\" colspan=\"4\" valign=\"top\"\u003e\n \u003cp\u003eAfter matching, n (%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"28.286852589641434%\" colspan=\"4\" valign=\"top\"\u003e\n \u003cp\u003eAfter matching, n (%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"11.007957559681698%\" valign=\"top\"\u003e\n \u003cp\u003eCharacteristics\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003eAll patients\u003c/p\u003e\n \u003cp\u003eN=186(%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.753315649867375%\" valign=\"top\"\u003e\n \u003cp\u003eCT+IT\u003c/p\u003e\n \u003cp\u003eN=80(43.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.885941644562335%\" valign=\"top\"\u003e\n \u003cp\u003eCT N=106(57.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.172413793103448%\" valign=\"top\"\u003e\n \u003cp\u003e\u003cem\u003eP\u003c/em\u003e-Value\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.488063660477454%\" valign=\"top\"\u003e\n \u003cp\u003eAll patients\u003c/p\u003e\n \u003cp\u003eN=120(%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.427055702917772%\" valign=\"top\"\u003e\n \u003cp\u003eCT+IT N=60(%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.222811671087532%\" valign=\"top\"\u003e\n \u003cp\u003eCT\u003c/p\u003e\n \u003cp\u003eN=60(%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.437665782493369%\" valign=\"top\"\u003e\n \u003cp\u003eP-value\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003eAll patients\u003c/p\u003e\n \u003cp\u003eN=122 (%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.896551724137931%\" valign=\"top\"\u003e\n \u003cp\u003eCT+RT\u003c/p\u003e\n \u003cp\u003eN=61(%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.6923076923076925%\" valign=\"top\"\u003e\n \u003cp\u003eCT N=61(%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.305039787798409%\" valign=\"top\"\u003e\n \u003cp\u003e\u003cem\u003eP\u003c/em\u003e-Value\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"11.007957559681698%\" valign=\"top\"\u003e\n \u003cp\u003eMedian age\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e65(32-85)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.753315649867375%\" valign=\"top\"\u003e\n \u003cp\u003e65(32-85)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.885941644562335%\" valign=\"top\"\u003e\n \u003cp\u003e65(44-81)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.172413793103448%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.488063660477454%\" valign=\"top\"\u003e\n \u003cp\u003e65(32-85)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.427055702917772%\" valign=\"top\"\u003e\n \u003cp\u003e65(32-85)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.222811671087532%\" valign=\"top\"\u003e\n \u003cp\u003e64.5(44-81)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.437665782493369%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.896551724137931%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.6923076923076925%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.305039787798409%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"11.007957559681698%\" valign=\"top\"\u003e\n \u003cp\u003eAge, year\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.753315649867375%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.885941644562335%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.172413793103448%\" valign=\"top\"\u003e\n \u003cp\u003e0.550\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.488063660477454%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.427055702917772%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.222811671087532%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.437665782493369%\" valign=\"top\"\u003e\n \u003cp\u003e0.713\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.896551724137931%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.6923076923076925%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.305039787798409%\" valign=\"top\"\u003e\n \u003cp\u003e0.856\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"11.007957559681698%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026le;65\u0026nbsp;yrs\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e100(53.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.753315649867375%\" valign=\"top\"\u003e\n \u003cp\u003e41(51.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.885941644562335%\" valign=\"top\"\u003e\n \u003cp\u003e59(55.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.172413793103448%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.488063660477454%\" valign=\"top\"\u003e\n \u003cp\u003e68(56.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.427055702917772%\" valign=\"top\"\u003e\n \u003cp\u003e33(55.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.222811671087532%\" valign=\"top\"\u003e\n \u003cp\u003e35(58.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.437665782493369%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e63(51.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.896551724137931%\" valign=\"top\"\u003e\n \u003cp\u003e32(52.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.6923076923076925%\" valign=\"top\"\u003e\n \u003cp\u003e31(50.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.305039787798409%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"11.007957559681698%\" valign=\"top\"\u003e\n \u003cp\u003e＞65\u0026nbsp;yrs\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e86(46.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.753315649867375%\" valign=\"top\"\u003e\n \u003cp\u003e39(48.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.885941644562335%\" valign=\"top\"\u003e\n \u003cp\u003e47(44.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.172413793103448%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.488063660477454%\" valign=\"top\"\u003e\n \u003cp\u003e52(43.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.427055702917772%\" valign=\"top\"\u003e\n \u003cp\u003e27(45.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.222811671087532%\" valign=\"top\"\u003e\n \u003cp\u003e25(41.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.437665782493369%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e59(48.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.896551724137931%\" valign=\"top\"\u003e\n \u003cp\u003e29(47.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.6923076923076925%\" valign=\"top\"\u003e\n \u003cp\u003e30(49.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.305039787798409%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"11.007957559681698%\" valign=\"top\"\u003e\n \u003cp\u003eGender\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.753315649867375%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.885941644562335%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.172413793103448%\" valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.022\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.488063660477454%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.427055702917772%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.222811671087532%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.437665782493369%\" valign=\"top\"\u003e\n \u003cp\u003e1.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.896551724137931%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.6923076923076925%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.305039787798409%\" valign=\"top\"\u003e\n \u003cp\u003e0.523\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"11.007957559681698%\" valign=\"top\"\u003e\n \u003cp\u003eFemale\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e45(24.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.753315649867375%\" valign=\"top\"\u003e\n \u003cp\u003e26(32.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.885941644562335%\" valign=\"top\"\u003e\n \u003cp\u003e19(17.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.172413793103448%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.488063660477454%\" valign=\"top\"\u003e\n \u003cp\u003e30(25.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.427055702917772%\" valign=\"top\"\u003e\n \u003cp\u003e15(25.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.222811671087532%\" valign=\"top\"\u003e\n \u003cp\u003e15(25.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.437665782493369%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e29(23.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.896551724137931%\" valign=\"top\"\u003e\n \u003cp\u003e16((26.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.6923076923076925%\" valign=\"top\"\u003e\n \u003cp\u003e13(21.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.305039787798409%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"11.007957559681698%\" valign=\"top\"\u003e\n \u003cp\u003eMale\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e141(75.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.753315649867375%\" valign=\"top\"\u003e\n \u003cp\u003e54(67.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.885941644562335%\" valign=\"top\"\u003e\n \u003cp\u003e87(72.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.172413793103448%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.488063660477454%\" valign=\"top\"\u003e\n \u003cp\u003e90(75.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.427055702917772%\" valign=\"top\"\u003e\n \u003cp\u003e45(75.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.222811671087532%\" valign=\"top\"\u003e\n \u003cp\u003e45(75.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.437665782493369%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e93(76.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.896551724137931%\" valign=\"top\"\u003e\n \u003cp\u003e45(73.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.6923076923076925%\" valign=\"top\"\u003e\n \u003cp\u003e48(78.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.305039787798409%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"11.007957559681698%\" valign=\"top\"\u003e\n \u003cp\u003eSmoking history\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.753315649867375%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.885941644562335%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.172413793103448%\" valign=\"top\"\u003e\n \u003cp\u003e0.519\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.488063660477454%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.427055702917772%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.222811671087532%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.437665782493369%\" valign=\"top\"\u003e\n \u003cp\u003e0.709\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.896551724137931%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.6923076923076925%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.305039787798409%\" valign=\"top\"\u003e\n \u003cp\u003e0.856\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"11.007957559681698%\" valign=\"top\"\u003e\n \u003cp\u003eNever smoked\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e81(43.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.753315649867375%\" valign=\"top\"\u003e\n \u003cp\u003e37(46.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.885941644562335%\" valign=\"top\"\u003e\n \u003cp\u003e44(41.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.172413793103448%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.488063660477454%\" valign=\"top\"\u003e\n \u003cp\u003e48(40.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.427055702917772%\" valign=\"top\"\u003e\n \u003cp\u003e25(41.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.222811671087532%\" valign=\"top\"\u003e\n \u003cp\u003e23(38.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.437665782493369%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e57(46.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.896551724137931%\" valign=\"top\"\u003e\n \u003cp\u003e29(47.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.6923076923076925%\" valign=\"top\"\u003e\n \u003cp\u003e28(45.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.305039787798409%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"11.007957559681698%\" valign=\"top\"\u003e\n \u003cp\u003eFormer/current\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e105(56.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.753315649867375%\" valign=\"top\"\u003e\n \u003cp\u003e43(53.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.885941644562335%\" valign=\"top\"\u003e\n \u003cp\u003e62(58.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.172413793103448%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.488063660477454%\" valign=\"top\"\u003e\n \u003cp\u003e72(60.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.427055702917772%\" valign=\"top\"\u003e\n \u003cp\u003e35(58.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.222811671087532%\" valign=\"top\"\u003e\n \u003cp\u003e37(61.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.437665782493369%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e65(53.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.896551724137931%\" valign=\"top\"\u003e\n \u003cp\u003e32(52.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.6923076923076925%\" valign=\"top\"\u003e\n \u003cp\u003e33(54.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.305039787798409%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"11.007957559681698%\" valign=\"top\"\u003e\n \u003cp\u003eFamily tumor history\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.753315649867375%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.885941644562335%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.172413793103448%\" valign=\"top\"\u003e\n \u003cp\u003e0.100\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.488063660477454%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.427055702917772%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.222811671087532%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.437665782493369%\" valign=\"top\"\u003e\n \u003cp\u003e0.068\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.896551724137931%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.6923076923076925%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.305039787798409%\" valign=\"top\"\u003e\n \u003cp\u003e0.839\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"11.007957559681698%\" valign=\"top\"\u003e\n \u003cp\u003eNo\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e140(75.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.753315649867375%\" valign=\"top\"\u003e\n \u003cp\u003e65(81.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.885941644562335%\" valign=\"top\"\u003e\n \u003cp\u003e75(70.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.172413793103448%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.488063660477454%\" valign=\"top\"\u003e\n \u003cp\u003e86(71.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.427055702917772%\" valign=\"top\"\u003e\n \u003cp\u003e48(80.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.222811671087532%\" valign=\"top\"\u003e\n \u003cp\u003e38(63.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.437665782493369%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e89(73.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.896551724137931%\" valign=\"top\"\u003e\n \u003cp\u003e44(72.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.6923076923076925%\" valign=\"top\"\u003e\n \u003cp\u003e45(73.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.305039787798409%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"11.007957559681698%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp; Yes\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e46(24.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.753315649867375%\" valign=\"top\"\u003e\n \u003cp\u003e15(18.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.885941644562335%\" valign=\"top\"\u003e\n \u003cp\u003e31(29.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.172413793103448%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.488063660477454%\" valign=\"top\"\u003e\n \u003cp\u003e34(28.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.427055702917772%\" valign=\"top\"\u003e\n \u003cp\u003e12(20.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.222811671087532%\" valign=\"top\"\u003e\n \u003cp\u003e22(36.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.437665782493369%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e33(27.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.896551724137931%\" valign=\"top\"\u003e\n \u003cp\u003e17(27.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.6923076923076925%\" valign=\"top\"\u003e\n \u003cp\u003e16(26.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.305039787798409%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"11.007957559681698%\" valign=\"top\"\u003e\n \u003cp\u003eHypertension\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.753315649867375%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.885941644562335%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.172413793103448%\" valign=\"top\"\u003e\n \u003cp\u003e0.626\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.488063660477454%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.427055702917772%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.222811671087532%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.437665782493369%\" valign=\"top\"\u003e\n \u003cp\u003e1.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.896551724137931%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.6923076923076925%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.305039787798409%\" valign=\"top\"\u003e\n \u003cp\u003e1.0\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"11.007957559681698%\" valign=\"top\"\u003e\n \u003cp\u003eNo\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e129(69.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.753315649867375%\" valign=\"top\"\u003e\n \u003cp\u003e57(71.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.885941644562335%\" valign=\"top\"\u003e\n \u003cp\u003e72(67.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.172413793103448%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.488063660477454%\" valign=\"top\"\u003e\n \u003cp\u003e86(71.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.427055702917772%\" valign=\"top\"\u003e\n \u003cp\u003e43(71.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.222811671087532%\" valign=\"top\"\u003e\n \u003cp\u003e43(71.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.437665782493369%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e84(68.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.896551724137931%\" valign=\"top\"\u003e\n \u003cp\u003e42(68.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.6923076923076925%\" valign=\"top\"\u003e\n \u003cp\u003e42(68.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.305039787798409%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"11.007957559681698%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp; Yes\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e57(30.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.753315649867375%\" valign=\"top\"\u003e\n \u003cp\u003e23(28.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.885941644562335%\" valign=\"top\"\u003e\n \u003cp\u003e34(32.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.172413793103448%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.488063660477454%\" valign=\"top\"\u003e\n \u003cp\u003e34(28.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.427055702917772%\" valign=\"top\"\u003e\n \u003cp\u003e17(28.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.222811671087532%\" valign=\"top\"\u003e\n \u003cp\u003e17(28.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.437665782493369%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e38(31.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.896551724137931%\" valign=\"top\"\u003e\n \u003cp\u003e19(31.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.6923076923076925%\" valign=\"top\"\u003e\n \u003cp\u003e19(31.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.305039787798409%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"11.007957559681698%\" valign=\"top\"\u003e\n \u003cp\u003eDiabetes\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.753315649867375%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.885941644562335%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.172413793103448%\" valign=\"top\"\u003e\n \u003cp\u003e0.871\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.488063660477454%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.427055702917772%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.222811671087532%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.437665782493369%\" valign=\"top\"\u003e\n \u003cp\u003e1.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.896551724137931%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.6923076923076925%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.305039787798409%\" valign=\"top\"\u003e\n \u003cp\u003e0.610\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"11.007957559681698%\" valign=\"top\"\u003e\n \u003cp\u003eNo\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e159(85.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.753315649867375%\" valign=\"top\"\u003e\n \u003cp\u003e68(85.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.885941644562335%\" valign=\"top\"\u003e\n \u003cp\u003e91(85.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.172413793103448%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.488063660477454%\" valign=\"top\"\u003e\n \u003cp\u003e104(86.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.427055702917772%\" valign=\"top\"\u003e\n \u003cp\u003e52(86.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.222811671087532%\" valign=\"top\"\u003e\n \u003cp\u003e52(86.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.437665782493369%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e104(85.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.896551724137931%\" valign=\"top\"\u003e\n \u003cp\u003e53(86.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.6923076923076925%\" valign=\"top\"\u003e\n \u003cp\u003e51(83.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.305039787798409%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"11.007957559681698%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp; Yes\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e27(14.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.753315649867375%\" valign=\"top\"\u003e\n \u003cp\u003e12(15.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.885941644562335%\" valign=\"top\"\u003e\n \u003cp\u003e15(14.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.172413793103448%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.488063660477454%\" valign=\"top\"\u003e\n \u003cp\u003e16(13.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.427055702917772%\" valign=\"top\"\u003e\n \u003cp\u003e8(13.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.222811671087532%\" valign=\"top\"\u003e\n \u003cp\u003e8(13.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.437665782493369%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e18(14.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.896551724137931%\" valign=\"top\"\u003e\n \u003cp\u003e8(13.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.6923076923076925%\" valign=\"top\"\u003e\n \u003cp\u003e10(16.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.305039787798409%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"11.007957559681698%\" valign=\"top\"\u003e\n \u003cp\u003eECOG PS\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.753315649867375%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.885941644562335%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.172413793103448%\" valign=\"top\"\u003e\n \u003cp\u003e0.584\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.488063660477454%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.427055702917772%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.222811671087532%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.437665782493369%\" valign=\"top\"\u003e\n \u003cp\u003e0.648\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.896551724137931%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.6923076923076925%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.305039787798409%\" valign=\"top\"\u003e\n \u003cp\u003e1.0\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"11.007957559681698%\" valign=\"top\"\u003e\n \u003cp\u003e0-1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e177(95.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.753315649867375%\" valign=\"top\"\u003e\n \u003cp\u003e77(96.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.885941644562335%\" valign=\"top\"\u003e\n \u003cp\u003e100(94.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.172413793103448%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.488063660477454%\" valign=\"top\"\u003e\n \u003cp\u003e115(95.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.427055702917772%\" valign=\"top\"\u003e\n \u003cp\u003e58(96.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.222811671087532%\" valign=\"top\"\u003e\n \u003cp\u003e57(95.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.437665782493369%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e120(98.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.896551724137931%\" valign=\"top\"\u003e\n \u003cp\u003e60(98.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.6923076923076925%\" valign=\"top\"\u003e\n \u003cp\u003e60(98.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.305039787798409%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"11.007957559681698%\" valign=\"top\"\u003e\n \u003cp\u003e2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e9(4.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.753315649867375%\" valign=\"top\"\u003e\n \u003cp\u003e3(3.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.885941644562335%\" valign=\"top\"\u003e\n \u003cp\u003e6(5.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.172413793103448%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.488063660477454%\" valign=\"top\"\u003e\n \u003cp\u003e5(4.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.427055702917772%\" valign=\"top\"\u003e\n \u003cp\u003e2(3.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.222811671087532%\" valign=\"top\"\u003e\n \u003cp\u003e3(5.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.437665782493369%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e2(1.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.896551724137931%\" valign=\"top\"\u003e\n \u003cp\u003e1(1.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.6923076923076925%\" valign=\"top\"\u003e\n \u003cp\u003e1(1.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.305039787798409%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"11.007957559681698%\" valign=\"top\"\u003e\n \u003cp\u003eBrain Metastasis\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.753315649867375%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.885941644562335%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.172413793103448%\" valign=\"top\"\u003e\n \u003cp\u003e0.329\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.488063660477454%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.427055702917772%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.222811671087532%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.437665782493369%\" valign=\"top\"\u003e\n \u003cp\u003e1.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.896551724137931%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.6923076923076925%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.305039787798409%\" valign=\"top\"\u003e\n \u003cp\u003e0.783\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"11.007957559681698%\" valign=\"top\"\u003e\n \u003cp\u003eNo\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e148(79.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.753315649867375%\" valign=\"top\"\u003e\n \u003cp\u003e61(76.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.885941644562335%\" valign=\"top\"\u003e\n \u003cp\u003e87(82.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.172413793103448%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.488063660477454%\" valign=\"top\"\u003e\n \u003cp\u003e94(78.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.427055702917772%\" valign=\"top\"\u003e\n \u003cp\u003e47(78.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.222811671087532%\" valign=\"top\"\u003e\n \u003cp\u003e47(78.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.437665782493369%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e107(87.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.896551724137931%\" valign=\"top\"\u003e\n \u003cp\u003e53(86.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.6923076923076925%\" valign=\"top\"\u003e\n \u003cp\u003e54(88.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.305039787798409%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"11.007957559681698%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp; Yes\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e38(20.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.753315649867375%\" valign=\"top\"\u003e\n \u003cp\u003e19(23.7）\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.885941644562335%\" valign=\"top\"\u003e\n \u003cp\u003e19(17.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.172413793103448%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.488063660477454%\" valign=\"top\"\u003e\n \u003cp\u003e26(21.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.427055702917772%\" valign=\"top\"\u003e\n \u003cp\u003e13(21.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.222811671087532%\" valign=\"top\"\u003e\n \u003cp\u003e13(21.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.437665782493369%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e15(12.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.896551724137931%\" valign=\"top\"\u003e\n \u003cp\u003e8(13.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.6923076923076925%\" valign=\"top\"\u003e\n \u003cp\u003e7(11.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.305039787798409%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"11.007957559681698%\" valign=\"top\"\u003e\n \u003cp\u003eLiver Metastasis\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.753315649867375%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.885941644562335%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.172413793103448%\" valign=\"top\"\u003e\n \u003cp\u003e0.057\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.488063660477454%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.427055702917772%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.222811671087532%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.437665782493369%\" valign=\"top\"\u003e\n \u003cp\u003e0.827\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.896551724137931%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.6923076923076925%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.305039787798409%\" valign=\"top\"\u003e\n \u003cp\u003e0.817\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"11.007957559681698%\" valign=\"top\"\u003e\n \u003cp\u003eNo\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e147(79.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.753315649867375%\" valign=\"top\"\u003e\n \u003cp\u003e58(72.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.885941644562335%\" valign=\"top\"\u003e\n \u003cp\u003e89(84.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.172413793103448%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.488063660477454%\" valign=\"top\"\u003e\n \u003cp\u003e93(77.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.427055702917772%\" valign=\"top\"\u003e\n \u003cp\u003e47(78.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.222811671087532%\" valign=\"top\"\u003e\n \u003cp\u003e46(76.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.437665782493369%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e99(81.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.896551724137931%\" valign=\"top\"\u003e\n \u003cp\u003e50(82.0)）\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.6923076923076925%\" valign=\"top\"\u003e\n \u003cp\u003e49(80.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.305039787798409%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"11.007957559681698%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp; Yes\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e39(21.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.753315649867375%\" valign=\"top\"\u003e\n \u003cp\u003e22(27.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.885941644562335%\" valign=\"top\"\u003e\n \u003cp\u003e17(16.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.172413793103448%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.488063660477454%\" valign=\"top\"\u003e\n \u003cp\u003e27(22.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.427055702917772%\" valign=\"top\"\u003e\n \u003cp\u003e13(21.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.222811671087532%\" valign=\"top\"\u003e\n \u003cp\u003e14(23.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.437665782493369%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e23(18.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.896551724137931%\" valign=\"top\"\u003e\n \u003cp\u003e11(18.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.6923076923076925%\" valign=\"top\"\u003e\n \u003cp\u003e12(19.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.305039787798409%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"11.007957559681698%\" valign=\"top\"\u003e\n \u003cp\u003eBone Metastasis\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.753315649867375%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.885941644562335%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.172413793103448%\" valign=\"top\"\u003e\n \u003cp\u003e0.385\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.488063660477454%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.427055702917772%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.222811671087532%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.437665782493369%\" valign=\"top\"\u003e\n \u003cp\u003e0.559\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.896551724137931%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.6923076923076925%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.305039787798409%\" valign=\"top\"\u003e\n \u003cp\u003e0.832\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"11.007957559681698%\" valign=\"top\"\u003e\n \u003cp\u003eNo\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e134(72.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.753315649867375%\" valign=\"top\"\u003e\n \u003cp\u003e55(68.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.885941644562335%\" valign=\"top\"\u003e\n \u003cp\u003e79(74.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.172413793103448%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.488063660477454%\" valign=\"top\"\u003e\n \u003cp\u003e81(67.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.427055702917772%\" valign=\"top\"\u003e\n \u003cp\u003e42(70.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.222811671087532%\" valign=\"top\"\u003e\n \u003cp\u003e39(65.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.437665782493369%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e93(76.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.896551724137931%\" valign=\"top\"\u003e\n \u003cp\u003e47(77.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.6923076923076925%\" valign=\"top\"\u003e\n \u003cp\u003e46(75.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.305039787798409%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"11.007957559681698%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp; Yes\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e52(28.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.753315649867375%\" valign=\"top\"\u003e\n \u003cp\u003e25(31.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.885941644562335%\" valign=\"top\"\u003e\n \u003cp\u003e27(25.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.172413793103448%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.488063660477454%\" valign=\"top\"\u003e\n \u003cp\u003e39(32.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.427055702917772%\" valign=\"top\"\u003e\n \u003cp\u003e18(30.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.222811671087532%\" valign=\"top\"\u003e\n \u003cp\u003e21(35.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.437665782493369%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e29(23.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.896551724137931%\" valign=\"top\"\u003e\n \u003cp\u003e14(23.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.6923076923076925%\" valign=\"top\"\u003e\n \u003cp\u003e15(24.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.305039787798409%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"11.007957559681698%\" valign=\"top\"\u003e\n \u003cp\u003eLung Metastasis\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.753315649867375%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.885941644562335%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.172413793103448%\" valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.010\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.488063660477454%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.427055702917772%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.222811671087532%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.437665782493369%\" valign=\"top\"\u003e\n \u003cp\u003e1.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.896551724137931%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.6923076923076925%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.305039787798409%\" valign=\"top\"\u003e\n \u003cp\u003e0.667\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"11.007957559681698%\" valign=\"top\"\u003e\n \u003cp\u003eNo\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e149(80.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.753315649867375%\" valign=\"top\"\u003e\n \u003cp\u003e71(88.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.885941644562335%\" valign=\"top\"\u003e\n \u003cp\u003e78(73.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.172413793103448%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.488063660477454%\" valign=\"top\"\u003e\n \u003cp\u003e102(85.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.427055702917772%\" valign=\"top\"\u003e\n \u003cp\u003e51(85.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.222811671087532%\" valign=\"top\"\u003e\n \u003cp\u003e51(85.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.437665782493369%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e94(77.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.896551724137931%\" valign=\"top\"\u003e\n \u003cp\u003e48(78.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.6923076923076925%\" valign=\"top\"\u003e\n \u003cp\u003e46(75.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.305039787798409%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"11.007957559681698%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp; Yes\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e37(19.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.753315649867375%\" valign=\"top\"\u003e\n \u003cp\u003e9(11.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.885941644562335%\" valign=\"top\"\u003e\n \u003cp\u003e28(26.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.172413793103448%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.488063660477454%\" valign=\"top\"\u003e\n \u003cp\u003e18(15.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.427055702917772%\" valign=\"top\"\u003e\n \u003cp\u003e9(15.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.222811671087532%\" valign=\"top\"\u003e\n \u003cp\u003e9(15.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.437665782493369%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e28(23.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.896551724137931%\" valign=\"top\"\u003e\n \u003cp\u003e13(21.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.6923076923076925%\" valign=\"top\"\u003e\n \u003cp\u003e15(24.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.305039787798409%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"11.007957559681698%\" valign=\"top\"\u003e\n \u003cp\u003eAdrenal gland Metastasis\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.753315649867375%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.885941644562335%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.172413793103448%\" valign=\"top\"\u003e\n \u003cp\u003e0.058\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.488063660477454%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.427055702917772%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.222811671087532%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.437665782493369%\" valign=\"top\"\u003e\n \u003cp\u003e0.697\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.896551724137931%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.6923076923076925%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.305039787798409%\" valign=\"top\"\u003e\n \u003cp\u003e0.464\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"11.007957559681698%\" valign=\"top\"\u003e\n \u003cp\u003eNo\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e169(90.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.753315649867375%\" valign=\"top\"\u003e\n \u003cp\u003e69(86.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.885941644562335%\" valign=\"top\"\u003e\n \u003cp\u003e100(94.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.172413793103448%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.488063660477454%\" valign=\"top\"\u003e\n \u003cp\u003e113(94.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.427055702917772%\" valign=\"top\"\u003e\n \u003cp\u003e56(93.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.222811671087532%\" valign=\"top\"\u003e\n \u003cp\u003e57(95.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.437665782493369%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e114(93.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.896551724137931%\" valign=\"top\"\u003e\n \u003cp\u003e58(95.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.6923076923076925%\" valign=\"top\"\u003e\n \u003cp\u003e56(91.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.305039787798409%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"11.007957559681698%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp; Yes\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e17(9.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.753315649867375%\" valign=\"top\"\u003e\n \u003cp\u003e11(13.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.885941644562335%\" valign=\"top\"\u003e\n \u003cp\u003e6(5.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.172413793103448%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.488063660477454%\" valign=\"top\"\u003e\n \u003cp\u003e7(5.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.427055702917772%\" valign=\"top\"\u003e\n \u003cp\u003e4(6.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.222811671087532%\" valign=\"top\"\u003e\n \u003cp\u003e3(5.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.437665782493369%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e8(6.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.896551724137931%\" valign=\"top\"\u003e\n \u003cp\u003e3(4.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.6923076923076925%\" valign=\"top\"\u003e\n \u003cp\u003e5(8.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.305039787798409%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"11.007957559681698%\" valign=\"top\"\u003e\n \u003cp\u003eRadiotherapy\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.753315649867375%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.885941644562335%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.172413793103448%\" valign=\"top\"\u003e\n \u003cp\u003e0.310\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.488063660477454%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.427055702917772%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.222811671087532%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.437665782493369%\" valign=\"top\"\u003e\n \u003cp\u003e1.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.896551724137931%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.6923076923076925%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.305039787798409%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"11.007957559681698%\" valign=\"top\"\u003e\n \u003cp\u003eYes\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e87(46.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.753315649867375%\" valign=\"top\"\u003e\n \u003cp\u003e34(42.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.885941644562335%\" valign=\"top\"\u003e\n \u003cp\u003e53(50.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.172413793103448%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.488063660477454%\" valign=\"top\"\u003e\n \u003cp\u003e56(46.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.427055702917772%\" valign=\"top\"\u003e\n \u003cp\u003e28(46.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.222811671087532%\" valign=\"top\"\u003e\n \u003cp\u003e28(46.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.437665782493369%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.896551724137931%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.6923076923076925%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.305039787798409%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"11.007957559681698%\" valign=\"top\"\u003e\n \u003cp\u003eNo\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e99(53.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.753315649867375%\" valign=\"top\"\u003e\n \u003cp\u003e46(57.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.885941644562335%\" valign=\"top\"\u003e\n \u003cp\u003e53(50.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.172413793103448%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.488063660477454%\" valign=\"top\"\u003e\n \u003cp\u003e64(53.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.427055702917772%\" valign=\"top\"\u003e\n \u003cp\u003e32(53.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.222811671087532%\" valign=\"top\"\u003e\n \u003cp\u003e32(53.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.437665782493369%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.896551724137931%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.6923076923076925%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.305039787798409%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"11.007957559681698%\" valign=\"top\"\u003e\n \u003cp\u003eImmunotherapy\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.753315649867375%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.885941644562335%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.172413793103448%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.488063660477454%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.427055702917772%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.222811671087532%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.437665782493369%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.896551724137931%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.6923076923076925%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.305039787798409%\" valign=\"top\"\u003e\n \u003cp\u003e0.127\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"11.007957559681698%\" valign=\"top\"\u003e\n \u003cp\u003eYes\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e80(43.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.753315649867375%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.885941644562335%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.172413793103448%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.488063660477454%\" valign=\"top\"\u003e\n \u003cp\u003e60(50.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.427055702917772%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.222811671087532%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.437665782493369%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e42(34.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.896551724137931%\" valign=\"top\"\u003e\n \u003cp\u003e25(41.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.6923076923076925%\" valign=\"top\"\u003e\n \u003cp\u003e17(27.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.305039787798409%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"11.007957559681698%\" valign=\"top\"\u003e\n \u003cp\u003eNo\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e106(57.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.753315649867375%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.885941644562335%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.172413793103448%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.488063660477454%\" valign=\"top\"\u003e\n \u003cp\u003e60(50.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.427055702917772%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.222811671087532%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.437665782493369%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e80(65.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.896551724137931%\" valign=\"top\"\u003e\n \u003cp\u003e36(59.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.6923076923076925%\" valign=\"top\"\u003e\n \u003cp\u003e44(72.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.305039787798409%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"11.007957559681698%\" valign=\"top\"\u003e\n \u003cp\u003eChemotherapy\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.753315649867375%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.885941644562335%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.172413793103448%\" valign=\"top\"\u003e\n \u003cp\u003e0.836\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.488063660477454%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.427055702917772%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.222811671087532%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.437665782493369%\" valign=\"top\"\u003e\n \u003cp\u003e0.618\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.896551724137931%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.6923076923076925%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.305039787798409%\" valign=\"top\"\u003e\n \u003cp\u003e0.069\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"11.007957559681698%\" valign=\"top\"\u003e\n \u003cp\u003eEC\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e67(36)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.753315649867375%\" valign=\"top\"\u003e\n \u003cp\u003e27(33.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.885941644562335%\" valign=\"top\"\u003e\n \u003cp\u003e40(37.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.172413793103448%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.488063660477454%\" valign=\"top\"\u003e\n \u003cp\u003e41(34.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.427055702917772%\" valign=\"top\"\u003e\n \u003cp\u003e18(30.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.222811671087532%\" valign=\"top\"\u003e\n \u003cp\u003e23(38.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.437665782493369%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e42(34.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.896551724137931%\" valign=\"top\"\u003e\n \u003cp\u003e18(29.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.6923076923076925%\" valign=\"top\"\u003e\n \u003cp\u003e24(39.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.305039787798409%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"11.007957559681698%\" valign=\"top\"\u003e\n \u003cp\u003eEP\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e107(57.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.753315649867375%\" valign=\"top\"\u003e\n \u003cp\u003e48(60.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.885941644562335%\" valign=\"top\"\u003e\n \u003cp\u003e59(55.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.172413793103448%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.488063660477454%\" valign=\"top\"\u003e\n \u003cp\u003e71(59.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.427055702917772%\" valign=\"top\"\u003e\n \u003cp\u003e38(63.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.222811671087532%\" valign=\"top\"\u003e\n \u003cp\u003e33(55.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.437665782493369%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e71(58.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.896551724137931%\" valign=\"top\"\u003e\n \u003cp\u003e41(67.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.6923076923076925%\" valign=\"top\"\u003e\n \u003cp\u003e30(49.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.305039787798409%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"11.007957559681698%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp; Other\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e12(6.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.753315649867375%\" valign=\"top\"\u003e\n \u003cp\u003e5(6.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.885941644562335%\" valign=\"top\"\u003e\n \u003cp\u003e7(6.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.172413793103448%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.488063660477454%\" valign=\"top\"\u003e\n \u003cp\u003e8(6.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.427055702917772%\" valign=\"top\"\u003e\n \u003cp\u003e4(6.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.222811671087532%\" valign=\"top\"\u003e\n \u003cp\u003e4(6.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.437665782493369%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e9(7.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.896551724137931%\" valign=\"top\"\u003e\n \u003cp\u003e2(3.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.6923076923076925%\" valign=\"top\"\u003e\n \u003cp\u003e7(11.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.305039787798409%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"11.02257636122178%\" valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003erwPFS\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"31.07569721115538%\" colspan=\"4\" valign=\"top\"\u003e\n \u003cp\u003eBefore matching, n (%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"29.614873837981406%\" colspan=\"4\" valign=\"top\"\u003e\n \u003cp\u003eAfter matching, n (%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"28.286852589641434%\" colspan=\"4\" valign=\"top\"\u003e\n \u003cp\u003eAfter matching, n (%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"11.007957559681698%\" valign=\"top\"\u003e\n \u003cp\u003eCharacteristics\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003eAll patients\u003c/p\u003e\n \u003cp\u003eN=176(%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.753315649867375%\" valign=\"top\"\u003e\n \u003cp\u003eCT+IT\u003c/p\u003e\n \u003cp\u003e\u0026nbsp;N=79(%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.885941644562335%\" valign=\"top\"\u003e\n \u003cp\u003eCT\u003c/p\u003e\n \u003cp\u003eN=97(%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.172413793103448%\" valign=\"top\"\u003e\n \u003cp\u003e\u003cem\u003eP\u003c/em\u003e-Value\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.488063660477454%\" valign=\"top\"\u003e\n \u003cp\u003eAll patients\u003c/p\u003e\n \u003cp\u003eN=116(%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.427055702917772%\" valign=\"top\"\u003e\n \u003cp\u003eCT+IT\u003c/p\u003e\n \u003cp\u003eN=58(%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.222811671087532%\" valign=\"top\"\u003e\n \u003cp\u003eCT\u003c/p\u003e\n \u003cp\u003eN=58(%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.437665782493369%\" valign=\"top\"\u003e\n \u003cp\u003eP-value\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003eAll patients\u003c/p\u003e\n \u003cp\u003eN=114 (%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.896551724137931%\" valign=\"top\"\u003e\n \u003cp\u003eCT+RT\u003c/p\u003e\n \u003cp\u003eN=57(%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.6923076923076925%\" valign=\"top\"\u003e\n \u003cp\u003eCT\u003c/p\u003e\n \u003cp\u003eN=57(%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.305039787798409%\" valign=\"top\"\u003e\n \u003cp\u003e\u003cem\u003eP\u003c/em\u003e-Value\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"11.007957559681698%\" valign=\"top\"\u003e\n \u003cp\u003eMedian age\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e65(41-85)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.753315649867375%\" valign=\"top\"\u003e\n \u003cp\u003e64(45-85)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.885941644562335%\" valign=\"top\"\u003e\n \u003cp\u003e65(41-81)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.172413793103448%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.488063660477454%\" valign=\"top\"\u003e\n \u003cp\u003e65(41-85)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.427055702917772%\" valign=\"top\"\u003e\n \u003cp\u003e65(32-85)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.222811671087532%\" valign=\"top\"\u003e\n \u003cp\u003e64.5(44-81)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.437665782493369%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.896551724137931%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.6923076923076925%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.305039787798409%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"11.007957559681698%\" valign=\"top\"\u003e\n \u003cp\u003eAge, year\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.753315649867375%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.885941644562335%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.172413793103448%\" valign=\"top\"\u003e\n \u003cp\u003e0.888\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.488063660477454%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.427055702917772%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.222811671087532%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.437665782493369%\" valign=\"top\"\u003e\n \u003cp\u003e0.264\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.896551724137931%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.6923076923076925%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.305039787798409%\" valign=\"top\"\u003e\n \u003cp\u003e0.183\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"11.007957559681698%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026le;65\u0026nbsp;yrs\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e97(55.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.753315649867375%\" valign=\"top\"\u003e\n \u003cp\u003e44(55.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.885941644562335%\" valign=\"top\"\u003e\n \u003cp\u003e53(54.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.172413793103448%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.488063660477454%\" valign=\"top\"\u003e\n \u003cp\u003e62(53.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.427055702917772%\" valign=\"top\"\u003e\n \u003cp\u003e34(58.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.222811671087532%\" valign=\"top\"\u003e\n \u003cp\u003e28(48.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.437665782493369%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e67(58.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.896551724137931%\" valign=\"top\"\u003e\n \u003cp\u003e37(64.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.6923076923076925%\" valign=\"top\"\u003e\n \u003cp\u003e30(52.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.305039787798409%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"11.007957559681698%\" valign=\"top\"\u003e\n \u003cp\u003e＞65 yrs\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e79(44.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.753315649867375%\" valign=\"top\"\u003e\n \u003cp\u003e35(44.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.885941644562335%\" valign=\"top\"\u003e\n \u003cp\u003e44(45.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.172413793103448%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.488063660477454%\" valign=\"top\"\u003e\n \u003cp\u003e54(46.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.427055702917772%\" valign=\"top\"\u003e\n \u003cp\u003e24(41.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.222811671087532%\" valign=\"top\"\u003e\n \u003cp\u003e30(51.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.437665782493369%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e47(41.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.896551724137931%\" valign=\"top\"\u003e\n \u003cp\u003e20(35.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.6923076923076925%\" valign=\"top\"\u003e\n \u003cp\u003e27(47.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.305039787798409%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"11.007957559681698%\" valign=\"top\"\u003e\n \u003cp\u003eGender\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.753315649867375%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.885941644562335%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.172413793103448%\" valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.044\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.488063660477454%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.427055702917772%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.222811671087532%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.437665782493369%\" valign=\"top\"\u003e\n \u003cp\u003e1.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.896551724137931%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.6923076923076925%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.305039787798409%\" valign=\"top\"\u003e\n \u003cp\u003e0.372\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"11.007957559681698%\" valign=\"top\"\u003e\n \u003cp\u003eFemale\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e43(24.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.753315649867375%\" valign=\"top\"\u003e\n \u003cp\u003e25(31.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.885941644562335%\" valign=\"top\"\u003e\n \u003cp\u003e18(18.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.172413793103448%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.488063660477454%\" valign=\"top\"\u003e\n \u003cp\u003e30(25.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.427055702917772%\" valign=\"top\"\u003e\n \u003cp\u003e15(25.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.222811671087532%\" valign=\"top\"\u003e\n \u003cp\u003e15(25.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.437665782493369%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e26(22.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.896551724137931%\" valign=\"top\"\u003e\n \u003cp\u003e15(26.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.6923076923076925%\" valign=\"top\"\u003e\n \u003cp\u003e11(19.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.305039787798409%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"11.007957559681698%\" valign=\"top\"\u003e\n \u003cp\u003eMale\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e133(75.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.753315649867375%\" valign=\"top\"\u003e\n \u003cp\u003e54(68.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.885941644562335%\" valign=\"top\"\u003e\n \u003cp\u003e79(71.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.172413793103448%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.488063660477454%\" valign=\"top\"\u003e\n \u003cp\u003e86(74.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.427055702917772%\" valign=\"top\"\u003e\n \u003cp\u003e43(74.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.222811671087532%\" valign=\"top\"\u003e\n \u003cp\u003e43(74.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.437665782493369%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e88(77.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.896551724137931%\" valign=\"top\"\u003e\n \u003cp\u003e42(73.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.6923076923076925%\" valign=\"top\"\u003e\n \u003cp\u003e46(80.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.305039787798409%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"11.007957559681698%\" valign=\"top\"\u003e\n \u003cp\u003eSmoking history\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.753315649867375%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.885941644562335%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.172413793103448%\" valign=\"top\"\u003e\n \u003cp\u003e0.733\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.488063660477454%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.427055702917772%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.222811671087532%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.437665782493369%\" valign=\"top\"\u003e\n \u003cp\u003e0.849\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.896551724137931%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.6923076923076925%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.305039787798409%\" valign=\"top\"\u003e\n \u003cp\u003e0.704\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"11.007957559681698%\" valign=\"top\"\u003e\n \u003cp\u003eNever smoked\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e76(43.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.753315649867375%\" valign=\"top\"\u003e\n \u003cp\u003e33(41.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.885941644562335%\" valign=\"top\"\u003e\n \u003cp\u003e43(44.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.172413793103448%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.488063660477454%\" valign=\"top\"\u003e\n \u003cp\u003e45(38.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.427055702917772%\" valign=\"top\"\u003e\n \u003cp\u003e22(37.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.222811671087532%\" valign=\"top\"\u003e\n \u003cp\u003e23(39.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.437665782493369%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e48(42.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.896551724137931%\" valign=\"top\"\u003e\n \u003cp\u003e25(43.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.6923076923076925%\" valign=\"top\"\u003e\n \u003cp\u003e23(40.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.305039787798409%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"11.007957559681698%\" valign=\"top\"\u003e\n \u003cp\u003eFormer/current\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e100(56.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.753315649867375%\" valign=\"top\"\u003e\n \u003cp\u003e46(58.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.885941644562335%\" valign=\"top\"\u003e\n \u003cp\u003e54(55.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.172413793103448%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.488063660477454%\" valign=\"top\"\u003e\n \u003cp\u003e71(61.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.427055702917772%\" valign=\"top\"\u003e\n \u003cp\u003e36(62.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.222811671087532%\" valign=\"top\"\u003e\n \u003cp\u003e35(60.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.437665782493369%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e66(57.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.896551724137931%\" valign=\"top\"\u003e\n \u003cp\u003e32(56.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.6923076923076925%\" valign=\"top\"\u003e\n \u003cp\u003e34(59.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.305039787798409%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"11.007957559681698%\" valign=\"top\"\u003e\n \u003cp\u003eFamily tumor history\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.753315649867375%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.885941644562335%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.172413793103448%\" valign=\"top\"\u003e\n \u003cp\u003e0.361\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.488063660477454%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.427055702917772%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.222811671087532%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.437665782493369%\" valign=\"top\"\u003e\n \u003cp\u003e0.150\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.896551724137931%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.6923076923076925%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.305039787798409%\" valign=\"top\"\u003e\n \u003cp\u003e0.663\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"11.007957559681698%\" valign=\"top\"\u003e\n \u003cp\u003eNo\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e130(73.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.753315649867375%\" valign=\"top\"\u003e\n \u003cp\u003e61(77.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.885941644562335%\" valign=\"top\"\u003e\n \u003cp\u003e69(71.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.172413793103448%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.488063660477454%\" valign=\"top\"\u003e\n \u003cp\u003e83(71.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.427055702917772%\" valign=\"top\"\u003e\n \u003cp\u003e45(77.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.222811671087532%\" valign=\"top\"\u003e\n \u003cp\u003e38(65.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.437665782493369%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e86(75.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.896551724137931%\" valign=\"top\"\u003e\n \u003cp\u003e42(73.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.6923076923076925%\" valign=\"top\"\u003e\n \u003cp\u003e44(77.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.305039787798409%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"11.007957559681698%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp; Yes\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e46(26.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.753315649867375%\" valign=\"top\"\u003e\n \u003cp\u003e18(22.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.885941644562335%\" valign=\"top\"\u003e\n \u003cp\u003e28(28.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.172413793103448%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.488063660477454%\" valign=\"top\"\u003e\n \u003cp\u003e33(28.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.427055702917772%\" valign=\"top\"\u003e\n \u003cp\u003e13(22.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.222811671087532%\" valign=\"top\"\u003e\n \u003cp\u003e20(34.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.437665782493369%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e28(24.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.896551724137931%\" valign=\"top\"\u003e\n \u003cp\u003e15(26.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.6923076923076925%\" valign=\"top\"\u003e\n \u003cp\u003e13(22.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.305039787798409%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"11.007957559681698%\" valign=\"top\"\u003e\n \u003cp\u003eHypertension\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.753315649867375%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.885941644562335%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.172413793103448%\" valign=\"top\"\u003e\n \u003cp\u003e0.626\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.488063660477454%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.427055702917772%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.222811671087532%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.437665782493369%\" valign=\"top\"\u003e\n \u003cp\u003e1.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.896551724137931%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.6923076923076925%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.305039787798409%\" valign=\"top\"\u003e\n \u003cp\u003e0.317\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"11.007957559681698%\" valign=\"top\"\u003e\n \u003cp\u003eNo\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e117(66.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.753315649867375%\" valign=\"top\"\u003e\n \u003cp\u003e51(64.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.885941644562335%\" valign=\"top\"\u003e\n \u003cp\u003e66(68.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.172413793103448%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.488063660477454%\" valign=\"top\"\u003e\n \u003cp\u003e72(62.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.427055702917772%\" valign=\"top\"\u003e\n \u003cp\u003e36(62.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.222811671087532%\" valign=\"top\"\u003e\n \u003cp\u003e36(62.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.437665782493369%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e77(67.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.896551724137931%\" valign=\"top\"\u003e\n \u003cp\u003e36(63.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.6923076923076925%\" valign=\"top\"\u003e\n \u003cp\u003e41(71.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.305039787798409%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"11.007957559681698%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp; Yes\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e59(33.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.753315649867375%\" valign=\"top\"\u003e\n \u003cp\u003e28(35.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.885941644562335%\" valign=\"top\"\u003e\n \u003cp\u003e31(32.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.172413793103448%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.488063660477454%\" valign=\"top\"\u003e\n \u003cp\u003e44(37.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.427055702917772%\" valign=\"top\"\u003e\n \u003cp\u003e22(37.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.222811671087532%\" valign=\"top\"\u003e\n \u003cp\u003e22(37.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.437665782493369%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e37(32.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.896551724137931%\" valign=\"top\"\u003e\n \u003cp\u003e21(36.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.6923076923076925%\" valign=\"top\"\u003e\n \u003cp\u003e16(28.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.305039787798409%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"11.007957559681698%\" valign=\"top\"\u003e\n \u003cp\u003eDiabetes\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.753315649867375%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.885941644562335%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.172413793103448%\" valign=\"top\"\u003e\n \u003cp\u003e0.711\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.488063660477454%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.427055702917772%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.222811671087532%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.437665782493369%\" valign=\"top\"\u003e\n \u003cp\u003e0.623\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.896551724137931%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.6923076923076925%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.305039787798409%\" valign=\"top\"\u003e\n \u003cp\u003e0.802\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"11.007957559681698%\" valign=\"top\"\u003e\n \u003cp\u003eNo\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e149(84.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.753315649867375%\" valign=\"top\"\u003e\n \u003cp\u003e66(83.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.885941644562335%\" valign=\"top\"\u003e\n \u003cp\u003e83(85.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.172413793103448%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.488063660477454%\" valign=\"top\"\u003e\n \u003cp\u003e96(82.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.427055702917772%\" valign=\"top\"\u003e\n \u003cp\u003e49(84.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.222811671087532%\" valign=\"top\"\u003e\n \u003cp\u003e47(81.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.437665782493369%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e95(83.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.896551724137931%\" valign=\"top\"\u003e\n \u003cp\u003e47(82.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.6923076923076925%\" valign=\"top\"\u003e\n \u003cp\u003e48(84.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.305039787798409%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"11.007957559681698%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp; Yes\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e27(15.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.753315649867375%\" valign=\"top\"\u003e\n \u003cp\u003e13(16.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.885941644562335%\" valign=\"top\"\u003e\n \u003cp\u003e14(14.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.172413793103448%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.488063660477454%\" valign=\"top\"\u003e\n \u003cp\u003e20(17.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.427055702917772%\" valign=\"top\"\u003e\n \u003cp\u003e9(15.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.222811671087532%\" valign=\"top\"\u003e\n \u003cp\u003e11(19.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.437665782493369%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e19(16.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.896551724137931%\" valign=\"top\"\u003e\n \u003cp\u003e10(17.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.6923076923076925%\" valign=\"top\"\u003e\n \u003cp\u003e9(15.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.305039787798409%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"11.007957559681698%\" valign=\"top\"\u003e\n \u003cp\u003eECOG PS\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.753315649867375%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.885941644562335%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.172413793103448%\" valign=\"top\"\u003e\n \u003cp\u003e0.506\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.488063660477454%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.427055702917772%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.222811671087532%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.437665782493369%\" valign=\"top\"\u003e\n \u003cp\u003e0.309\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.896551724137931%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.6923076923076925%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.305039787798409%\" valign=\"top\"\u003e\n \u003cp\u003e0.079\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"11.007957559681698%\" valign=\"top\"\u003e\n \u003cp\u003e0-1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e169(96.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.753315649867375%\" valign=\"top\"\u003e\n \u003cp\u003e75(94.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.885941644562335%\" valign=\"top\"\u003e\n \u003cp\u003e94(96.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.172413793103448%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.488063660477454%\" valign=\"top\"\u003e\n \u003cp\u003e112(96.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.427055702917772%\" valign=\"top\"\u003e\n \u003cp\u003e57(98.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.222811671087532%\" valign=\"top\"\u003e\n \u003cp\u003e55(94.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.437665782493369%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e111(97.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.896551724137931%\" valign=\"top\"\u003e\n \u003cp\u003e57(100)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.6923076923076925%\" valign=\"top\"\u003e\n \u003cp\u003e54(94.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.305039787798409%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"11.007957559681698%\" valign=\"top\"\u003e\n \u003cp\u003e2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e7(4.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.753315649867375%\" valign=\"top\"\u003e\n \u003cp\u003e4(5.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.885941644562335%\" valign=\"top\"\u003e\n \u003cp\u003e3(3.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.172413793103448%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.488063660477454%\" valign=\"top\"\u003e\n \u003cp\u003e4(3.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.427055702917772%\" valign=\"top\"\u003e\n \u003cp\u003e1(1.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.222811671087532%\" valign=\"top\"\u003e\n \u003cp\u003e3(5.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.437665782493369%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e3(2.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.896551724137931%\" valign=\"top\"\u003e\n \u003cp\u003e0(0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.6923076923076925%\" valign=\"top\"\u003e\n \u003cp\u003e3(5.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.305039787798409%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"11.007957559681698%\" valign=\"top\"\u003e\n \u003cp\u003eBrain Metastasis\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.753315649867375%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.885941644562335%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.172413793103448%\" valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.044\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.488063660477454%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.427055702917772%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.222811671087532%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.437665782493369%\" valign=\"top\"\u003e\n \u003cp\u003e0.623\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.896551724137931%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.6923076923076925%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.305039787798409%\" valign=\"top\"\u003e\n \u003cp\u003e0.646\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"11.007957559681698%\" valign=\"top\"\u003e\n \u003cp\u003eNo\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e143(81.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.753315649867375%\" valign=\"top\"\u003e\n \u003cp\u003e59(74.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.885941644562335%\" valign=\"top\"\u003e\n \u003cp\u003e84(86.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.172413793103448%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.488063660477454%\" valign=\"top\"\u003e\n \u003cp\u003e96(82.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.427055702917772%\" valign=\"top\"\u003e\n \u003cp\u003e49(84.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.222811671087532%\" valign=\"top\"\u003e\n \u003cp\u003e47(81.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.437665782493369%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e90(78.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.896551724137931%\" valign=\"top\"\u003e\n \u003cp\u003e44(77.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.6923076923076925%\" valign=\"top\"\u003e\n \u003cp\u003e46(80.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.305039787798409%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"11.007957559681698%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp; Yes\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e33(28.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.753315649867375%\" valign=\"top\"\u003e\n \u003cp\u003e20(25.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.885941644562335%\" valign=\"top\"\u003e\n \u003cp\u003e13(13.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.172413793103448%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.488063660477454%\" valign=\"top\"\u003e\n \u003cp\u003e20(17.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.427055702917772%\" valign=\"top\"\u003e\n \u003cp\u003e9(15.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.222811671087532%\" valign=\"top\"\u003e\n \u003cp\u003e11(19.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.437665782493369%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e24(21.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.896551724137931%\" valign=\"top\"\u003e\n \u003cp\u003e13(22.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.6923076923076925%\" valign=\"top\"\u003e\n \u003cp\u003e11(19.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.305039787798409%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"11.007957559681698%\" valign=\"top\"\u003e\n \u003cp\u003eLiver Metastasis\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.753315649867375%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.885941644562335%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.172413793103448%\" valign=\"top\"\u003e\n \u003cp\u003e0.143\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.488063660477454%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.427055702917772%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.222811671087532%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.437665782493369%\" valign=\"top\"\u003e\n \u003cp\u003e0.816\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.896551724137931%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.6923076923076925%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.305039787798409%\" valign=\"top\"\u003e\n \u003cp\u003e0.395\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"11.007957559681698%\" valign=\"top\"\u003e\n \u003cp\u003eNo\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e136(77.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.753315649867375%\" valign=\"top\"\u003e\n \u003cp\u003e57(72.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.885941644562335%\" valign=\"top\"\u003e\n \u003cp\u003e79(81.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.172413793103448%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.488063660477454%\" valign=\"top\"\u003e\n \u003cp\u003e93(80.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.427055702917772%\" valign=\"top\"\u003e\n \u003cp\u003e46(79.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.222811671087532%\" valign=\"top\"\u003e\n \u003cp\u003e47(81.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.437665782493369%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e84(73.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.896551724137931%\" valign=\"top\"\u003e\n \u003cp\u003e40(70.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.6923076923076925%\" valign=\"top\"\u003e\n \u003cp\u003e44(77.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.305039787798409%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"11.007957559681698%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp; Yes\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e40(22.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.753315649867375%\" valign=\"top\"\u003e\n \u003cp\u003e22(27.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.885941644562335%\" valign=\"top\"\u003e\n \u003cp\u003e18(18.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.172413793103448%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.488063660477454%\" valign=\"top\"\u003e\n \u003cp\u003e23(19.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.427055702917772%\" valign=\"top\"\u003e\n \u003cp\u003e12(20.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.222811671087532%\" valign=\"top\"\u003e\n \u003cp\u003e11(19.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.437665782493369%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e30(26.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.896551724137931%\" valign=\"top\"\u003e\n \u003cp\u003e17(29.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.6923076923076925%\" valign=\"top\"\u003e\n \u003cp\u003e13(22.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.305039787798409%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"11.007957559681698%\" valign=\"top\"\u003e\n \u003cp\u003eBone Metastasis\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.753315649867375%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.885941644562335%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.172413793103448%\" valign=\"top\"\u003e\n \u003cp\u003e0.689\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.488063660477454%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.427055702917772%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.222811671087532%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.437665782493369%\" valign=\"top\"\u003e\n \u003cp\u003e0.844\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.896551724137931%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.6923076923076925%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.305039787798409%\" valign=\"top\"\u003e\n \u003cp\u003e0.558\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"11.007957559681698%\" valign=\"top\"\u003e\n \u003cp\u003eNo\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e123(69.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.753315649867375%\" valign=\"top\"\u003e\n \u003cp\u003e54(68.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.885941644562335%\" valign=\"top\"\u003e\n \u003cp\u003e69(71.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.172413793103448%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.488063660477454%\" valign=\"top\"\u003e\n \u003cp\u003e77(66.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.427055702917772%\" valign=\"top\"\u003e\n \u003cp\u003e39(67.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.222811671087532%\" valign=\"top\"\u003e\n \u003cp\u003e38(65.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.437665782493369%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e73(64.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.896551724137931%\" valign=\"top\"\u003e\n \u003cp\u003e35(61.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.6923076923076925%\" valign=\"top\"\u003e\n \u003cp\u003e38(66.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.305039787798409%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"11.007957559681698%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp; Yes\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e53(30.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.753315649867375%\" valign=\"top\"\u003e\n \u003cp\u003e25(31.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.885941644562335%\" valign=\"top\"\u003e\n \u003cp\u003e28(28.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.172413793103448%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.488063660477454%\" valign=\"top\"\u003e\n \u003cp\u003e39(33.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.427055702917772%\" valign=\"top\"\u003e\n \u003cp\u003e19(32.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.222811671087532%\" valign=\"top\"\u003e\n \u003cp\u003e20(34.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.437665782493369%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e41(36.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.896551724137931%\" valign=\"top\"\u003e\n \u003cp\u003e22(38.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.6923076923076925%\" valign=\"top\"\u003e\n \u003cp\u003e19(33.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.305039787798409%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"11.007957559681698%\" valign=\"top\"\u003e\n \u003cp\u003eLung Metastasis\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.753315649867375%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.885941644562335%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.172413793103448%\" valign=\"top\"\u003e\n \u003cp\u003e0.275\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.488063660477454%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.427055702917772%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.222811671087532%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.437665782493369%\" valign=\"top\"\u003e\n \u003cp\u003e1.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.896551724137931%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.6923076923076925%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.305039787798409%\" valign=\"top\"\u003e\n \u003cp\u003e0.590\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"11.007957559681698%\" valign=\"top\"\u003e\n \u003cp\u003eNo\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e143(81.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.753315649867375%\" valign=\"top\"\u003e\n \u003cp\u003e67(84.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.885941644562335%\" valign=\"top\"\u003e\n \u003cp\u003e76(78.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.172413793103448%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.488063660477454%\" valign=\"top\"\u003e\n \u003cp\u003e94(81.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.427055702917772%\" valign=\"top\"\u003e\n \u003cp\u003e47(81.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.222811671087532%\" valign=\"top\"\u003e\n \u003cp\u003e47(81.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.437665782493369%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e98(86.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.896551724137931%\" valign=\"top\"\u003e\n \u003cp\u003e48(84.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.6923076923076925%\" valign=\"top\"\u003e\n \u003cp\u003e50(87.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.305039787798409%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"11.007957559681698%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp; Yes\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e33(28.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.753315649867375%\" valign=\"top\"\u003e\n \u003cp\u003e12(15.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.885941644562335%\" valign=\"top\"\u003e\n \u003cp\u003e21(21.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.172413793103448%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.488063660477454%\" valign=\"top\"\u003e\n \u003cp\u003e22(19.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.427055702917772%\" valign=\"top\"\u003e\n \u003cp\u003e11(19.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.222811671087532%\" valign=\"top\"\u003e\n \u003cp\u003e11(19.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.437665782493369%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e16(14.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.896551724137931%\" valign=\"top\"\u003e\n \u003cp\u003e9(15.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.6923076923076925%\" valign=\"top\"\u003e\n \u003cp\u003e7(12.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.305039787798409%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"11.007957559681698%\" valign=\"top\"\u003e\n \u003cp\u003eAdrenal gland Metastasis\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.753315649867375%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.885941644562335%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.172413793103448%\" valign=\"top\"\u003e\n \u003cp\u003e0.076\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.488063660477454%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.427055702917772%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.222811671087532%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.437665782493369%\" valign=\"top\"\u003e\n \u003cp\u003e1.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.896551724137931%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.6923076923076925%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.305039787798409%\" valign=\"top\"\u003e\n \u003cp\u003e0.728\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"11.007957559681698%\" valign=\"top\"\u003e\n \u003cp\u003eNo\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e161(91.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.753315649867375%\" valign=\"top\"\u003e\n \u003cp\u003e69(87.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.885941644562335%\" valign=\"top\"\u003e\n \u003cp\u003e92(94.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.172413793103448%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.488063660477454%\" valign=\"top\"\u003e\n \u003cp\u003e108(93.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.427055702917772%\" valign=\"top\"\u003e\n \u003cp\u003e54(93.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.222811671087532%\" valign=\"top\"\u003e\n \u003cp\u003e54(93.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.437665782493369%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e105(92.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.896551724137931%\" valign=\"top\"\u003e\n \u003cp\u003e52(91.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.6923076923076925%\" valign=\"top\"\u003e\n \u003cp\u003e53(93.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.305039787798409%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"11.007957559681698%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp; Yes\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e15(8.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.753315649867375%\" valign=\"top\"\u003e\n \u003cp\u003e10(12.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.885941644562335%\" valign=\"top\"\u003e\n \u003cp\u003e5(5.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.172413793103448%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.488063660477454%\" valign=\"top\"\u003e\n \u003cp\u003e8(6.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.427055702917772%\" valign=\"top\"\u003e\n \u003cp\u003e4(6.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.222811671087532%\" valign=\"top\"\u003e\n \u003cp\u003e4(6.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.437665782493369%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e9(7.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.896551724137931%\" valign=\"top\"\u003e\n \u003cp\u003e5(8.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.6923076923076925%\" valign=\"top\"\u003e\n \u003cp\u003e4(7.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.305039787798409%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"11.007957559681698%\" valign=\"top\"\u003e\n \u003cp\u003eRadiotherapy\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.753315649867375%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.885941644562335%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.172413793103448%\" valign=\"top\"\u003e\n \u003cp\u003e0.256\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.488063660477454%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.427055702917772%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.222811671087532%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.437665782493369%\" valign=\"top\"\u003e\n \u003cp\u003e1.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.896551724137931%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.6923076923076925%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.305039787798409%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"11.007957559681698%\" valign=\"top\"\u003e\n \u003cp\u003eYes\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e93(52.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.753315649867375%\" valign=\"top\"\u003e\n \u003cp\u003e38(48.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.885941644562335%\" valign=\"top\"\u003e\n \u003cp\u003e55(56.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.172413793103448%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.488063660477454%\" valign=\"top\"\u003e\n \u003cp\u003e54(46.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.427055702917772%\" valign=\"top\"\u003e\n \u003cp\u003e27(46.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.222811671087532%\" valign=\"top\"\u003e\n \u003cp\u003e27(46.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.437665782493369%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e57(50.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.896551724137931%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.6923076923076925%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.305039787798409%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"11.007957559681698%\" valign=\"top\"\u003e\n \u003cp\u003eNo\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e83(47.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.753315649867375%\" valign=\"top\"\u003e\n \u003cp\u003e41(51.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.885941644562335%\" valign=\"top\"\u003e\n \u003cp\u003e42(43.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.172413793103448%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.488063660477454%\" valign=\"top\"\u003e\n \u003cp\u003e62(53.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.427055702917772%\" valign=\"top\"\u003e\n \u003cp\u003e31(53.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.222811671087532%\" valign=\"top\"\u003e\n \u003cp\u003e31(53.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.437665782493369%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e57(50.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.896551724137931%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.6923076923076925%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.305039787798409%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"11.007957559681698%\" valign=\"top\"\u003e\n \u003cp\u003eImmunotherapy\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.753315649867375%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.885941644562335%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.172413793103448%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.488063660477454%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.427055702917772%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.222811671087532%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.437665782493369%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.896551724137931%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.6923076923076925%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.305039787798409%\" valign=\"top\"\u003e\n \u003cp\u003e0.450\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"11.007957559681698%\" valign=\"top\"\u003e\n \u003cp\u003eYes\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e79(44.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.753315649867375%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.885941644562335%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.172413793103448%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.488063660477454%\" valign=\"top\"\u003e\n \u003cp\u003e58(50.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.427055702917772%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.222811671087532%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.437665782493369%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e50(43.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.896551724137931%\" valign=\"top\"\u003e\n \u003cp\u003e27(47.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.6923076923076925%\" valign=\"top\"\u003e\n \u003cp\u003e23(40.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.305039787798409%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"11.007957559681698%\" valign=\"top\"\u003e\n \u003cp\u003eNo\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e97(55.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.753315649867375%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.885941644562335%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.172413793103448%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.488063660477454%\" valign=\"top\"\u003e\n \u003cp\u003e58(50.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.427055702917772%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.222811671087532%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.437665782493369%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e64(56.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.896551724137931%\" valign=\"top\"\u003e\n \u003cp\u003e30(52.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.6923076923076925%\" valign=\"top\"\u003e\n \u003cp\u003e34(59.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.305039787798409%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"11.007957559681698%\" valign=\"top\"\u003e\n \u003cp\u003echemotherapy\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.753315649867375%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.885941644562335%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.172413793103448%\" valign=\"top\"\u003e\n \u003cp\u003e0.812\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.488063660477454%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.427055702917772%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.222811671087532%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.437665782493369%\" valign=\"top\"\u003e\n \u003cp\u003e0.893\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.896551724137931%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.6923076923076925%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.305039787798409%\" valign=\"top\"\u003e\n \u003cp\u003e0.925\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"11.007957559681698%\" valign=\"top\"\u003e\n \u003cp\u003eEC\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e56(31.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.753315649867375%\" valign=\"top\"\u003e\n \u003cp\u003e27(34.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.885941644562335%\" valign=\"top\"\u003e\n \u003cp\u003e29(29.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.172413793103448%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.488063660477454%\" valign=\"top\"\u003e\n \u003cp\u003e35(30.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.427055702917772%\" valign=\"top\"\u003e\n \u003cp\u003e18(31.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.222811671087532%\" valign=\"top\"\u003e\n \u003cp\u003e17(29.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.437665782493369%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e30(26.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.896551724137931%\" valign=\"top\"\u003e\n \u003cp\u003e15(26.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.6923076923076925%\" valign=\"top\"\u003e\n \u003cp\u003e15(26.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.305039787798409%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"11.007957559681698%\" valign=\"top\"\u003e\n \u003cp\u003eEP\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e110(62.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.753315649867375%\" valign=\"top\"\u003e\n \u003cp\u003e48(60.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.885941644562335%\" valign=\"top\"\u003e\n \u003cp\u003e62(63.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.172413793103448%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.488063660477454%\" valign=\"top\"\u003e\n \u003cp\u003e74(63.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.427055702917772%\" valign=\"top\"\u003e\n \u003cp\u003e36(62.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.222811671087532%\" valign=\"top\"\u003e\n \u003cp\u003e38(65.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.437665782493369%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e77(67.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.896551724137931%\" valign=\"top\"\u003e\n \u003cp\u003e39(68.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.6923076923076925%\" valign=\"top\"\u003e\n \u003cp\u003e38(66.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.305039787798409%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"11.007957559681698%\" valign=\"top\"\u003e\n \u003cp\u003eOther\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e10(5.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.753315649867375%\" valign=\"top\"\u003e\n \u003cp\u003e4(5.0）\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.885941644562335%\" valign=\"top\"\u003e\n \u003cp\u003e6(6.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.172413793103448%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.488063660477454%\" valign=\"top\"\u003e\n \u003cp\u003e7(6.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.427055702917772%\" valign=\"top\"\u003e\n \u003cp\u003e4(6.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.222811671087532%\" valign=\"top\"\u003e\n \u003cp\u003e3(5.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.437665782493369%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.355437665782494%\" valign=\"top\"\u003e\n \u003cp\u003e7(6.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.896551724137931%\" valign=\"top\"\u003e\n \u003cp\u003e3(5.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.6923076923076925%\" valign=\"top\"\u003e\n \u003cp\u003e4(7.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.305039787798409%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003cstrong\u003eSurvival analysis\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eOS\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eA total of 186 patients were included in the OS analysis. The median OS\u0026nbsp;(mOS) was 16.5 months (95% CI 16.0-23.7) for all patients. The 1-year and 5-year OS rates were 66.2% and 7.0%, respectively.\u003cstrong\u003e(Table 2)\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eTable 2. The survival rate of OS and rwPFS.\u003c/strong\u003e\u003c/p\u003e\n\u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"0\" width=\"644\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd width=\"13.043478260869565%\" valign=\"top\"\u003e\u0026nbsp;\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"54.6583850931677%\" colspan=\"5\" valign=\"top\"\u003e\n \u003cp\u003eOS (n=186)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"32.298136645962735%\" colspan=\"3\" valign=\"top\"\u003e\n \u003cp\u003erwPFS (n=176)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"13.043478260869565%\" valign=\"top\"\u003e\n \u003cp\u003eTime\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.559006211180124%\" valign=\"top\"\u003e\n \u003cp\u003e1-year\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"11.180124223602485%\" valign=\"top\"\u003e\n \u003cp\u003e2-year\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"11.490683229813664%\" valign=\"top\"\u003e\n \u003cp\u003e3-year\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"11.180124223602485%\" valign=\"top\"\u003e\n \u003cp\u003e4-year\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.248447204968944%\" valign=\"top\"\u003e\n \u003cp\u003e5-year\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"11.490683229813664%\" valign=\"top\"\u003e\n \u003cp\u003e6-month\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.267080745341614%\" valign=\"top\"\u003e\n \u003cp\u003e12-month\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.540372670807454%\" valign=\"top\"\u003e\n \u003cp\u003e18-month\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"13.043478260869565%\" valign=\"top\"\u003e\n \u003cp\u003eAll patients\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.559006211180124%\" valign=\"top\"\u003e\n \u003cp\u003e66.2%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"11.180124223602485%\" valign=\"top\"\u003e\n \u003cp\u003e33.7%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"11.490683229813664%\" valign=\"top\"\u003e\n \u003cp\u003e17.2%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"11.180124223602485%\" valign=\"top\"\u003e\n \u003cp\u003e11.1%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.248447204968944%\" valign=\"top\"\u003e\n \u003cp\u003e7.0%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"11.490683229813664%\" valign=\"top\"\u003e\n \u003cp\u003e59.0%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.267080745341614%\" valign=\"top\"\u003e\n \u003cp\u003e13.9%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.540372670807454%\" valign=\"top\"\u003e\n \u003cp\u003e6.8%\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"13.043478260869565%\" valign=\"top\"\u003e\n \u003cp\u003eCT+IT\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.559006211180124%\" valign=\"top\"\u003e\n \u003cp\u003e72.5%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"11.180124223602485%\" valign=\"top\"\u003e\n \u003cp\u003e42.7%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"11.490683229813664%\" valign=\"top\"\u003e\n \u003cp\u003e22.9%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"11.180124223602485%\" valign=\"top\"\u003e\n \u003cp\u003e11.4%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.248447204968944%\" valign=\"top\"\u003e\n \u003cp\u003e0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"11.490683229813664%\" valign=\"top\"\u003e\n \u003cp\u003e63.2%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.267080745341614%\" valign=\"top\"\u003e\n \u003cp\u003e19.8%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.540372670807454%\" valign=\"top\"\u003e\n \u003cp\u003e12.1%\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"13.043478260869565%\" valign=\"top\"\u003e\n \u003cp\u003eCT\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.559006211180124%\" valign=\"top\"\u003e\n \u003cp\u003e61.8%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"11.180124223602485%\" valign=\"top\"\u003e\n \u003cp\u003e28.6%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"11.490683229813664%\" valign=\"top\"\u003e\n \u003cp\u003e14.4%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"11.180124223602485%\" valign=\"top\"\u003e\n \u003cp\u003e10.2%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.248447204968944%\" valign=\"top\"\u003e\n \u003cp\u003e7.3%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"11.490683229813664%\" valign=\"top\"\u003e\n \u003cp\u003e55.7%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.267080745341614%\" valign=\"top\"\u003e\n \u003cp\u003e9.3%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.540372670807454%\" valign=\"top\"\u003e\n \u003cp\u003e3.1%\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"13.043478260869565%\" valign=\"top\"\u003e\n \u003cp\u003eCT+RT\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.559006211180124%\" valign=\"top\"\u003e\n \u003cp\u003e75.4%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"11.180124223602485%\" valign=\"top\"\u003e\n \u003cp\u003e43.8%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"11.490683229813664%\" valign=\"top\"\u003e\n \u003cp\u003e28.5%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"11.180124223602485%\" valign=\"top\"\u003e\n \u003cp\u003e19.8%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.248447204968944%\" valign=\"top\"\u003e\n \u003cp\u003e12.3%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"11.490683229813664%\" valign=\"top\"\u003e\n \u003cp\u003e68.8%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.267080745341614%\" valign=\"top\"\u003e\n \u003cp\u003e14.3%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.540372670807454%\" valign=\"top\"\u003e\n \u003cp\u003e6.2%\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"13.043478260869565%\" valign=\"top\"\u003e\n \u003cp\u003eCT\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.559006211180124%\" valign=\"top\"\u003e\n \u003cp\u003e58.0%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"11.180124223602485%\" valign=\"top\"\u003e\n \u003cp\u003e23.7%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"11.490683229813664%\" valign=\"top\"\u003e\n \u003cp\u003e4.7%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"11.180124223602485%\" valign=\"top\"\u003e\n \u003cp\u003e0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.248447204968944%\" valign=\"top\"\u003e\n \u003cp\u003e0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"11.490683229813664%\" valign=\"top\"\u003e\n \u003cp\u003e48.1%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.267080745341614%\" valign=\"top\"\u003e\n \u003cp\u003e13.6%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.540372670807454%\" valign=\"top\"\u003e\n \u003cp\u003e7.7%\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003eAmong\u0026nbsp;these\u0026nbsp;patients, 80\u0026nbsp;(43.0%) received CT+IT,\u0026nbsp;and 106 (57.0%) were treated\u0026nbsp;with\u0026nbsp;CT\u0026nbsp;alone. During the follow-up period, 138\u0026nbsp;(74.2%)\u0026nbsp;patients reached the primary endpoint, including 48 (60.0%)\u0026nbsp;in the CT+IT group\u0026nbsp;and 90 (84.9%) in the CT-alone group.\u0026nbsp;There were no significant differences in OS\u0026nbsp;between\u0026nbsp;patients\u0026nbsp;who received\u0026nbsp;CT+IT and\u0026nbsp;those who received CT\u0026nbsp;alone (18.0\u0026nbsp;m\u0026nbsp;vs. 15.7 m, respectively; p = 0.208).\u0026nbsp;The 1-year\u0026nbsp;OS rates in the CT+IT and CT alone group were 72.5% and 61.8%, respectively; the 2-year OS rates were 42.7% and 28.6%, respectively, and the 3-year OS rates were 22.9% and 14.4%, respectively. In addition, 87\u0026nbsp;(46.8%)\u0026nbsp;patients\u0026nbsp;received\u0026nbsp;chemoradiotherapy\u0026nbsp;(CT+RT),\u0026nbsp;and 99\u0026nbsp;(53.2%)\u0026nbsp;patients\u0026nbsp;were treated\u0026nbsp;with\u0026nbsp;CT\u0026nbsp;alone. During the follow-up period, 62 (71.7%) patients in the CT+RT group and 76 (76.8%) in the CT-alone group reached the primary endpoint. Patients who\u0026nbsp;received\u0026nbsp;RT\u0026nbsp;had a\u0026nbsp;better prognosis\u0026nbsp;(22.0 m; 95% CI [16.1-27.9] vs. 13.6 m; 95% CI [10.8-16.4]; p \u0026lt;0.001). The 1-year OS rates in the CT+RT and CT alone group were 75.4% and 58.0%, respectively; the 2-year OS rates were 43.8% and 23.7%, respectively; and the 3-year OS rates were 28.5% and 4.7%, respectively.\u003cstrong\u003e(Figure 2, Table 2)\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFigure 2. (A)Kaplan-Mier curves showing OS based on immunotherapy. (B) Kaplan-Mier curves showing PFS based on immunotherapy. (C) Kaplan-Mier curves showing OS based on radiotherapy. (D) Kaplan-Mier curves showing PFS based on radiotherapy.\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eUnivariate survival analysis was used to determine the\u0026nbsp;associations\u0026nbsp;between OS and clinical features.\u0026nbsp;Sex\u0026nbsp;(p=0.002), liver metastasis\u0026nbsp;(p=0.015), and radiotherapy\u0026nbsp;(p\u0026lt;0.001) were found to be significant prognostic factors for OS.\u0026nbsp;Multivariate\u0026nbsp;analysis\u0026nbsp;revealed that sex\u0026nbsp;(HR, 0.571; 95% CI [0.370-0.882]; p=0.011), liver metastasis (HR, 0.661; 95% CI [0.444-0.984]; p=0.041), and radiotherapy (HR, 0.524; 95% CI [0.367-0.748]; p\u0026lt;0.001) were independent prognostic factors for OS.\u003cstrong\u003e(Table 3)\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eTable 3. Analysis of potential risk factors for OS and rwPFS using univariate and multivariate Cox proportional hazard models\u003c/strong\u003e\u003c/p\u003e\n\u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"0\" width=\"733\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd width=\"20.435967302452315%\" rowspan=\"3\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003cp\u003eCharacteristics\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"39.1008174386921%\" colspan=\"4\" valign=\"top\"\u003e\n \u003cp\u003eOS\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"40.463215258855584%\" colspan=\"4\" valign=\"top\"\u003e\n \u003cp\u003erwPFS\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"24.528301886792452%\" colspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003eUnivariate analysis\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.528301886792452%\" colspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003eMultivariate analysis\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"25.042881646655232%\" colspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003eUnivariate analysis\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"25.900514579759864%\" colspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003eMultivariate analysis\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"15.95197255574614%\" valign=\"top\"\u003e\n \u003cp\u003eHR (95% CI)\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.576329331046312%\" valign=\"top\"\u003e\n \u003cp\u003e\u003cem\u003eP\u003c/em\u003e-Value\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.95197255574614%\" valign=\"top\"\u003e\n \u003cp\u003eHR (95% CI)\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.576329331046312%\" valign=\"top\"\u003e\n \u003cp\u003e\u003cem\u003eP\u003c/em\u003e-Value\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16.46655231560892%\" valign=\"top\"\u003e\n \u003cp\u003eHR (95% CI)\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.576329331046312%\" valign=\"top\"\u003e\n \u003cp\u003e\u003cem\u003eP\u003c/em\u003e-Valu\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16.123499142367066%\" valign=\"top\"\u003e\n \u003cp\u003eHR (95% CI)\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"9.777015437392796%\" valign=\"top\"\u003e\n \u003cp\u003e\u003cem\u003eP\u003c/em\u003e-Value\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"20.463847203274216%\" valign=\"top\"\u003e\n \u003cp\u003eAge, year(\u0026le;65\u0026nbsp;yrs vs. \u0026gt;65\u0026nbsp;yrs)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.687585266030014%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.8212824010914055%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.687585266030014%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.8212824010914055%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.096862210095498%\" valign=\"top\"\u003e\n \u003cp\u003e0.846(0.622-1.152)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.8212824010914055%\" valign=\"top\"\u003e\n \u003cp\u003e0.289\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.824010914051842%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.776261937244202%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"20.463847203274216%\" valign=\"top\"\u003e\n \u003cp\u003eGender(Female vs. Male)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.687585266030014%\" valign=\"top\"\u003e\n \u003cp\u003e0.509(0.331-0.782)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.8212824010914055%\" valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.002\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.687585266030014%\" valign=\"top\"\u003e\n \u003cp\u003e0.571(0.370-0.882)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.8212824010914055%\" valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.011\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.096862210095498%\" valign=\"top\"\u003e\n \u003cp\u003e0.722(0.501-1.040)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.8212824010914055%\" valign=\"top\"\u003e\n \u003cp\u003e0.080\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.824010914051842%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.776261937244202%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"20.463847203274216%\" valign=\"top\"\u003e\n \u003cp\u003eSmoking history(Never vs. Former/current)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.687585266030014%\" valign=\"top\"\u003e\n \u003cp\u003e0.719(0.514-1.007)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.8212824010914055%\" valign=\"top\"\u003e\n \u003cp\u003e0.055\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.687585266030014%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.8212824010914055%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.096862210095498%\" valign=\"top\"\u003e\n \u003cp\u003e0.863(0.633-1.176)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.8212824010914055%\" valign=\"top\"\u003e\n \u003cp\u003e0.351\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.824010914051842%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.776261937244202%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"20.463847203274216%\" valign=\"top\"\u003e\n \u003cp\u003eFamily tumor history(No vs. Yes)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.687585266030014%\" valign=\"top\"\u003e\n \u003cp\u003e1.189(0.795-1.778)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.8212824010914055%\" valign=\"top\"\u003e\n \u003cp\u003e0.398\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.687585266030014%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.8212824010914055%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.096862210095498%\" valign=\"top\"\u003e\n \u003cp\u003e1.093(0.769-1.552)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.8212824010914055%\" valign=\"top\"\u003e\n \u003cp\u003e0.620\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.824010914051842%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.776261937244202%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"20.463847203274216%\" valign=\"top\"\u003e\n \u003cp\u003eHypertension(No vs. Yes)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.687585266030014%\" valign=\"top\"\u003e\n \u003cp\u003e0.994(0.658-1.354)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.8212824010914055%\" valign=\"top\"\u003e\n \u003cp\u003e0.755\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.687585266030014%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.8212824010914055%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.096862210095498%\" valign=\"top\"\u003e\n \u003cp\u003e1.146(0.827-1.589)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.8212824010914055%\" valign=\"top\"\u003e\n \u003cp\u003e0.413\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.824010914051842%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.776261937244202%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"20.463847203274216%\" valign=\"top\"\u003e\n \u003cp\u003eDiabetes(No vs. Yes)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.687585266030014%\" valign=\"top\"\u003e\n \u003cp\u003e0.737(0.463-1.175)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.8212824010914055%\" valign=\"top\"\u003e\n \u003cp\u003e0.200\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.687585266030014%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.8212824010914055%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.096862210095498%\" valign=\"top\"\u003e\n \u003cp\u003e0.714(0.469-1.088)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.8212824010914055%\" valign=\"top\"\u003e\n \u003cp\u003e0.117\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.824010914051842%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.776261937244202%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"20.463847203274216%\" valign=\"top\"\u003e\n \u003cp\u003eECOG PS(0-1 vs. \u0026ge;2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.687585266030014%\" valign=\"top\"\u003e\n \u003cp\u003e0.704(0.344-1.441)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.8212824010914055%\" valign=\"top\"\u003e\n \u003cp\u003e0.337\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.687585266030014%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.8212824010914055%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.096862210095498%\" valign=\"top\"\u003e\n \u003cp\u003e0.881(0.412-1.883)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.8212824010914055%\" valign=\"top\"\u003e\n \u003cp\u003e0.744\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.824010914051842%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.776261937244202%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"20.463847203274216%\" valign=\"top\"\u003e\n \u003cp\u003eBrain Metastatic(No vs. Yes)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.687585266030014%\" valign=\"top\"\u003e\n \u003cp\u003e1.056(0.688-1.620)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.8212824010914055%\" valign=\"top\"\u003e\n \u003cp\u003e0.802\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.687585266030014%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.8212824010914055%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.096862210095498%\" valign=\"top\"\u003e\n \u003cp\u003e0.897(0.609-1.320)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.8212824010914055%\" valign=\"top\"\u003e\n \u003cp\u003e0.580\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.824010914051842%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.776261937244202%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"20.463847203274216%\" valign=\"top\"\u003e\n \u003cp\u003eLiver Metastatic(No vs. Yes)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.687585266030014%\" valign=\"top\"\u003e\n \u003cp\u003e0.612(0.412-0.908)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.8212824010914055%\" valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.015\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.687585266030014%\" valign=\"top\"\u003e\n \u003cp\u003e0.661(0.444-0.984)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.8212824010914055%\" valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.041\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.096862210095498%\" valign=\"top\"\u003e\n \u003cp\u003e0.621(0.434-0.889)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.8212824010914055%\" valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.009\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.824010914051842%\" valign=\"top\"\u003e\n \u003cp\u003e0.609(0.425-0.872)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.776261937244202%\" valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.007\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"20.463847203274216%\" valign=\"top\"\u003e\n \u003cp\u003eBone Metastatic(No vs. Yes)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.687585266030014%\" valign=\"top\"\u003e\n \u003cp\u003e0.855(0.590-1.239)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.8212824010914055%\" valign=\"top\"\u003e\n \u003cp\u003e0.408\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.687585266030014%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.8212824010914055%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.096862210095498%\" valign=\"top\"\u003e\n \u003cp\u003e1.145(0.819-1.600)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.8212824010914055%\" valign=\"top\"\u003e\n \u003cp\u003e0.429\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.824010914051842%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.776261937244202%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"20.463847203274216%\" valign=\"top\"\u003e\n \u003cp\u003eLung Metastatic(No vs. Yes)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.687585266030014%\" valign=\"top\"\u003e\n \u003cp\u003e0.972(0.645-1.465)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.8212824010914055%\" valign=\"top\"\u003e\n \u003cp\u003e0.892\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.687585266030014%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.8212824010914055%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.096862210095498%\" valign=\"top\"\u003e\n \u003cp\u003e0.939(0.631-1.397)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.8212824010914055%\" valign=\"top\"\u003e\n \u003cp\u003e0.756\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.824010914051842%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.776261937244202%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"20.463847203274216%\" valign=\"top\"\u003e\n \u003cp\u003eAdrenal gland Metastasis(No vs. Yes)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.687585266030014%\" valign=\"top\"\u003e\n \u003cp\u003e1.184(0.622-2.256)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.8212824010914055%\" valign=\"top\"\u003e\n \u003cp\u003e0.607\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.687585266030014%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.8212824010914055%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.096862210095498%\" valign=\"top\"\u003e\n \u003cp\u003e0.969(0.549-1.170)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.8212824010914055%\" valign=\"top\"\u003e\n \u003cp\u003e0.914\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.824010914051842%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.776261937244202%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"20.463847203274216%\" valign=\"top\"\u003e\n \u003cp\u003eRadiotherapy(Yes vs. No)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.687585266030014%\" valign=\"top\"\u003e\n \u003cp\u003e0.497(0.349-0.708)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.8212824010914055%\" valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026lt;0.001\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.687585266030014%\" valign=\"top\"\u003e\n \u003cp\u003e0.524(0.367-0.748)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.8212824010914055%\" valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026lt;0.001\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.096862210095498%\" valign=\"top\"\u003e\n \u003cp\u003e0.812(0.597-1.104)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.8212824010914055%\" valign=\"top\"\u003e\n \u003cp\u003e0.184\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.824010914051842%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.776261937244202%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"20.463847203274216%\" valign=\"top\"\u003e\n \u003cp\u003eImmunotherapy(Yes vs. No)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.687585266030014%\" valign=\"top\"\u003e\n \u003cp\u003e0.799(0.561-1.138)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.8212824010914055%\" valign=\"top\"\u003e\n \u003cp\u003e0.214\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.687585266030014%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.8212824010914055%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.096862210095498%\" valign=\"top\"\u003e\n \u003cp\u003e0.730(0.535-0.998)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.8212824010914055%\" valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.048\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.824010914051842%\" valign=\"top\"\u003e\n \u003cp\u003e0.716(0.524-0.979)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.776261937244202%\" valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.037\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"20.463847203274216%\" valign=\"top\"\u003e\n \u003cp\u003eChemotherapy(EC vs. EP)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.687585266030014%\" valign=\"top\"\u003e\n \u003cp\u003e1.360(0.950-1.947)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.8212824010914055%\" valign=\"top\"\u003e\n \u003cp\u003e0.093\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.687585266030014%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.8212824010914055%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.096862210095498%\" valign=\"top\"\u003e\n \u003cp\u003e1.132(0.811-1.579)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.8212824010914055%\" valign=\"top\"\u003e\n \u003cp\u003e0.468\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.824010914051842%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.776261937244202%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003cstrong\u003erwPFS\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eA total of 176 patients were included in the rwPFS analysis. The median rwPFS\u0026nbsp;(mrwPFS) was 7.0 months (95% CI 6.5-7.5) for all patients. The\u0026nbsp;6-month, 12-month and 18-month PFS rates were 59.0%, 13.9% and 6.8%, respectively.\u003cstrong\u003e(Table 2)\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAmong these patients, 79 (44.9%) received CT+IT, and 97 (55.1%) were treated with CT alone. During the follow-up period, \u003cstrong\u003e166\u003c/strong\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003cstrong\u003e(94.3%)\u0026nbsp;\u003c/strong\u003epatients reached the endpoint: 69 (87.3%)\u0026nbsp;in the CT+IT group and 97 (100%) in the CT-alone group. The mrwPFS was 7.7 months (95% CI [6.8-8.6]) in the CT+IT cohort and 6.8 months (95% CI [6.1-7.5]) in the CT-alone cohort (\u003cstrong\u003ep=0.043\u003c/strong\u003e).\u0026nbsp;The 6-month rwPFS rates in the CT+IT and CT alone group were\u0026nbsp;63.2% and 55.7%, respectively; the 12-month\u0026nbsp;rwPFS rates\u0026nbsp;were 19.8% and 9.3%, respectively; and the 18-month\u0026nbsp;rwPFS rates were\u0026nbsp;12.1% and 3.1%, respectively. In addition, 93\u0026nbsp;(52.8%)\u0026nbsp;patients\u0026nbsp;received CT+RT,\u0026nbsp;and 83\u0026nbsp;(47.2%)\u0026nbsp;were treated\u0026nbsp;with\u0026nbsp;CT\u0026nbsp;alone. During the follow-up period, 90 (96.8%) patients in the CT+RT group and 76 (91.6%) in the CT-alone group reached the endpoint. There were no significant differences in rwPFS\u0026nbsp;between\u0026nbsp;the two groups (7.4\u0026nbsp;m\u0026nbsp;vs. 6.0 m, p = 0.175). The 6-month rwPFS rates in the CT+RT and CT alone group were 68.8% and 48.1%,\u0026nbsp;respectively; the 12-month\u0026nbsp;rwPFS rates\u0026nbsp;were\u0026nbsp;14.3% and 13.6%,\u0026nbsp;respectively; and the 18-month\u0026nbsp;rwPFS rates were 6.2% and 7.7%, respectively.\u003cstrong\u003e(Figure 2, Table 2)\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eUnivariate\u0026nbsp;analysis revealed that liver metastasis\u0026nbsp;(p=0.009) and immunotherapy\u0026nbsp;(p=0.048) were significant prognostic factors for rwPFS.\u0026nbsp;Multivariate\u0026nbsp;analysis\u0026nbsp;revealed\u0026nbsp;that liver metastasis (HR, 0.609; 95% CI [0.425-0.872]; p=0.007) and immunotherapy\u0026nbsp;(HR, 0.716; 95% CI [0.524-0.979]; p=0.037) were independent prognostic factors for rwPFS.\u003cstrong\u003e(Table 3)\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eSurvival outcomes after PSM\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eOS\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eTo\u0026nbsp;reduce the interference of confounding factors and potential biases, PSM was carried out. PSM was used to match the CT+IT group and the CT\u0026nbsp;group.\u0026nbsp;A total of 60 pairs completed PSM, with comparable baseline\u0026nbsp;characteristics. The mOS was 23.2\u0026nbsp;m\u0026nbsp;(95% CI [15.1-31.3]) in the CT+IT cohort and 13.0\u0026nbsp;m\u0026nbsp;(95% CI [10.3-15.7]) in the CT cohort (\u003cstrong\u003ep=0.008\u003c/strong\u003e).\u0026nbsp;Similarly, PSM was also used to match the CT+RT group and the control group. Among the\u0026nbsp;61 pairs completed, the mOS was 21.4\u0026nbsp;m\u0026nbsp;(95% CI [13.4-29.4]) in the CT+RT group and 12.5\u0026nbsp;m\u0026nbsp;(95% CI [11.2-13.8]) in the control cohort (\u003cstrong\u003ep \u0026lt;0.001\u003c/strong\u003e).\u003cstrong\u003e(Figure 3, Table 1)\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFigure 3.(A)Kaplan-Mier curves showing OS based on immunotherapy after PSM. (B) Kaplan-Mier curves showing PFS based on immunotherapy after PSM. (C) Kaplan-Mier curves showing OS based on radiotherapy after PSM. (D) Kaplan-Mier curves showing PFS based on radiotherapy after PSM.\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003erwPFS\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003ePSM was used to match the CT+IT group and the control group. Among the 58 pairs that were subjected to PSM, there was no significant difference in the mrwPFS (7.3 m; 95% CI [6.5-8.1] vs. 6.2 m; 95% CI [5.5-6.9]; \u003cstrong\u003ep =0.096)\u003c/strong\u003e, but we\u0026nbsp;found that IT tended\u0026nbsp;to improve PFS\u003cstrong\u003e.\u003c/strong\u003e Similarly, PSM was also used to match the CT+RT group and the control group. Among the 57 pairs that were subjected to PSM, the mrwPFS was not significantly different (7.3 m vs. 5.2 m,\u003cstrong\u003e\u0026nbsp;p = 0.220)\u003c/strong\u003e.\u003cstrong\u003e(Figure 3, Table 1)\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eSurvival Outcomes in Selected Patient Subgroups\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eDivision\u003c/strong\u003e\u003cstrong\u003e\u0026nbsp;into four groups according to RT and IT\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eWe divided all\u0026nbsp;patients\u0026nbsp;into four groups: 34 patients in the RT+IT group, 53 in the RT group, 46 in the IT group, and 53 in the CT-alone group. The mOS for these groups was 25.0 m, 21.4 m, 16.6 m, and 12.0 m, respectively. The three groups showed significant\u0026nbsp;improvements in OS\u0026nbsp;compared with the CT-alone group (\u003cstrong\u003ep\u0026lt;0.001, p\u0026lt;0.001, p=0.021\u003c/strong\u003e), but there was no significant difference\u0026nbsp;among\u0026nbsp;the 3 groups. In terms of rwPFS, there were 38 patients in the RT+IT group, 55 in the RT group, 41 in the IT group, and 42 in the CT group. The mrwPFS for these groups was 7.8 m, 7.1 m, 6.8 m, and 5.3 m, respectively. Similarly, the 3 groups showed significant\u0026nbsp;improvements in PFS\u0026nbsp;compared with the CT-alone group (\u003cstrong\u003ep=0.005, p=0.005, p=0.015\u003c/strong\u003e), and there was no significant difference among the 3 groups. \u003cstrong\u003e(Figure 4, Table 4)\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFigure 4. (A)\u0026nbsp;\u003c/strong\u003eKaplan-Mier curves showing OS about four groups. \u003cstrong\u003e(B)\u003c/strong\u003e Kaplan-Mier curves showing PFS about four groups.\u003cstrong\u003e\u0026nbsp;(C)\u0026nbsp;\u003c/strong\u003eKaplan-Mier curves showing OS in the PD-1 group.\u003cstrong\u003e\u0026nbsp;(D)\u003c/strong\u003e Kaplan-Mier curves showing OS based on radiotherapy combined with PD-1/PD-L1 inhibitors.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eTable 4. Survival outcomes of four groups\u003c/strong\u003e\u003c/p\u003e\n\u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"0\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd width=\"52.41157556270097%\" colspan=\"6\" valign=\"top\"\u003e\n \u003cp\u003eOS\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"47.58842443729903%\" colspan=\"5\" valign=\"top\"\u003e\n \u003cp\u003erwPFS\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"8.507223113964686%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.704654895666132%\" valign=\"top\"\u003e\n \u003cp\u003eN\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"9.309791332263242%\" valign=\"top\"\u003e\n \u003cp\u003emOS\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.704654895666132%\" valign=\"top\"\u003e\n \u003cp\u003eRT\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"9.149277688603531%\" valign=\"top\"\u003e\n \u003cp\u003eIT\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"9.791332263242376%\" valign=\"top\"\u003e\n \u003cp\u003eCT\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.025682182985554%\" valign=\"top\"\u003e\n \u003cp\u003eN\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"9.791332263242376%\" valign=\"top\"\u003e\n \u003cp\u003emPFS\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.754414125200642%\" valign=\"top\"\u003e\n \u003cp\u003eRT\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"11.717495987158909%\" valign=\"top\"\u003e\n \u003cp\u003eIT\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.544141252006421%\" valign=\"top\"\u003e\n \u003cp\u003eCT\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"8.507223113964686%\" valign=\"top\"\u003e\n \u003cp\u003eRT+IT\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.704654895666132%\" valign=\"top\"\u003e\n \u003cp\u003e34\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"9.309791332263242%\" valign=\"top\"\u003e\n \u003cp\u003e25.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.704654895666132%\" valign=\"top\"\u003e\n \u003cp\u003e0.951\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"9.149277688603531%\" valign=\"top\"\u003e\n \u003cp\u003e0.149\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"9.791332263242376%\" valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026lt;0.001\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.025682182985554%\" valign=\"top\"\u003e\n \u003cp\u003e38\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"9.791332263242376%\" valign=\"top\"\u003e\n \u003cp\u003e7.8\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.754414125200642%\" valign=\"top\"\u003e\n \u003cp\u003e0.589\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"11.717495987158909%\" valign=\"top\"\u003e\n \u003cp\u003e0.895\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.544141252006421%\" valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.005\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"8.507223113964686%\" valign=\"top\"\u003e\n \u003cp\u003eRT\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.704654895666132%\" valign=\"top\"\u003e\n \u003cp\u003e53\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"9.309791332263242%\" valign=\"top\"\u003e\n \u003cp\u003e21.4\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.704654895666132%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"9.149277688603531%\" valign=\"top\"\u003e\n \u003cp\u003e0.148\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"9.791332263242376%\" valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026lt;0.001\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.025682182985554%\" valign=\"top\"\u003e\n \u003cp\u003e55\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"9.791332263242376%\" valign=\"top\"\u003e\n \u003cp\u003e7.1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.754414125200642%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"11.717495987158909%\" valign=\"top\"\u003e\n \u003cp\u003e0.571\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.544141252006421%\" valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.005\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"8.507223113964686%\" valign=\"top\"\u003e\n \u003cp\u003eIT\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.704654895666132%\" valign=\"top\"\u003e\n \u003cp\u003e46\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"9.309791332263242%\" valign=\"top\"\u003e\n \u003cp\u003e16.6\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.704654895666132%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"9.149277688603531%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"9.791332263242376%\" valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.021\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.025682182985554%\" valign=\"top\"\u003e\n \u003cp\u003e41\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"9.791332263242376%\" valign=\"top\"\u003e\n \u003cp\u003e6.8\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.754414125200642%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"11.717495987158909%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.544141252006421%\" valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.015\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"8.507223113964686%\" valign=\"top\"\u003e\n \u003cp\u003eCT\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.704654895666132%\" valign=\"top\"\u003e\n \u003cp\u003e53\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"9.309791332263242%\" valign=\"top\"\u003e\n \u003cp\u003e12.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.704654895666132%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"9.149277688603531%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"9.791332263242376%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.025682182985554%\" valign=\"top\"\u003e\n \u003cp\u003e42\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"9.791332263242376%\" valign=\"top\"\u003e\n \u003cp\u003e5.3\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.754414125200642%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"11.717495987158909%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.544141252006421%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003cstrong\u003eComparison of PD-1 inhibitors, PD-L1 inhibitors and radiotherapy\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eFor OS, 80 patients received IT, including 35 patients in the PD-1 group and 45 patients in the PD-L1 group, and the mOS was 23.2 m versus 18.0 m (p=0.380). In the PD-1 group, RT significantly improved patient survival (36.0 m vs. 15.8 m, \u003cstrong\u003ep=0.041\u003c/strong\u003e). The same results were not observed in the PD-L1 group (15.0 m vs. 21.0, p=0.926). In addition, 34 patients received RT, 46 did not receive RT, and the mOS was 25.0 m versus 16.6 m (p=0.149). In the RT group, PD-1 inhibitors tended to improve OS compared with PD-L1 inhibitors (36.0 m vs. 15.0 m, \u003cstrong\u003ep=0.086\u003c/strong\u003e).\u003cstrong\u003e(Figure 4-5, Table 5)\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFigure 5. (A)\u003c/strong\u003eThe bar chart showing OS comparison of PD-1/PD-Ll inhibitors and radiotherapy. \u003cstrong\u003e(B)\u0026nbsp;\u003c/strong\u003eTreatment-related adverse events in all ES-SCLC patients.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eTable 5. Comparison of PD-1 inhibitors, PD-L1 inhibitors and radiotherapy\u003c/strong\u003e\u003c/p\u003e\n\u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"0\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd width=\"10.103626943005182%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"44.4300518134715%\" colspan=\"6\" valign=\"top\"\u003e\n \u003cp\u003eOS\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"45.46632124352332%\" colspan=\"5\" valign=\"top\"\u003e\n \u003cp\u003erwPFS\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"10.12987012987013%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.909090909090908%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.584415584415584%\" valign=\"top\"\u003e\n \u003cp\u003eN\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.753246753246753%\" valign=\"top\"\u003e\n \u003cp\u003emOS\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.142857142857143%\" valign=\"top\"\u003e\n \u003cp\u003e\u003cem\u003eP\u003c/em\u003e-Value\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.012987012987013%\" valign=\"top\"\u003e\n \u003cp\u003emOS\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.012987012987013%\" valign=\"top\"\u003e\n \u003cp\u003e\u003cem\u003eP\u003c/em\u003e-Value\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"11.03896103896104%\" valign=\"top\"\u003e\n \u003cp\u003eN\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"11.03896103896104%\" valign=\"top\"\u003e\n \u003cp\u003emrwPFS\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.441558441558442%\" valign=\"top\"\u003e\n \u003cp\u003e\u003cem\u003eP\u003c/em\u003e-Value\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.922077922077922%\" valign=\"top\"\u003e\n \u003cp\u003emrwPFS\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.012987012987013%\" valign=\"top\"\u003e\n \u003cp\u003e\u003cem\u003eP\u003c/em\u003e-Value\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"10.12987012987013%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003ePD-1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.909090909090908%\" valign=\"top\"\u003e\n \u003cp\u003eIT\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.584415584415584%\" valign=\"top\"\u003e\n \u003cp\u003e19\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.753246753246753%\" valign=\"top\"\u003e\n \u003cp\u003e15.8\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.142857142857143%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.041\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.012987012987013%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e23.2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.012987012987013%\" rowspan=\"4\" valign=\"top\"\u003e\n \u003cp\u003e0.380\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"11.03896103896104%\" valign=\"top\"\u003e\n \u003cp\u003e16\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"11.03896103896104%\" valign=\"top\"\u003e\n \u003cp\u003e5.9\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.441558441558442%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e0.505\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.922077922077922%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e8.3\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.012987012987013%\" rowspan=\"4\" valign=\"top\"\u003e\n \u003cp\u003e0.785\u003c/p\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"24.068767908309457%\" valign=\"top\"\u003e\n \u003cp\u003eRT+IT\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.320916905444125%\" valign=\"top\"\u003e\n \u003cp\u003e16\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.899713467048711%\" valign=\"top\"\u003e\n \u003cp\u003e36.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.355300859598852%\" valign=\"top\"\u003e\n \u003cp\u003e21\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.355300859598852%\" valign=\"top\"\u003e\n \u003cp\u003e9.2\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"11.782477341389727%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003ePD-L1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.688821752265861%\" valign=\"top\"\u003e\n \u003cp\u003eIT\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.495468277945619%\" valign=\"top\"\u003e\n \u003cp\u003e27\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.854984894259819%\" valign=\"top\"\u003e\n \u003cp\u003e21.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.308157099697885%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e0.926\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.157099697885196%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e18.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.83987915407855%\" valign=\"top\"\u003e\n \u003cp\u003e25\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.83987915407855%\" valign=\"top\"\u003e\n \u003cp\u003e6.8\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"9.818731117824774%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e0.817\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"9.214501510574019%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e7.0\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"24.068767908309457%\" valign=\"top\"\u003e\n \u003cp\u003eRT+IT\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.320916905444125%\" valign=\"top\"\u003e\n \u003cp\u003e18\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.899713467048711%\" valign=\"top\"\u003e\n \u003cp\u003e15.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.355300859598852%\" valign=\"top\"\u003e\n \u003cp\u003e17\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.355300859598852%\" valign=\"top\"\u003e\n \u003cp\u003e7.3\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"10.12987012987013%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003eRT+IT\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.909090909090908%\" valign=\"top\"\u003e\n \u003cp\u003ePD-1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.584415584415584%\" valign=\"top\"\u003e\n \u003cp\u003e16\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.753246753246753%\" valign=\"top\"\u003e\n \u003cp\u003e36.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.142857142857143%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.085\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.012987012987013%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e25.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.012987012987013%\" rowspan=\"4\" valign=\"top\"\u003e\n \u003cp\u003e0.149\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"11.03896103896104%\" valign=\"top\"\u003e\n \u003cp\u003e21\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"11.03896103896104%\" valign=\"top\"\u003e\n \u003cp\u003e9.2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.441558441558442%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e0.571\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.922077922077922%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e7.8\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.012987012987013%\" rowspan=\"4\" valign=\"top\"\u003e\n \u003cp\u003e0.895\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"24.068767908309457%\" valign=\"top\"\u003e\n \u003cp\u003ePD-L1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.320916905444125%\" valign=\"top\"\u003e\n \u003cp\u003e18\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.899713467048711%\" valign=\"top\"\u003e\n \u003cp\u003e15.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.355300859598852%\" valign=\"top\"\u003e\n \u003cp\u003e17\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.355300859598852%\" valign=\"top\"\u003e\n \u003cp\u003e7.3\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"11.782477341389727%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003eIT\u003c/p\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.688821752265861%\" valign=\"top\"\u003e\n \u003cp\u003ePD-1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.495468277945619%\" valign=\"top\"\u003e\n \u003cp\u003e19\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.854984894259819%\" valign=\"top\"\u003e\n \u003cp\u003e15.8\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.308157099697885%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e0.533\u003c/p\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.157099697885196%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e16.6\u003c/p\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.83987915407855%\" valign=\"top\"\u003e\n \u003cp\u003e16\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.83987915407855%\" valign=\"top\"\u003e\n \u003cp\u003e5.9\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"9.818731117824774%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e0.540\u003c/p\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"9.214501510574019%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e6.8\u003c/p\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"24.068767908309457%\" valign=\"top\"\u003e\n \u003cp\u003ePD-L1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.320916905444125%\" valign=\"top\"\u003e\n \u003cp\u003e27\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.899713467048711%\" valign=\"top\"\u003e\n \u003cp\u003e21.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.355300859598852%\" valign=\"top\"\u003e\n \u003cp\u003e25\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.355300859598852%\" valign=\"top\"\u003e\n \u003cp\u003e6.8\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003eFor rwPFS, 79\u0026nbsp;patients\u0026nbsp;received IT, including 37\u0026nbsp;patients\u0026nbsp;in the PD-1 group and 42\u0026nbsp;patients\u0026nbsp;in the PD-L1 group, and thirty-eight\u0026nbsp;patients\u0026nbsp;received RT. We found that\u0026nbsp;treatment\u0026nbsp;with PD-1 inhibitors\u0026nbsp;combined with RT\u0026nbsp;(9.2\u0026nbsp;m\u0026nbsp;vs. 5.9 m) prolonged the mrwPFS more than treatment\u0026nbsp;with PD-L1 inhibitors\u0026nbsp;(7.3\u0026nbsp;m\u0026nbsp;vs. 6.8 m), but there\u0026nbsp;were no\u0026nbsp;significant\u0026nbsp;differences (p\u0026gt;0.05). Additionally, patients who underwent RT\u0026nbsp;had\u0026nbsp;longer\u0026nbsp;mPFS\u0026nbsp;when\u0026nbsp;treated\u0026nbsp;with PD-L1\u0026nbsp;inhibitors\u0026nbsp;were combined with RT, whereas those who did not receive RT had longer mPFS in the PD-L1 group. This\u0026nbsp;finding\u0026nbsp;is similar to the results obtained in the OS analysis\u0026nbsp;(p\u0026gt;0.05).(\u003cstrong\u003eTable 5)\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eSynchronous and sequential radiotherapy\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eFor OS, a total of 87 patients received RT. After excluding 1 patient who received prophylactic cranial irradiation, the mOS for synchronous\u0026nbsp;(n=15) and sequential\u0026nbsp;(n=71) RT was 31.0\u0026nbsp;m\u0026nbsp;versus\u0026nbsp;18.0\u0026nbsp;m\u0026nbsp;(p=0.854).\u0026nbsp;After\u0026nbsp;excluding 21 patients who received brain radiation and 2\u0026nbsp;who\u0026nbsp;received bone radiation, a total of 63 patients received thoracic radiotherapy (TRT),\u0026nbsp;and\u0026nbsp;the mOS for synchronous\u0026nbsp;(n=11) and sequential\u0026nbsp;(n=52) TRT was 32.0 m and\u0026nbsp;25.0 m, respectively\u0026nbsp;(p=0.955). To eliminate the impact of IT on RT, we further analyzed the survival of patients who did not receive IT. The results\u0026nbsp;also\u0026nbsp;showed\u0026nbsp;no statistically significant difference\u0026nbsp;(32.0\u0026nbsp;m\u0026nbsp;vs. 24.0 m, p=0.925). Similarly, in the analysis of the PFS population, no favorable outcomes were observed.(\u003cstrong\u003eTable 6)\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eTable 6. Synchronous and sequential radiotherapy\u003c/strong\u003e\u003c/p\u003e\n\u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"0\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd width=\"12.716763005780347%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"11.84971098265896%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.08092485549133%\" valign=\"top\"\u003e\n \u003cp\u003eN\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.236994219653178%\" valign=\"top\"\u003e\n \u003cp\u003emOS\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.803468208092486%\" valign=\"top\"\u003e\n \u003cp\u003e\u003cem\u003eP\u003c/em\u003e-Value\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.404624277456648%\" valign=\"top\"\u003e\n \u003cp\u003emOS\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.83815028901734%\" valign=\"top\"\u003e\n \u003cp\u003eN\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"11.416184971098266%\" valign=\"top\"\u003e\n \u003cp\u003emrwPFS\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"11.416184971098266%\" valign=\"top\"\u003e\n \u003cp\u003e\u003cem\u003eP\u003c/em\u003e-Value\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.236994219653178%\" valign=\"top\"\u003e\n \u003cp\u003emrwPFS\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"12.716763005780347%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003eRT\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"11.84971098265896%\" valign=\"top\"\u003e\n \u003cp\u003esynchronous\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.08092485549133%\" valign=\"top\"\u003e\n \u003cp\u003e15\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.236994219653178%\" valign=\"top\"\u003e\n \u003cp\u003e31.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.803468208092486%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e0.854\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.404624277456648%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e22.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.83815028901734%\" valign=\"top\"\u003e\n \u003cp\u003e13\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"11.416184971098266%\" valign=\"top\"\u003e\n \u003cp\u003e7.3\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"11.416184971098266%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e0.806\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.236994219653178%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e7.4m\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"23.976608187134502%\" valign=\"top\"\u003e\n \u003cp\u003esequential\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.32748538011696%\" valign=\"top\"\u003e\n \u003cp\u003e71\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16.666666666666668%\" valign=\"top\"\u003e\n \u003cp\u003e18.5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"21.92982456140351%\" valign=\"top\"\u003e\n \u003cp\u003e79\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.099415204678362%\" valign=\"top\"\u003e\n \u003cp\u003e7.4\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"12.716763005780347%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003eTRT\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"11.84971098265896%\" valign=\"top\"\u003e\n \u003cp\u003esynchronous\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.08092485549133%\" valign=\"top\"\u003e\n \u003cp\u003e11\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.236994219653178%\" valign=\"top\"\u003e\n \u003cp\u003e32.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.803468208092486%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e0.955\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.404624277456648%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e28.5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.83815028901734%\" valign=\"top\"\u003e\n \u003cp\u003e11\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"11.416184971098266%\" valign=\"top\"\u003e\n \u003cp\u003e7.3\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"11.416184971098266%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e0.466\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.236994219653178%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e8.0m\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"23.976608187134502%\" valign=\"top\"\u003e\n \u003cp\u003esequential\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.32748538011696%\" valign=\"top\"\u003e\n \u003cp\u003e52\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16.666666666666668%\" valign=\"top\"\u003e\n \u003cp\u003e25.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"21.92982456140351%\" valign=\"top\"\u003e\n \u003cp\u003e56\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.099415204678362%\" valign=\"top\"\u003e\n \u003cp\u003e8.0\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"12.716763005780347%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003eRT(no IT)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"11.84971098265896%\" valign=\"top\"\u003e\n \u003cp\u003esynchronous\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.08092485549133%\" valign=\"top\"\u003e\n \u003cp\u003e10\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.236994219653178%\" valign=\"top\"\u003e\n \u003cp\u003e23.2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.803468208092486%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e0.913\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.404624277456648%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e18.5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.83815028901734%\" valign=\"top\"\u003e\n \u003cp\u003e7\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"11.416184971098266%\" valign=\"top\"\u003e\n \u003cp\u003e7.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"11.416184971098266%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e0.722\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.236994219653178%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e7.0m\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"23.976608187134502%\" valign=\"top\"\u003e\n \u003cp\u003esequential\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.32748538011696%\" valign=\"top\"\u003e\n \u003cp\u003e42\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16.666666666666668%\" valign=\"top\"\u003e\n \u003cp\u003e18.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"21.92982456140351%\" valign=\"top\"\u003e\n \u003cp\u003e47\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.099415204678362%\" valign=\"top\"\u003e\n \u003cp\u003e7.1\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"12.716763005780347%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003eTRT(no IT)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"11.84971098265896%\" valign=\"top\"\u003e\n \u003cp\u003esynchronous\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.08092485549133%\" valign=\"top\"\u003e\n \u003cp\u003e8\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.236994219653178%\" valign=\"top\"\u003e\n \u003cp\u003e32.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.803468208092486%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e0.925\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.404624277456648%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e24.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.83815028901734%\" valign=\"top\"\u003e\n \u003cp\u003e6\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"11.416184971098266%\" valign=\"top\"\u003e\n \u003cp\u003e7.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"11.416184971098266%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e0.495\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.236994219653178%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e8.0m\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"23.976608187134502%\" valign=\"top\"\u003e\n \u003cp\u003esequential\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.32748538011696%\" valign=\"top\"\u003e\n \u003cp\u003e30\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16.666666666666668%\" valign=\"top\"\u003e\n \u003cp\u003e24.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"21.92982456140351%\" valign=\"top\"\u003e\n \u003cp\u003e33\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.099415204678362%\" valign=\"top\"\u003e\n \u003cp\u003e8.0\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003cstrong\u003eTreatment-related adverse events\u003c/strong\u003e\u003cstrong\u003e\u0026nbsp;(trAEs)\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAmong all eligible patients, 207 (80.5%)\u0026nbsp;experienced\u0026nbsp;at least one trAE, including 124\u0026nbsp;(48.2%) with\u0026nbsp;grades\u0026nbsp;1-2 and 83\u0026nbsp;(32.3%) with\u0026nbsp;grades\u0026nbsp;3-4. The rates of trAEs in the 4 groups were not\u0026nbsp;significantly different\u0026nbsp;(p = 0.385). No patient exhibited grade 5\u0026nbsp;trAEs. Pneumonitis and esophagitis were the most common immune-related or radiation-related toxicities.\u0026nbsp;Eleven\u0026nbsp;patients developed grade 3 pneumonitis,\u0026nbsp;and 4 patients developed grade 3 esophagitis.(\u003cstrong\u003eTable 7, Figure 5)\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eTable 7. Treatment-related adverse event\u003c/strong\u003e\u003c/p\u003e\n\u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"0\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd width=\"15.88785046728972%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"18.38006230529595%\" valign=\"top\"\u003e\n \u003cp\u003eTotal(257)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.88785046728972%\" valign=\"top\"\u003e\n \u003cp\u003eRT+IT(53)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.576323987538942%\" valign=\"top\"\u003e\n \u003cp\u003eRT(72)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.77258566978193%\" valign=\"top\"\u003e\n \u003cp\u003eIT(63)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.77258566978193%\" valign=\"top\"\u003e\n \u003cp\u003eCT(69)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.722741433021806%\" valign=\"top\"\u003e\n \u003cp\u003e\u003cem\u003eP\u003c/em\u003e-Value\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"15.88785046728972%\" valign=\"top\"\u003e\n \u003cp\u003eNo\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"18.38006230529595%\" valign=\"top\"\u003e\n \u003cp\u003e50(19.5%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.88785046728972%\" valign=\"top\"\u003e\n \u003cp\u003e10(18.9%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.576323987538942%\" valign=\"top\"\u003e\n \u003cp\u003e9(12.5%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.77258566978193%\" valign=\"top\"\u003e\n \u003cp\u003e16(25.4%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.77258566978193%\" valign=\"top\"\u003e\n \u003cp\u003e15(21.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.722741433021806%\" rowspan=\"3\" valign=\"top\"\u003e\n \u003cp\u003e0.385\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"17.406143344709896%\" valign=\"top\"\u003e\n \u003cp\u003eGrade 1-2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"20.13651877133106%\" valign=\"top\"\u003e\n \u003cp\u003e124(48.2%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.406143344709896%\" valign=\"top\"\u003e\n \u003cp\u003e23(43.4%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.064846416382252%\" valign=\"top\"\u003e\n \u003cp\u003e35(48.6%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.993174061433447%\" valign=\"top\"\u003e\n \u003cp\u003e31(49.2%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.993174061433447%\" valign=\"top\"\u003e\n \u003cp\u003e35(50.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"17.406143344709896%\" valign=\"top\"\u003e\n \u003cp\u003eGrade 3-4\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"20.13651877133106%\" valign=\"top\"\u003e\n \u003cp\u003e83(32.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.406143344709896%\" valign=\"top\"\u003e\n \u003cp\u003e20(37.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.064846416382252%\" valign=\"top\"\u003e\n \u003cp\u003e28(38.9%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.993174061433447%\" valign=\"top\"\u003e\n \u003cp\u003e16(25.4%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.993174061433447%\" valign=\"top\"\u003e\n \u003cp\u003e19(27.6%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"15.88785046728972%\" valign=\"top\"\u003e\n \u003cp\u003ePneumonia\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"18.38006230529595%\" valign=\"top\"\u003e\n \u003cp\u003e11(4.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.88785046728972%\" valign=\"top\"\u003e\n \u003cp\u003e5(9.4%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.576323987538942%\" valign=\"top\"\u003e\n \u003cp\u003e3(4.2%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.77258566978193%\" valign=\"top\"\u003e\n \u003cp\u003e3(4.8%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.77258566978193%\" valign=\"top\"\u003e\n \u003cp\u003e0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.722741433021806%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"15.88785046728972%\" valign=\"top\"\u003e\n \u003cp\u003eEsophagitis\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"18.38006230529595%\" valign=\"top\"\u003e\n \u003cp\u003e4(1.6%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.88785046728972%\" valign=\"top\"\u003e\n \u003cp\u003e2(3.8%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.576323987538942%\" valign=\"top\"\u003e\n \u003cp\u003e1(1.4%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.77258566978193%\" valign=\"top\"\u003e\n \u003cp\u003e1(1.6%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.77258566978193%\" valign=\"top\"\u003e\n \u003cp\u003e0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.722741433021806%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e"},{"header":"Discussion","content":"\u003cp\u003eES-SCLC\u0026nbsp;represents a particularly challenging subset of lung cancer characterized by a poor prognosis and limited therapeutic\u0026nbsp;options. Platinum-based chemotherapy\u0026nbsp;(CT) has been the mainstay treatment for ES-SCLC patients. Despite\u0026nbsp;the achievement of\u0026nbsp;objective response rates ranging from 50-70%, the median survival\u0026nbsp;time is\u0026nbsp;limited to 9-12 months, with a dismal 5-year survival rate of less than 7% owing to rapid progression posttreatment resistance\u0026nbsp;[11]. Recently, the most promising development in the treatment of ES-SCLC was the addition of immunotherapy\u0026nbsp;(IT) to standard\u0026nbsp;platinum-based first-line CT. Various clinical trials, including Checkmate032, Keynote028, IMpower133, ASTRUM005 and CASPIAN, have explored the safety and efficacy of anti-PD-1/PD-L1\u0026nbsp;therapy in SCLC patients, demonstrating encouraging outcomes marked by significant enhancements in survival metrics compared to historical data with CT alone\u0026nbsp;[4, 5, 8, 12, 13].\u0026nbsp;Based on the results of these clinical studies, the relevant diagnosis and treatment guidelines approved PD-1/PD-L1 inhibitors combined with CT for the first-line treatment of ES-SCLC. However, the clinical benefits\u0026nbsp;of\u0026nbsp;IT in real-world\u0026nbsp;patients with\u0026nbsp;ES-SCLC are still worth exploring. Therefore, we conducted a real-world study to investigate the application of IT in\u0026nbsp;patients with\u0026nbsp;ES-SCLC.\u003c/p\u003e\n\u003cp\u003eOur study\u0026nbsp;demonstrated\u0026nbsp;that in terms of OS, there was no significant\u0026nbsp;improvement\u0026nbsp;in the CT+IT\u0026nbsp;group compared to the CT-alone group in the entire cohort (18.0\u0026nbsp;m\u0026nbsp;vs. 15.7 m, p = 0.208). Due to the baseline imbalance between the two groups, we conducted PSM and ultimately matched 60 pairs of data. Further analysis revealed a significant\u0026nbsp;increase of\u0026nbsp;9.8 months in survival time for the CT+IT\u0026nbsp;group compared to the CT-alone group (23.2 months\u0026nbsp;vs. 13.0 months, \u003cstrong\u003ep=0.008\u003c/strong\u003e). Regarding rwPFS, there was\u0026nbsp;a\u0026nbsp;significant\u0026nbsp;improvement\u0026nbsp;in the CT+IT group compared to the CT-alone group in the overall cohort (7.7\u0026nbsp;m\u0026nbsp;vs. 6.8 m,\u0026nbsp;\u003cstrong\u003ep=0.043\u003c/strong\u003e), and IT\u0026nbsp;tended\u0026nbsp;to improve rwPFS in the matched cohort (7.3\u0026nbsp;m\u0026nbsp;vs. 6.2 m, \u003cstrong\u003ep =0.096).\u0026nbsp;\u003c/strong\u003eIt is worth noting that our OS outcomes in patients treated with CT+IT were numerically better than\u0026nbsp;those in\u0026nbsp;some prospective studies, such as\u0026nbsp;the\u0026nbsp;IMpower133, CASPIAN, CAPSTONE-1 and ASTRUM-005\u0026nbsp;studies\u0026nbsp;[4, 5, 8, 14],\u0026nbsp;and\u0026nbsp;retrospective studies (17.3\u0026nbsp;m\u0026nbsp;vs. 13.4 m; p = 0.001)\u0026nbsp;[15]. Similarly, our study data\u0026nbsp;surpass those of several\u0026nbsp;prospective studies\u0026nbsp;on the\u0026nbsp;mrwPFS, such as the\u0026nbsp;mPFS of the IT group\u0026nbsp;and CT\u0026nbsp;group, which\u0026nbsp;were 4.5-5.8 months and 4.3-5.6 months, respectively. This could be attributed to approximately half of the patients receiving RT in our study.\u003c/p\u003e\n\u003cp\u003ePreviously, the CREST trial showed that thoracic radiotherapy (TRT) after first-line CT could\u0026nbsp;increase\u0026nbsp;local control rates and improve OS\u0026nbsp;[9].\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003eIn the era of CT, several prospective studies and meta-analyses have demonstrated that consolidative TRT offers survival benefits in comparison with CT alone [16,17].\u0026nbsp;Moreover,\u0026nbsp;studies have shown that RT can prolong the survival of patients with SCLC\u0026nbsp;[18, 19]. Our research\u0026nbsp;revealed\u0026nbsp;that in terms of OS, both in the overall population and in the 61 matched pairs, RT significantly extended the OS of\u0026nbsp;patients with\u0026nbsp;ES-SCLC\u0026nbsp;(22.0\u0026nbsp;m\u0026nbsp;vs. 13.6 m, \u003cstrong\u003ep\u0026lt;0.001\u003c/strong\u003e; 21.4\u0026nbsp;m\u0026nbsp;vs. 12.5 m, \u003cstrong\u003ep\u0026lt;0.001\u003c/strong\u003e).\u0026nbsp;These findings are consistent with previous research. Regarding rwPFS, no significant benefit was observed in either the overall cohort (7.4\u0026nbsp;m\u0026nbsp;vs. 6.0 m, \u003cstrong\u003ep = 0.175\u003c/strong\u003e) or the matched cohort (7.3\u0026nbsp;m\u0026nbsp;vs. 5.2 m,\u003cstrong\u003e\u0026nbsp;p = 0.220)\u003c/strong\u003e, which may be due to the heterogeneity in the timing of RT in our retrospective study. Furthermore, subgroup analysis\u0026nbsp;suggested\u0026nbsp;that synchronous RT may confer greater benefits with or without IT for ES-SCLC\u0026nbsp;patients, although this\u0026nbsp;difference\u0026nbsp;did not reach statistical significance (31.0\u0026nbsp;m\u0026nbsp;vs. 18.5 m; p=0.854).\u003c/p\u003e\n\u003cp\u003ePrevious studies have demonstrated that both PD-1 and PD-L1 inhibitors combined with CT can prolong the survival of patients with ES-SCLC. One meta-analysis suggested that anti-PD-1 agents and anti-PD-L1 agents are likely to have comparable effectiveness\u0026nbsp;[20]. Another meta-analysis revealed that\u0026nbsp;compared with\u0026nbsp;anti-PD-L1 agents, anti-PD-1 agents\u0026nbsp;were linked to favorable survival results\u0026nbsp;[21]. For anti-PD-1 agents,\u0026nbsp;the RATIONAL-312 study\u0026nbsp;suggested\u0026nbsp;that\u0026nbsp;the OS of patients treated with tislelizumab combined with CT\u0026nbsp;reached 15.5 months\u0026nbsp;[22]; in the ASTRUM-005 study, the OS of patients treated with serplulimab reached 15.4 months\u0026nbsp;[8]; in\u0026nbsp;the\u0026nbsp;EXTENTORCH study, the OS of patients treated with toripalimab reached 14.6 months\u0026nbsp;[23]. Regarding anti-PD-L1 agents, the IMpower133 study showed that the OS of patients treated with\u0026nbsp;atezolizumab\u0026nbsp;reached 12.3 months\u0026nbsp;[5]; in the CASPIAN study, the OS of patients treated with durvalumab reached 12.9 months\u0026nbsp;[4];\u0026nbsp;and in\u0026nbsp;the CAPSTONE-1 study, the OS of patients treated with adebrelimab reached 15.3 months\u0026nbsp;[15]. The first\u0026nbsp;large\u0026nbsp;prospective real-world study The ORIENTAL study was the first large, prospective, real-world study on this topic and reported that theOS of ES-SCLC patients treated with durvalumab reached 14.8 months. These studies suggest that there is a trend\u0026nbsp;toward stronger improvement\u0026nbsp;with anti-PD-1 agents\u0026nbsp;than with\u0026nbsp;anti-PD-L1 agents\u0026nbsp;[24].\u0026nbsp;According to our findings, no significant difference was\u0026nbsp;observed between\u0026nbsp;patients\u0026nbsp;who\u0026nbsp;received anti-PD-1\u0026nbsp;agents\u0026nbsp;and\u0026nbsp;those who received anti-PD-L1 agents, although the survival was longer in the PD-1 group\u0026nbsp;(23.2\u0026nbsp;m\u0026nbsp;vs. 18.0 m, p=0.380).\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003eHowever, after controlling for the effect of RT, we found that there appeared to be a greater survival benefit with anti-PD-L1 agents than with anti-PD-1 agents\u0026nbsp;(21.0\u0026nbsp;m\u0026nbsp;vs.\u0026nbsp;15.8 m, p=0.533). A similar trend was observed\u0026nbsp;for\u0026nbsp;rwPFS.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eThis suggests that there is an interaction\u0026nbsp;effect\u0026nbsp;between RT and IT in the treatment of ES-SCLC. Daher et al. showed\u0026nbsp;that\u0026nbsp;patients\u0026nbsp;who underwent\u0026nbsp;TRT after IT had a significantly longer OS (27.7\u0026nbsp;m\u0026nbsp;vs. 13.2 m, p \u0026lt; 0.007) and PFS (8.5\u0026nbsp;m\u0026nbsp;vs. 5.6 m, p \u0026lt; 0.003),\u0026nbsp;with an acceptable safety profile in\u0026nbsp;patients with\u0026nbsp;ES-SCLC\u0026nbsp;[25]. In addition, studies have demonstrated that\u0026nbsp;RT has the potential to increase the expression of tumor antigens on the surface of tumor cells and enhance the binding of\u0026nbsp;antibodies\u0026nbsp;to tumor cells, and IT could enhance the abscopal effect of RT [26, 27]. Several preclinical and clinical investigations have indicated that the combination of RT and IT can bolster local control and\u0026nbsp;improve\u0026nbsp;systemic\u0026nbsp;antitumor\u0026nbsp;immune responses through synergistic mechanisms\u0026nbsp;[27,28].\u0026nbsp;The LEAD study, presented at this year\u0026apos;s ELCC, highlighted the feasibility and potential application of combining systemic therapy with local treatments in clinical practice\u0026nbsp;[29].\u0026nbsp;According to\u0026nbsp;our subgroup analysis, the mOS was 25.0\u0026nbsp;m\u0026nbsp;for the RT+IT+CT group, 21.4\u0026nbsp;m\u0026nbsp;for the RT+CT group, 16.6\u0026nbsp;m\u0026nbsp;for the IT+CT group\u0026nbsp;and 12.0\u0026nbsp;m\u0026nbsp;for the CT group. Moreover,\u0026nbsp;our\u0026nbsp;research revealed that the combination of anti-PD-1 agents with RT\u0026nbsp;significantly improved\u0026nbsp;survival (36.0 vs. 15.8 m,\u0026nbsp;p=\u003cstrong\u003e0.041).\u003c/strong\u003e Conversely, the combination of anti-PD-L1\u0026nbsp;agents with RT not only failed to confer benefits but also\u0026nbsp;had\u0026nbsp;detrimental effects on patients\u0026nbsp;(15.0\u0026nbsp;m\u0026nbsp;vs. 21.0 m, p=0.926). A similar trend was observed\u0026nbsp;for\u0026nbsp;rwPFS.\u0026nbsp;These\u0026nbsp;findings suggest a potentially greater synergistic effect between RT and anti-PD-1 agents.\u0026nbsp;However,\u0026nbsp;whether anti-PD-1 and PD-L1 agents combined with RT cause different clinical outcomes remains unclear,\u0026nbsp;and\u0026nbsp;additional research is\u0026nbsp;needed.\u003c/p\u003e\n\u003cp\u003eRecent retrospective studies have assessed the safety and efficacy of the combination of IT with TRT in\u0026nbsp;patients with\u0026nbsp;ES-SCLC and\u0026nbsp;revealed\u0026nbsp;that the addition of TRT to IT did not exhibit an apparent association with increased toxicity in\u0026nbsp;patients with\u0026nbsp;SCLC\u0026nbsp;[30]. Furthermore, the occurrence of TRT-related adverse events was in line with previous findings from other studies and was considered manageable\u0026nbsp;[18, 19]. Our retrospective study,\u0026nbsp;which was\u0026nbsp;conducted across three medical centers, revealed similar rates of adverse events across the four cohorts, confirming the safety of combining IT with RT in ES-SCLC\u0026nbsp;patients.\u003c/p\u003e\n\u003cp\u003eThe main strength of this article is that it not only confirms the efficacy and safety but also further validates the synergistic effects of RT and IT in patients with ES-SCLC. Additionally, the combination of anti-PD-1 agents with RT resulted in significant survival benefits, and anti-PD-L1 agents without RT seemed to be more effective. This will be the focus of our subsequent research. However, our study has some limitations worth considering. First, as the study design was retrospective, PSM could not completely exclude confounding variables and selection bias. Second, although half of the total patients underwent RT, it included TRT, brain RT, and bone RT, which also affected the results of our analysis. Third, there was no examination of the optimal dose and timing of RT. Last, the small number of patients receiving IT, along with the use of multiple anti-PD-1/PD-L1 agents, was likely to have impacted the analysis outcomes. Therefore, further large-scale studies are warranted to validate our results.\u003c/p\u003e"},{"header":"Conclusions","content":"\u003cp\u003eAn increasing number of treatment options are being explored for ES-SCLC, and chemotherapy is the cornerstone. Our study demonstrated that both IT and RT can prolong survival in patients with ES-SCLC and have excellent safety profiles. In addition, these data reflect a synergistic effect between RT and anti-PD-1 agents. Despite some limitations, this combination therapy is worthy of further investigation for optimizing treatment strategies in patients with ES-SCLC.\u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003eEthics approval and consent to participate\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThis study was approved by the Medical Ethics Committee of each hospital. Because this study was retrospective, informed consent from the included patients was not required, and patient information was anonymized. This study was conducted in accordance with the World Medical Association Declaration of Helsinki, Good Clinical Practices, and local ethical/legal requirements.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConsent for publication\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eNot applicable.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAvailability of data and materials\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe datasets generated and/or analysed during the current study are not publicly available due these data will be prepared for further studies, we will release relevant data when all the studies are completed, but are available from the corresponding author on reasonable request. To request data please contact Huaijun Ji (email: [email protected]).\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompeting interests\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe authors declare that they have no competing interests.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFunding\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eNot applicable.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthors\u0026rsquo; contributions\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eMS and HJ drafted the manuscript. YL and HJ were involved in conception and design. MS and HJ were involved in analysis and interpretation of data. MS, HJ, FD and NX were involved in data collection. All authors contributed in review, revise and approve the manuscript; and agree to be accountable to all aspects of the work.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAcknowledgments\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eWe express our gratitude to all the patients participated in this retrospective study. We are grateful to all the doctors at the participating institutions.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\u003cli\u003e\u003cspan\u003eRudin CM, Brambilla E, Faivre-Finn C, et al. Small-cell lung cancer. Nat Rev Dis Primers. 2021;7(1):3.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKim D, Kim HJ, Wu HG, et al. Intrathoracic Progression Is Still the Most Dominant Failure Pattern after First-Line Chemo-immunotherapy in Extensive-Stage Small-Cell Lung Cancer: Implications for Thoracic Radiotherapy. Cancer Res Treat. 2024;56:430\u0026ndash;41.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSocinski MA, Smit EF, Lorigan P, et al. Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer. J Clin Oncol. 2009;28:4787\u0026ndash;92.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGoldman JW, Dvorkin M, Chen Y, et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2021;22:51\u0026ndash;65.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLiu SV, Reck M, Mansfield AS, et al. Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133). J Clin Oncol. 2021;39:619\u0026ndash;30.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHorn L, Mansfield AS, Szczęsna A, et al. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. N Engl J Med. 2018;23:2220\u0026ndash;9.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRudin CM, Awad MM, Navarro A, et al. Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study. J Clin Oncol. 2020;21:2369\u0026ndash;79.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCheng Y, Han L, Wu L, et al. Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer: The ASTRUM-005 Randomized Clinical Trial. JAMA. 2022;12:1223\u0026ndash;32.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSlotman BJ, van Tinteren H, Praag JO, et al. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Lancet. 2015;385:36\u0026ndash;42.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLi H, Zhao Y, Ma T, et al. Radiotherapy for extensive-stage small-cell lung cancer in the immunotherapy era. Front Immunol. 2023;14:1132482.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eTian Y, Ma J, Jing X, et al. Radiation therapy for extensive-stage small-cell lung cancer in the era of immunotherapy. Cancer Lett. 2022;541:215719.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAntonia SJ, L\u0026oacute;pez-Martin JA, Bendell J, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol. 2016;17:883\u0026ndash;95.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eOtt PA, Elez E, Hiret S, et al. Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study. J Clin Oncol. 2017;34:3823\u0026ndash;9.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWang J, Zhou C, Yao W, et al. Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022;23:739\u0026ndash;47.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eXie J, Chen M, Han H, et al. Clinical impact of first-line PD-1 or PD-L1 inhibitors combined with chemotherapy in extensive-stage small cell lung cancer patients: A real-world multicenter propensity score-matched study. Thorac Cancer. 2023;15:1327\u0026ndash;38.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDuan J, Cui L, Zhao X, et al. Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysis. JAMA Oncol. 2020;6:375\u0026ndash;84.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCheng Y, Fan Y, Zhao Y et al. Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage SCLC (RATIONALE-312): A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical Trial. J Thorac Oncol. 2024; 7:S1556-0864(24)00115-1.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCheng Y, Liu Y, Zhang W, et al. EXTENTORCH: A randomized, phase III trial of toripalimab versus placebo, in combination with chemotherapy as a first-line therapy for patients with extensive stage small cell lung cancer (ES-SCLC). ESMO; 2023. p. LBA93.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCheng Y, Wang J, Yao W et al. Final results and subgroup analysis of ORIENTAL: A phase IIIB study of durvalumab plus platinum-etoposide in first-line treatment of Chinese patients with extensive-stage small-cell lung cancer (ES-SCLC). 2023; ESMO Asia. 519P.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRathod S, Jeremic B, Dubey A, et al. Role of thoracic consolidation radiation in extensive stage small cell lung cancer: A systematic review and meta-analysis of randomised controlled trials. Eur J Cancer. 2019;110:110\u0026ndash;9.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLi AM, Zhou H, Xu YY, et al. Role of thoracic radiotherapy in extensive stage small cell lung cancer: a systemic review and meta-analysis. Ann Transl Med. 2021;9:299.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePeng J, Zhang L, Wang L, et al. Real-world outcomes of PD-L1 inhibitors combined with thoracic radiotherapy in the first-line treatment of extensive stage small cell lung cancer. Radiat Oncol. 2023;18:111.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eXie Z, Liu J, Wu M, et al. Real-World Efficacy and Safety of Thoracic Radiotherapy after First-Line Chemo-Immunotherapy in Extensive-Stage Small-Cell Lung Cancer. J Clin Med. 2023;12:3828.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePillai RN, Behera M, Owonikoko TK, et al. Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: A systematic analysis of the literature. Cancer. 2018;124:271\u0026ndash;7.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDaher SNAA, Rottenberg Y, et al. Real-world data of consolidative radiotherapy for extensive stage (ES)-SCLC treated by chemo-immunotherapy (chemo-IO). Ann Oncol. 2022;33:S97\u0026ndash;104.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eZhang Z, Liu X, Chen D, et al. Radiotherapy combined with immunotherapy: the dawn of cancer treatment. Signal Transduct Target Ther. 2022;7:258.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eFormenti SC, Rudqvist NP, Golden E, et al. Radiotherapy induces responses of lung cancer to CTLA-4 blockade. Nat Med. 2018;24:1845\u0026ndash;51.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLongo V, Della Corte CM, Russo A, et al. Consolidative thoracic radiation therapy for extensive-stage small cell lung cancer in the era of first-line chemoimmunotherapy: preclinical data and a retrospective study in Southern Italy. Front Immunol. 2024;14:1289434.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eZhang Y. Phase II study of low-dose radiation (LDRT) plus durvalumab (D) and etoposide/platinum (EP) as first-line treatment in ES-SCLC (LEAD): Efficacy and safety results. 2024; ELCC 2024.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDiamond BH, Verma N, Shukla UC, et al. Consolidative Thoracic Radiation Therapy After First-Line Chemotherapy and Immunotherapy in Extensive-Stage Small Cell Lung Cancer: A Multi-Institutional Case Series. Adv Radiat Oncol. 2021;7:100883.\u003c/span\u003e\u003c/li\u003e\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":false,"highlight":"","institution":"","isAcceptedByJournal":true,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"bmc-cancer","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"bcan","sideBox":"Learn more about [BMC Cancer](http://bmccancer.biomedcentral.com/)","snPcode":"","submissionUrl":"https://www.editorialmanager.com/bcan/default.aspx","title":"BMC Cancer","twitterHandle":"BMC_series","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"em","reportingPortfolio":"BMC Series","inReviewEnabled":true,"inReviewRevisionsEnabled":true},"keywords":"Extensive-stage small cell lung cancer, chemotherapy, immunotherapy, radiotherapy, propensity score matching","lastPublishedDoi":"10.21203/rs.3.rs-4594148/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-4594148/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003ch2\u003eBackground\u003c/h2\u003e \u003cp\u003ePatients with extensive-stage small cell lung cancer (ES-SCLC) experience significant therapeutic challenges and limited survival rates. This study aimed to investigate the efficacy of combining immunotherapy (IT) with chemotherapy (CT) for treating ES-SCLC and to explore the synergistic effect between radiotherapy (RT) and IT.\u003c/p\u003e\u003ch2\u003eMethods\u003c/h2\u003e \u003cp\u003eThis retrospective analysis examined patients with ES-SCLC who received treatment at three centers. Furthermore, propensity score-matched (PSM) analysis was conducted. The Kaplan‒Meier method and Cox proportional hazards regression were used to compare the survival outcomes.\u003c/p\u003e\u003ch2\u003eResults\u003c/h2\u003e \u003cp\u003eA total of 257 eligible patients with ES-SCLC were included in the analysis. Among all patients, the median overall survival (mOS) was 18.0m in the chemoimmunotherapy (CT\u0026thinsp;+\u0026thinsp;IT) group and 15.7m in the CT group (\u003cb\u003ep\u0026thinsp;=\u0026thinsp;0.208\u003c/b\u003e). The median real-world progression-free survival (mrwPFS) was 7.7m and 6.8m (p\u0026thinsp;=\u0026thinsp;\u003cb\u003e0.043\u003c/b\u003e) in the CT\u0026thinsp;+\u0026thinsp;IT and CT group, respectively. Moreover, the mOS was 22.0m in the chemoradiotherapy (CT\u0026thinsp;+\u0026thinsp;RT) group and 13.6m in the CT group (\u003cb\u003ep\u0026thinsp;\u0026lt;\u0026thinsp;0.001\u003c/b\u003e). The mrwPFS was 7.4m and 6.0m (\u003cb\u003ep\u0026thinsp;=\u0026thinsp;0.175\u003c/b\u003e) in the CT\u0026thinsp;+\u0026thinsp;RT group and CT group, respectively. The multivariate analyses revealed that sex, liver metastasis and RT were independent prognostic factors for OS (p\u0026thinsp;\u0026lt;\u0026thinsp;0.05), while liver metastasis and IT were found to be independent predictive factors of rwPFS (p\u0026thinsp;\u0026lt;\u0026thinsp;0.05). After PSM, the mOS was 23.2m in the CT\u0026thinsp;+\u0026thinsp;IT group and 13.0m in the CT group (\u003cb\u003ep\u0026thinsp;=\u0026thinsp;0.008\u003c/b\u003e). The mrwPFS was 7.3m and 6.2m (p\u0026thinsp;=\u0026thinsp;\u003cb\u003e0.096)\u003c/b\u003e in the CT\u0026thinsp;+\u0026thinsp;IT group and the CT group, respectively. Moreover, the mOS was 21.4m in the CT\u0026thinsp;+\u0026thinsp;RT group and 12.5m in the CT group (\u003cb\u003ep\u0026thinsp;\u0026lt;\u0026thinsp;0.001\u003c/b\u003e). The mrwPFS was 7.3m and 5.2m (\u003cb\u003ep\u0026thinsp;=\u0026thinsp;0.220\u003c/b\u003e) in the CT\u0026thinsp;+\u0026thinsp;RT group and the CT group, respectively. Additionally, our study revealed that in the PD-1 group, RT significantly improved patient survival (36.0m vs. 15.8m, \u003cb\u003ep\u0026thinsp;=\u0026thinsp;0.041\u003c/b\u003e).\u003c/p\u003e\u003ch2\u003eConclusion\u003c/h2\u003e \u003cp\u003eAn increasing number of treatment options are being explored for ES-SCLC, and CT is the cornerstone of treatment for this disease. Combining CT with IT and RT has demonstrated remarkable efficacy and excellent safety profiles, and such treatments are worthy of further exploration.\u003c/p\u003e","manuscriptTitle":"Clinical outcomes and synergistic effect between radiotherapy and immunotherapy in patients with extensive-stage small cell lung cancer: A real-world study","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2024-07-15 23:42:35","doi":"10.21203/rs.3.rs-4594148/v1","editorialEvents":[{"type":"communityComments","content":0},{"type":"decision","content":"Revision requested","date":"2024-06-18T17:56:06+00:00","index":"","fulltext":""},{"type":"editorAssigned","content":"","date":"2024-06-18T01:33:31+00:00","index":"","fulltext":""},{"type":"checksComplete","content":"","date":"2024-06-18T01:31:39+00:00","index":"","fulltext":""},{"type":"submitted","content":"BMC Cancer","date":"2024-06-17T12:32:02+00:00","index":"","fulltext":""}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"bmc-cancer","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"bcan","sideBox":"Learn more about [BMC Cancer](http://bmccancer.biomedcentral.com/)","snPcode":"","submissionUrl":"https://www.editorialmanager.com/bcan/default.aspx","title":"BMC Cancer","twitterHandle":"BMC_series","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"em","reportingPortfolio":"BMC Series","inReviewEnabled":true,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"328506d7-c006-4123-8890-1fcac80c3e03","owner":[],"postedDate":"July 15th, 2024","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"published-in-journal","subjectAreas":[],"tags":[],"updatedAt":"2024-10-07T16:08:41+00:00","versionOfRecord":{"articleIdentity":"rs-4594148","link":"https://doi.org/10.1186/s12885-024-12942-y","journal":{"identity":"bmc-cancer","isVorOnly":false,"title":"BMC Cancer"},"publishedOn":"2024-09-30 15:58:02","publishedOnDateReadable":"September 30th, 2024"},"versionCreatedAt":"2024-07-15 23:42:35","video":"","vorDoi":"10.1186/s12885-024-12942-y","vorDoiUrl":"https://doi.org/10.1186/s12885-024-12942-y","workflowStages":[]},"version":"v1","identity":"rs-4594148","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-4594148","identity":"rs-4594148","version":["v1"]},"buildId":"qtupq5eGEP_6zYnWcrvyt","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}